Document:

<PAGE>

                                                                    EXHIBIT 10.2

CERTAIN MATERIAL (INDICATED BY AN ASTERISK) HAS BEEN OMITTED FROM THIS DOCUMENT
PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED MATERIAL HAS BEEN
FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

                                                                    CONFIDENTIAL

                                   EGF VACCINE

            LICENSE, DEVELOPMENT, MANUFACTURING AND SUPPLY AGREEMENT

                                 BY AND BETWEEN

                                 TARCANTA INC.,
                                 TARCANTA, LTD.

                                       AND

                                   CIMAB, S.A.

                               DATED JULY 13, 2004

                                       1
<PAGE>

                                                                    CONFIDENTIAL

                                TABLE OF CONTENTS

Exhibit A    Licensed Patent Rights
Exhibit B    Transferred Assets
Exhibit C    Form of Quality Agreement
Exhibit D    Patent and Know-How Agreement between CIM and CIMAB
Exhibit E    Patent License Agreement between HEBER BIOTEC, S.A.
             and CIMAB

                                       2
<PAGE>

                                   EGF VACCINE

            LICENSE, DEVELOPMENT, MANUFACTURING AND SUPPLY AGREEMENT

      THIS EGF VACCINE LICENSE, DEVELOPMENT, MANUFACTURING AND SUPPLY AGREEMENT
(the "Agreement") is made effective as of the 13th day of July, 2004 (the
"Effective Date") by and between CIMAB, S.A., a corporation organized under the
laws of Cuba, having offices at Calle 206, No. 1926, e/ 19 y 21, Atabey, Playa,
Ciudad de La Habana, Cuba ("CIMAB") on the one hand, and TARCANTA Inc., a
corporation organized under the laws of the State of Delaware, United States of
America, having offices at 2110 Rutherford Road, Carlsbad, California 92008
("TARCANTA") and TARCANTA, Ltd., a corporation organized under the laws of the
Republic of Ireland, having offices at 30 Herbert Street, Dublin 2, Ireland
("TARCANTA LTD."), on the other hand. TARCANTA, TARCANTA LTD. and CIMAB are
sometimes referred to herein individually as a "Party" and collectively as the
"Parties."

                                    RECITALS

      1. CIMAB, S.A. is a corporation with independent juridical personality
organized under the laws of Cuba, with offices at Calle 206, No. 1926, e/ 19 y
21, Atabey, Playa, Ciudad de La Habana, Cuba.

      2. Centro de Inmunologia Molecular, located at Calle 216 y 15, Atabey,
Playa, Ciudad de La Habana, 11600, Cuba ("CIM"), and HEBER BIOTEC, S.A. located
at Ave. 31 e/ 158 y 190 Cubanacan, Playa, Ciudad de La Habana 10600, Cuba
("HEBER") have granted CIMAB licenses, with the right to grant the sublicenses
to TARCANTA and TARCANTA LTD. contemplated under this Agreement, of certain
patents, patent applications, other valuable technology and know-how owned or
controlled by CIM and/or HEBER, to wit, certain patents, patent applications,
other valuable technology and know-how relating to certain products, defined
below as the Licensed Products. Such rights granted to CIMAB by HEBER are
non-exclusive. Copies of such license agreements are attached hereto and
incorporated herein as Exhibits D and E. Neither CIM nor HEBER is a party to
this Agreement, nor are they responsible for the debts, obligations or actions
of CIMAB under this Agreement or arising from or in connection with this
Agreement.

      3. CIM has developed and may develop certain Adjuvants (as such term is
defined herein) that it has licensed to CIMAB, with the right to grant
sublicenses, and CIMAB wishes to license such Adjuvants to TARCANTA and TARCANTA
LTD. for use only in connection with the Licensed Products and other therapeutic
cancer vaccines or therapeutic cancer products licensed by CIMAB to TARCANTA and
TARCANTA LTD. CIMAB wishes to retain the right to license such Adjuvants to
other parties for uses other than in connection with the Licensed Products and
other therapeutic cancer vaccines or therapeutic cancer products licensed by
CIMAB to TARCANTA and TARCANTA LTD.

      4. TARCANTA is a corporation with independent juridical personality
organized under the laws of the State of Delaware, United States of America
("U.S."), with offices at 2110

                                       1
<PAGE>

Rutherford Road, Carlsbad, California, 92008.

      5. TARCANTA LTD. is a corporation with independent juridical personality
organized under the laws of the Republic of Ireland, with offices at 30 Herbert
Street, Dublin 2, Ireland.

      6. TARCANTA and TARCANTA LTD. believe that conducting international
clinical trials in countries throughout the Territory, including the Other
Countries, will significantly advance their ability to obtain Regulatory
Approvals of the Licensed Products in the U.S. and throughout the Territory in a
timely manner by increasing the number and diversity of patients that may be
enrolled in clinical trials of the Licensed Products. Accordingly, TARCANTA,
TARCANTA LTD. and CIMAB agree to further develop the Licensed Products and
TARCANTA and TARCANTA LTD. agree to conduct clinical trials for the Licensed
Products and to obtain Regulatory Approvals that are necessary in order to
market and sell the Licensed Products in the Territory (as such terms are
defined below) in accordance with the terms and conditions of this Agreement.
For the purposes of this Agreement, all countries in the Territory other than
the U.S., Canada and Mexico shall be referred to herein as the "Other
Countries."

      7. TARCANTA and TARCANTA LTD. agree, upon receipt of applicable Regulatory
Approvals, to manufacture, market and sell the Licensed Products in the U.S.,
Canada and Mexico.

      8. Consistent with normal industry practices in a licensing arrangement of
this nature, and in an effort to advance the potential for making the Licensed
Products available for the treatment of cancer patients in the U.S. and
throughout the Territory, TARCANTA LTD. and TARCANTA agree, upon receipt of
applicable Regulatory Approvals, to market and sell the Licensed Products
purchased from CIMAB in the Other Countries, in accordance with the terms and
conditions of this Agreement.

      9. In order to ensure an adequate supply of the Licensed Products for
clinical testing and, upon commercialization, for the treatment of patients in
the U.S. and throughout the Territory, TARCANTA and TARCANTA LTD. agree to
purchase the Licensed Products from CIMAB, and CIMAB agrees to manufacture and
sell such Licensed Products to TARCANTA and TARCANTA LTD., in accordance with
the terms and conditions of this Agreement.

      10. Because the Parties believe that a more effective vaccine for the
treatment of some types of cancer may be created by the sequential use or the
combination of the EGF Vaccine with TGF-(alpha) and/or HER-1 Vaccines Controlled
By CIMAB, simultaneously with the execution of this Agreement, the Parties will
also enter into a certain TGF-(alpha) / HER-1 Vaccine License, Development and
Supply Agreement (the "TGF-(alpha) / HER-1 Agreement") with YM Biosciences,
Inc., a corporation organized under the laws of Nova Scotia, Canada, and CIMYM,
Inc., a corporation organized under the laws of Barbados, West Indies (which is
jointly owned by CIMAB and YM Biosciences for purposes of the development of the
TGF-(alpha) and HER-1 Vaccines), pursuant to which TARCANTA and TARCANTA LTD.
will further develop, conduct clinical trials, manufacture and sell the
TGF-(alpha) / HER-1 Vaccines (as such terms are defined therein) in the
Territory.

                                       2
<PAGE>

      In consideration of the premises and of the mutual covenants and
obligations set forth herein, the Parties hereby agree as set forth below.

                                   ARTICLE 1.

                                   DEFINITIONS

      The following capitalized and italicized terms shall have the following
meanings:

      1.1 "Adjuvant" shall mean any and all compounds, compositions, components
or formulations of components, intended to induce, enhance or modify an
antigen-specific, active response of the Licensed Product in combination with
one or more antigens.

      1.2 "Affiliate" means any individual, corporation, association or other
business entity which directly or indirectly controls, is controlled by or is
under common control with the Party in question. As used in this definition of
"Affiliate," the term "control" means the direct or indirect ownership of more
than fifty percent (50%) of the stock having the right to vote for directors
thereof or the ability to otherwise control the management of the corporation or
other business entity whether through the ownership of voting securities, by
contract, resolution, regulation or otherwise; provided, however, that the term
"Affiliate" shall not include subsidiaries or other entities in which a Party or
its Affiliates owns a majority of the ordinary voting power necessary to elect a
majority of the board of directors or other governing body, but is restricted
from electing such majority by contract or otherwise until the time such
restrictions are no longer in effect.

      1.3 "Applicable Laws" means all laws, statutes, ordinances, codes, rules
and regulations that have been enacted by a Government Authority and are in
force as of the Effective Date or come into force during the term of this
Agreement, in each case to the extent that the same are applicable to the
performance by the Parties of their respective obligations under this Agreement.
For purposes of this Agreement, GCPs, GLPs and cGMPs (as such terms are defined
below) shall be deemed to be within the term "Applicable Laws."

      1.4 "Barter" means that offsetting mechanism under which TARCANTA and
TARCANTA LTD. discharge certain of their payment obligations hereunder by
placing funds in the Barter Escrow Account against which the value of Barter
Goods purchased by CIMAB shall be accredited according to the provisions set
forth in Section 5.10.3.

      1.5 "Barter Escrow Account" means an escrow account opened with a
reputable bank located in London, England, or Ireland, as agent bank, strictly
for the purpose of receiving payments owed by TARCANTA and TARCANTA LTD. to
CIMAB as provided by Section 5.10.3 herein, and against which CIMAB's purchase
of Barter Goods and Payments in Cash to CIMAB shall be debited pursuant to
Section 5.10.3. Such bank must (a) be a U.S. bank, a foreign subsidiary or
branch of a U.S. bank, or a bank that is owned and controlled by a U.S. bank,
and (b) be incorporated in a country that is a member of the European Union. Any
bank on the list of specially designated nationals issued by the U.S. Treasury
Department's Office of Foreign Assets Control, or which is a Cuban national, is
not qualified to be a bank at which the "Barter Escrow Account" may be
maintained. The funds in the Barter Escrow Account may be released

                                       3
<PAGE>

only upon confirmation by TARCANTA or TARCANTA LTD. to such bank and its escrow
agent that the goods listed on the purchase order received from CIMAB conform to
the definition of Barter Goods, and upon further confirmation by such bank and
its escrow agent that CIMAB has declared on the purchase order that said Barter
Goods are to be used for public health purposes of the Cuban people.

      1.6 "Barter Goods" shall mean U.S.-origin food, medicines and/or medical
supplies to be exported to Cuba and destined for the public health purposes of
the Cuban people. As used in this Section 1.6, "food" means "agricultural
commodities" that qualify for export under the Trade Sanctions Reform and Export
Enhancement Act of 2000, P.L. 106-387, Title IX, and the implementing
regulations of the U.S. government. As used in this Section 1.6, "medicine" and
"medical supplies" have the meaning of "medicine" and "medical device" that
qualify for export under the Trade Sanctions Reform and Export Enhancement Act
of 2000, P.L. 106-387, Title IX, and any implementing regulations of the U.S.
government.

      1.7 "Barter Payments" means payments by TARCANTA, TARCANTA LTD., their
Affiliates or Sublicensees into the "Barter Escrow Account" in accordance with
the provisions set out in Section 5.10.3.

      1.8 "BLA" means a Biologics License Application to the FDA or an
equivalent application to any other Government Authority within the Territory
requesting market approval for a new biological product (or a New Drug
Application (NDA), or equivalent application, in the event that the FDA or other
Government Authority determines that an NDA, rather than a BLA, is the
appropriate mechanism for requesting such approval).

      1.9 "Carrier Protein" means any immunogenic carrier or fusion protein
including, without limitation, P64K.

      1.10 "CIMAB's Licensors" or "its Licensors" means CIM and HEBER.

      1.11 "Commercialization Phase" means the period after the approval by the
U.S. FDA of the first BLA for any Licensed Product filed by TARCANTA, TARCANTA
LTD. or their Affiliates or Sublicensees.

      1.12 "Committee I" shall have the meaning set forth in Article 3.

      1.13 "Committee II" shall have the meaning set forth in Article 4.

      1.14 "Confidential Information" shall have the meaning set forth in
Article 11.

      1.15 "Contract Manufacturer" means any Person contracted by TARCANTA,
TARCANTA LTD., their Affiliates or Sublicensees, or by CIMAB to manufacture,
Finish (as such term is defined herein), or supply the Licensed Products, or any
component or ingredient thereof, in accordance with the terms and conditions of
this Agreement; provided, however, that no assignment of rights to a Contract
Manufacturer hereunder shall relieve CIMAB, TARCANTA or TARCANTA LTD., or their
Affiliates or Sublicensees of their obligations to fully comply with the terms
and conditions of this Agreement. In the case of TARCANTA,

                                       4
<PAGE>

TARCANTA LTD. or their Affiliates or Sublicensees, "Contract Manufacturer" shall
not include any entity that is a Cuban national.

      1.16 "Controlled By" means with respect to any Licensed Know-How, Licensed
Patent Rights, or other intellectual property right that a Party owns, has a
license to, or otherwise uses and has the ability to grant to the other party
access, a license or a sublicense (as applicable) to such Licensed Know-How,
Licensed Patent Rights, or other intellectual property right as provided for in
this Agreement, without violating the terms of any agreement or other
arrangement with any Third Party, including a Third Party Cuban National,
existing at the time such Party would be first required under this Agreement to
grant the other Party such access, license or sublicense.

      1.17 "Cost of Goods Sold" means TARCANTA or TARCANTA LTD.'s documented,
actual costs of manufacture of the Licensed Product, including costs of
packaging, labeling and insurance and transportation. Cost of Goods Sold shall
not include the costs of conducting clinical trials or performing pre-clinical
testing; sales, general and administrative costs; capital expenditures; research
and development costs; or interest expenses.

      1.18 "Cuban national" means, unless otherwise stated, a "national" of Cuba
within the meaning of the Cuban Assets Control Regulations, 31 C.F.R. 515.302,
issued by the U.S. Treasury Department's Office of Foreign Assets Control.

      1.19 "Delivery Date" shall have the meaning set forth in Article 7.

      1.20 "Delivery Location" shall have the meaning set forth in Article 7.

      1.21 "Development Phase" means the period prior to the approval by the
U.S. FDA of the first BLA filed by TARCANTA or TARCANTA LTD. for any Licensed
Product.

      1.22 "Development Plan" shall have the meaning set forth in Article 3.

      1.23 "Development Work" shall have the meaning set forth in Article 3.

      1.24 "Disclosing Party" shall have the meaning set forth in Article 11.

      1.25 "Dispute Resolution Procedures" means the procedures established by
Article 14.

      1.26 "Effective Date" means the date set forth in the first paragraph of
this Agreement.

      1.27 "Europe" means Austria, Belgium, Denmark, Finland, France, Germany,
Greece, Ireland, Italy, Luxembourg, Portugal, Spain, Sweden, The Netherlands,
United Kingdom, Cyprus, Czech Republic, Estonia, Hungary, Latvia, Lithuania,
Malta, Poland, Slovakia, Slovenia, Bulgaria, Romania, Turkey, Norway,
Liechtenstein, San Marino, Monaco, and the Vatican.

      1.28 "FDA" means the U.S. Food and Drug Administration, and any successor
thereto.

      1.29 "FFDCA" means the Federal Food, Drug, and Cosmetic Act, 21 U.S. Code
321 et seq., as amended from time to time.

                                       5
<PAGE>

      1.30 "Finish" means to fill, package and label the Licensed Products in
their final packaging configurations for sale to an end-user.

      1.31 "Firm Commitment Quantities" shall have the meaning set forth in
Section 7.1.1.

      1.32 "First Commercial Sale" means the first sale of a Licensed Product by
TARCANTA, TARCANTA LTD., or their Affiliates or Sublicensees for use or
consumption of such Licensed Product in a country in the Territory where
Regulatory Approval of such Licensed Product has been obtained. Sale of a
Licensed Product to an Affiliate or a Sublicensee shall not constitute a First
Commercial Sale unless such Affiliate or such Sublicensee is the end user of
such Licensed Product.

      1.33 "Force Majeure" shall have the meaning set forth in Section 15.2.

      1.34 "GCPs" means good clinical practices equivalent to those applicable
in the U.S. and specifically including the International Committee on
Harmonization Guidelines for Good Clinical Practices.

      1.35 "GLPs" means current good laboratory practices equivalent to those
applicable in the U.S. and in effect from time to time during the term of this
Agreement.

      1.36 "cGMPs" means current good manufacturing practices equivalent to
those applicable in the U.S. and in effect from time to time during the term of
this Agreement.

      1.37 "Government Authority" means any supranational, national, regional,
state or local government, court, governmental agency, authority, board, bureau,
instrumentality or regulatory body.

      1.38 "Importer" shall have the meaning set forth in Section 7.1.1.

      1.39 "Improvement" means any improvement in or modification to an
existing Licensed Product, Licensed Patent Right, or Licensed Know-How,
including, without limitation, any new method of treating cancer patients using
the Licensed Products, developed, individually by or on behalf of CIMAB or by or
on behalf of TARCANTA, TARCANTA LTD. or their Affiliates or its Subsidiaries, or
jointly by the any of the Parties and/or their respective Affiliates or
Subsidiaries, under the Development Plan. Any patent rights resulting from any
Improvement shall be included within the definition of Licensed Patent Rights
for purposes of this Agreement. Any Know-How resulting from any Improvement
shall be included within the definition of Know-How for purposes of this
Agreement. Notwithstanding anything in the foregoing to the contrary, neither
TARCANTA, TARCANTA LTD. nor their respective Affiliates or Subsidiaries shall be
required to transfer or license, nor shall they transfer or license, to CIMAB
any Know-How unrelated to the Licensed Products, and neither CIMAB nor its
Licensors shall be required to transfer or license, nor shall they transfer or
license, to TARCANTA, TARCANTA LTD. or their respective Affiliates or
Subsidiaries any Know-How unrelated to the Licensed Products.

      1.40 "IND Submission" means an "Investigational New Drug" application to
the FDA requesting approval to initiate a clinical trial on a new drug or
biological product.

                                       6
<PAGE>

      1.41 "Infringement" shall have the meaning set forth in Article 10.

      1.42 "Know-How" means information, data and proprietary rights of any type
whatsoever (other than the Licensed Patent Rights) in any tangible or intangible
form whatsoever relevant to the development, manufacture and commercialization
of any Licensed Product, including, without limitation, inventions, practices,
methods, techniques, specifications, formulations, formulae, knowledge,
know-how, skill, experience, test data (including pharmacological, biological,
chemical, biochemical, toxicological and clinical test data), analytical and
quality control data, stability data, results of studies, technical drawings and
related copyrights, and other similar information.

      1.43 "Licensed Know-How" means Know-How Controlled By CIMAB related to any
Licensed Product at any time during the term of this Agreement and the Know-How
Controlled By either Party related to the Improvements at any time during the
term of this Agreement.

      1.44 "Licensed Patent Rights" means (i) the patents and patent
applications listed on Exhibit A attached hereto and incorporated herein by
reference, covering Licensed Products or methods of manufacture or use thereof
owned or Controlled By CIMAB; (ii) all divisional, continuation,
continuation-in-part, reissue, extension, re-examination, renewal, or substitute
applications within the Territory; (iii) all patents and patent applications
within the Territory that result from the Improvements; (iv) all patents that
may issue on any of the patent applications within (i), (ii) or (iii) above; and
(v) all foreign patent applications and patents within the Territory
corresponding to any of the patent applications or patents within (i), (ii),
(iii) or (iv) above. In addition, if within three (3) years of the Effective
Date of this agreement, TARCANTA, TARCANTA LTD. or their respective Affiliates
discover that they require a license to additional patents, patent applications,
technology or Know-How Controlled By CIMAB that are directly related to the
Licensed Products and are required by TARCANTA, TARCANTA LTD. or their
respective Affiliates to accomplish the objectives of this Agreement, such
patents, patent applications, technology or Know-How will automatically be added
to the appropriate list or exhibits attached to this Agreement and by such
addition be included as "Licensed Patent Rights" under this Agreement.

      1.45 "Licensed Product(s)" means any product(s) containing (i) an
EGF-based therapeutic cancer vaccine licensed to CIMAB composed of recombinant
human epidermal growth factor conjugated, fused or otherwise joined to a Carrier
Protein (referred to herein as the "EGF Vaccine"), and (ii) any Adjuvant
Controlled By, or that becomes Controlled By, CIMAB during the Term of this
Agreement, and any portion, component or derivatives of the EGF Vaccine and/or
any such Adjuvant, or combination thereof that are otherwise co-administered to
a patient as a means of treating cancer, and any Improvements thereto.

      1.46 "Marketing Plan" shall have the meaning set forth in Article 4.

      1.47 "Manufacturing Facilities" means the production plants used by any
Party hereto to manufacture, supply or Finish the Licensed Products, or any
portion, component or derivatives of the Licensed Products for sale in the
Territory in accordance with the terms of this Agreement.

                                       7
<PAGE>

      1.48 "Net Sales" means the gross amount invoiced by TARCANTA, TARCANTA
LTD., their Affiliates or Sublicensees in connection with sales of the Licensed
Products to any Person in the Territory that is not an Affiliate, subsidiary or
Sublicensee of TARCANTA or TARCANTA LTD., after deduction of all documented
trade, case and quantity credits, discounts, refunds, rebates and administrative
fees, allowances or credits for returns, sales commissions, and prepaid freight,
transportation insurance, sales taxes and other government charges (including,
without limitation, value-added taxes), and less either (a) the documented,
applicable Cost of Goods Sold for such Licensed Products, in the case of
Licensed Products manufactured by or on behalf of TARCANTA or TARCANTA LTD., or
(b) the applicable Transfer Price paid to CIMAB, in the case of Licensed
Products manufactured by on or on behalf of CIMAB.

      1.49 "Other Countries" means all countries in the Territory excluding the
U.S., Canada and Mexico.

      1.50 "Party(ies)" means CIMAB, TARCANTA and TARCANTA LTD.

      1.51 "Payment in Cash" means all payments to CIMAB other than Barter
Payments.

      1.52 "Person" means any person or legal entity.

      1.53 "Purchase Orders" shall have the meaning set forth in Article 7.

      1.54 "Quality Agreement" shall have the meaning set forth in Article 7.

      1.55 "Reasonable Commercial Efforts" means, with respect to the efforts to
be expended by a Party with respect to any objective, reasonable, diligent, good
faith efforts to accomplish such objective as typically made by commercial
businesses in similar circumstances and context to achieve a particular result
in a timely manner and maximize the economic return to the parties from its
commercialization but shall not require a Party to take action that would be
commercially unreasonable under the particular circumstances and context, but
without taking into account alternate opportunities available to such Party.

      1.56 "Receiving Party" shall have the meaning set forth in Article 11.

      1.57 "Regulatory Approval" means, with respect to a jurisdiction or, where
applicable, a multinational jurisdiction, (i) any approvals, licenses,
registrations or authorizations necessary to conduct clinical trials of any
Licensed Product, or for the manufacture, marketing and sale of any Licensed
Product in such jurisdiction, and (ii) where relevant, pricing approvals
necessary to obtain reimbursement from a Government Authority with respect to
such Licensed Product. For the sake of clarity, except as otherwise expressly
provided, "Regulatory Approval" shall not be achieved for any Licensed Product
in a nation or, where applicable, a multinational jurisdiction until any
applicable approvals relating to pricing and reimbursement from a Government
Authority have been obtained in such nation or such jurisdiction. However,
notwithstanding anything in this paragraph to the contrary, for purposes of
determining the "Commercialization Phase" only, "Regulatory Approval" shall mean
only any approvals, licenses, registrations or authorizations for the marketing
and sale of any Licensed Product in a jurisdiction.

                                       8
<PAGE>

      1.58 "Regulatory Application" means any application necessary and
appropriate to obtain a Regulatory Approval, including, without limitation, all
required documents, data and information concerning, filed or required to be
filed, or otherwise submitted by either Party to a Governmental Authority in
connection with obtaining such Regulatory Approval.

      1.59 "Royalty(ies)" shall have the meaning set forth in Section 5.3.

      1.60 "Specifications" means the specifications for any Licensed Product,
consistent with the stage of development of such Licensed Product, as adopted or
amended by Committee I from time to time.

      1.61 "Sublicensee" means a sublicensee of CIMAB, TARCANTA or TARCANTA
LTD., authorized or permitted in accordance with the terms of this Agreement;
provided, however, that no sublicense or assignment of rights to a Sublicensee
hereunder shall relieve CIMAB, TARCANTA or TARCANTA LTD. of their obligations to
fully comply with the terms and conditions of this Agreement.

      1.62 "Term" shall have the meaning set forth in Section 12.1.1.

      1.63 "Territory" means the U.S., the countries of "Europe" as defined
above, Canada, Japan, Mexico, Australia, New Zealand and any other countries
added by mutual agreement of the Parties in writing.

      1.64 "Third Country" means a country that is not Cuba or the U.S.

      1.65 "Third Party(ies)" means any Person(s) other than CIMAB, Cuban
nationals (except where Cuban nationals are expressly included), TARCANTA,
TARCANTA LTD. and their respective Affiliates.

      1.66 "Transfer Price" shall have the meaning set forth in Section 6.1.2.

      1.67 "Transferred Assets" means the biological materials, documentation
and other items listed on Exhibit B hereto.

                                   ARTICLE 2

                      GRANT OF RIGHTS AND RELATED COVENANTS

      2.1 Grant of Sublicenses by CIMAB to TARCANTA and TARCANTA LTD.

            2.1.1 Licensed Products - U.S., Canada and Mexico. Subject to the
terms and conditions of this Agreement, CIMAB hereby grants to TARCANTA and
TARCANTA LTD. an exclusive sublicense under the Licensed Patent Rights, the
Licensed Know-How, and the Improvements to make, have made, use, offer for sale,
market and sell the Licensed Products in the U.S., Canada and Mexico.

            2.1.2 Notwithstanding the foregoing Section 2.1.1, TARCANTA and
TARCANTA LTD.'s rights under this Agreement to any Adjuvant and to any Carrier
Protein

                                       9
<PAGE>

with respect to the U.S., Canada and Mexico, shall be limited to making, having
made, using, offering for sale, marketing and selling such Adjuvant and Carrier
Protein in connection with the EGF Vaccine or any other therapeutic cancer
vaccines or therapeutic cancer products licensed by CIMAB to TARCANTA or
TARCANTA LTD. or any of their Affiliates or Sublicensees.

            2.1.3 Also notwithstanding the foregoing Section 2.1.1, CIMAB shall
have the right to grant a sublicense to the Government of Mexico or to a
government-owned instrumentality designated by the Government of Mexico to
purchase from CIMAB and provide the Licensed Products for use only by healthcare
facilities owned, controlled and managed by said government within Mexico for
public health purposes, subject to the advance approval by TARCANTA of the terms
and conditions of any such sublicense agreement, which approval shall not be
unreasonably withheld, and provided that CIMAB shall use its best efforts to
ensure that any Licensed Product provided by CIMAB or its Licensors to the
Government of Mexico shall not subsequently be shipped to any of the countries
within the Territory.

            2.1.4 Licensed Products - Other Countries. Subject to the terms and
conditions of this Agreement, CIMAB hereby grants to TARCANTA LTD. and TARCANTA
an exclusive sublicense under the Licensed Patent Rights, the Licensed Know-How,
and the Improvements to use, offer for sale, market, sell, and import the
Licensed Products in the Other Countries.

            2.1.5 Notwithstanding the foregoing Section 2.1.4, TARCANTA and
TARCANTA LTD.'s rights under this Agreement to any Adjuvant and to any Carrier
Protein with respect to any of the Other Countries, shall be limited to using,
offering for sale, marketing selling and importing such Adjuvant and Carrier
Protein in connection with the EGF Vaccine or any other therapeutic cancer
vaccines or therapeutic cancer products licensed by CIMAB to TARCANTA or
TARCANTA LTD. or any of their Affiliates or Sublicensees.

      2.2 Rights to Sublicense. TARCANTA and/or TARCANTA LTD. may sublicense
their rights to use, offer for sale, market, sell and import the Licensed
Products anywhere in the Territory to a Third Party, provided, however that (i)
TARCANTA and/or TARCANTA LTD. shall amend the Marketing Plan developed, from
time to time, by TARCANTA and/or TARCANTA LTD., to include the anticipated
sublicense arrangement, and discuss same with Committee II in accordance with
Article 4 of this Agreement (ii) CIMAB retains the exclusive right to
manufacture the Licensed Products for the Other Countries, (iii) that the
applicable terms of the Sublicense Agreement (with the exception of the portion
of the Royalties payable to CIMAB as a result of any such Sublicense Agreement
in accordance with Section 5.6 of this Agreement), shall not be less favorable
to CIMAB, in the aggregate, than the applicable terms of this Agreement, and
(iv) that no such assignment of rights to a Sublicensee hereunder shall relieve
TARCANTA or TARCANTA LTD. of their obligations to fully comply fully with the
terms and conditions of this Agreement.

      2.3 It is understood and agreed that neither TARCANTA nor TARCANTA LTD.
shall be required to undertake, and TARCANTA and TARCANTA LTD. shall not
undertake, to sell any CIMAB product unrelated to the Licensed Products. It is
understood and agreed that neither TARCANTA nor TARCANTA LTD. shall be required
to transfer, and neither TARCANTA nor TARCANTA LTD. (including their officers,
directors, employees and agents) will transfer to CIMAB, any technology or
know-how unrelated to the Licensed Products.

                                       10
<PAGE>

      2.4 Covenant To Take No Action. Subject to the terms and conditions of
this Agreement, CIMAB hereby represents, warrants and agrees that if any of
CIMAB's or its Licensors' intellectual property rights are required to make,
have made, use, offer for sale, sell ands import Licensed Products anywhere in
the Territory, neither CIMAB nor its Licensors shall take any action of any
nature whatsoever during the term of this Agreement under such intellectual
property rights which would prevent or interfere with such activities by
TARCANTA, TARCANTA LTD. and their respective Affiliates and Sublicensees.

      2.5 Non-Competition. Neither TARCANTA, TARCANTA LTD. nor their respective
Affiliates shall enter into other agreements with Third Parties to develop
and/or market any molecularly defined therapeutic cancer vaccines that include
substantially the same human epidermal growth factor receptor sequences or human
epidermal growth factor receptor ligand sequences during the Term of this
Agreement.

      2.6 Right of First Refusal. TARCANTA and TARCANTA LTD. shall have a right
of first refusal to negotiate in good faith and in a timely manner with CIMAB
for the acquisition of other EGF-based therapeutic cancer vaccines Controlled By
CIMAB during the Term of this Agreement.

                                    ARTICLE 3

                                   DEVELOPMENT

      3.1 Development Plan. In an effort to develop the most efficacious version
of the EGF Vaccine for the treatment of cancer patients in the U.S. and
throughout the Territory, the Parties agree to coordinate efforts to improve the
manufacturing, quality control and quality assurance processes and methods for
the Licensed Products, as well as to cooperate in the design and development of
all pre-clinical and clinical trial testing protocols required to obtain
Regulatory Approvals for the Licensed Products. Such further development of the
Licensed Product ("Development Work") will be conducted by the Parties pursuant
to a mutually agreed development plan to be established by the Parties within
ninety (90) days after the Effective Date (as such plan is in effect from time
to time, the "Development Plan"), in accordance with the terms and conditions
set forth below.

      3.2 Committee I. Within twenty (20) business days after the Effective
Date, TARCANTA and TARCANTA LTD. shall appoint three (3) individuals and CIMAB
shall appoint three (3) individuals to serve as its representatives on Committee
I. Each Party shall have the right to change any or all of its representatives
on Committee I upon written notice to the other Party. Committee I may appoint
individuals to serve as representatives on subcommittees to assist Committee I
with respect to any particular area required for development of the Licensed
Products under the Development Plan, including product manufacturing, process
development, qualification and validation of Manufacturing Facilities necessary
for the licensing and supply of the Licensed Product, research, quality control
and assurance, pre-clinical studies design, implementation and evaluation,
clinical protocols design, implementation and evaluation, and regulatory filings
directly related to the Licensed Products. Committee I shall:

                                       11
<PAGE>

      (a) Elaborate written plans for the transfer to TARCANTA or TARCANTA LTD.,
as designated by TARCANTA, of the Transferred Assets and all related materials
and documentation;

      (b) Prepare and approve the Development Plan, including, without
limitation, go/no-go criteria, timelines and responsibilities;

      (c) Monitor and make recommendations regarding the performance of the
Parties under the Development Plan and the conduct of the Development Work,
including, without limitation, the design of clinical trial protocols and
elaboration of quality controls;

      (d) Prepare and approve modifications to the Development Plan;

      (e) Adopt Specifications for the Licensed Products, taking into account
any Applicable Laws;

      (f) Comment and advise on each Party's plans for obtaining Regulatory
Approvals relating to the Licensed Products;

      (g) Develop adverse event reporting criteria and procedures in accordance
with Applicable Laws; and

      (h) Review any and all proposed publications or communications relating to
the Development Plan, and activities relating to any Improvement, if applicable,
and the results therefrom, and any and all proposed filings of patent
applications in connection therewith.

      3.3 Committee I shall meet not less frequently than twice per calendar
year during the Development Period, on such dates and at such times and
locations as agreed to by the Parties. In the event that the Parties'
representatives disagree upon any decision to be made with respect to the
Development Plan, the decision shall be referred to the chief executive officers
of the Parties for resolution. In the event that the chief executive officers
are not able to reach a timely resolution to the matter in question, TARCANTA
and TARCANTA LTD. will have the right to make a final decision with respect to
all activities that impact the development of the Licensed Products for eventual
commercialization within the Territory, provided, however, that if the chief
executive officers of the Parties are unable to reach timely resolution on
decisions that require a material expenditure of funds by CIMAB, the
disagreement shall be referred to the Dispute Resolution procedure detailed in
this Agreement. Members of Committee I may attend a meeting of Committee I
either in person, by telephone, or by videoconference, but not by proxy. In the
event any of CIMAB's representatives on Committee I are not granted a visa to
attend a meeting scheduled to be held in the U.S., the meeting shall be held in
a third country or, upon mutual agreement, in Cuba.

      3.4 It is understood and agreed that neither TARCANTA nor TARCANTA LTD.
shall have any obligation to transfer to CIMAB, and shall not transfer, directly
or indirectly, to CIMAB or to any other Cuban national, any technology unrelated
to the Licensed Products. It is further understood and agreed that no officer,
director, employee or agent of TARCANTA or TARCANTA LTD. (whether he or she is a
citizen or resident of the U.S. or of any other

                                       12
<PAGE>

nationality) shall engage in technology transfer activity that is unrelated to
the research and development of the Licensed Products.

      3.5 Responsibilities of the Parties.

            3.5.1 Without limitation, TARCANTA and TARCANTA LTD. and their
respective its Affiliates or Sublicensees shall use Reasonable Commercial
Efforts to:

      (a) Submit all Regulatory Applications relating to Licensed Products to
jurisdictions within the Territory,

      (b) Obtain and maintain Regulatory Approvals for the Licensed Products in
the Territory.

      (c) Perform the work to be performed by TARCANTA and TARCANTA LTD. under
the Development Plan;

      (d) Conduct clinical trials necessary to obtain Regulatory Approvals
required to market and sell Licensed Products in the Territory;

      (e) Correspond with all Government Authorities in the Territory with
respect to the Licensed Products;

      (f) Market, sell, and distribute Licensed Product in the Territory;

      (g) Manufacture Licensed Product for sale and distribution in the U.S.,
Canada and Mexico, in accordance with Applicable Law; and

      (h) Disclose and communicate Improvements to CIMAB in a timely manner.

            3.5.2 Without limitation, CIMAB shall use Reasonable Commercial
Efforts to:

      (a) Assist TARCANTA and TARCANTA LTD. in their submissions of Regulatory
Applications relating to Licensed Products to jurisdictions within the Territory

      (b) Perform the work to be performed by CIMAB under the Development Plan;

      (c) Obtain and maintain Regulatory Approvals required to manufacture
Licensed Products for supply to TARCANTA LTD., TARCANTA and their Affiliates and
Sublicensees for sale in the Other Countries under this Agreement;

      (d) Disclose and communicate the Licensed Know-How to TARCANTA and
TARCANTA LTD. in a timely manner;

      (e) Disclose and communicate Improvements to TARCANTA and TARCANTA LTD. in
a timely manner; and

      (f) Manufacture the Licensed Products for sale and distribution by
TARCANTA LTD., its Affiliates and Sublicensees in the Other Countries, in
accordance with this Agreement.

                                       13
<PAGE>

            3.5.3 As part of TARCANTA and TARCANTA LTD.'s efforts to obtain any
Regulatory Approvals in the Territory, TARCANTA and TARCANTA LTD. may, during
the Term of this Agreement, use any data generated by CIMAB, its Licensors and
Sublicensees with respect to the Licensed Products without additional cost to
TARCANTA or TARCANTA LTD.

            3.5.4 As part of CIMAB's efforts to obtain any Regulatory Approvals
outside the Territory, CIMAB may, during the Term of this Agreement, use outside
the Territory any data generated by TARCANTA and TARCANTA LTD., their Affiliates
and Sublicensees with respect to the Licensed Products without additional cost
to CIMAB.

      3.6 Cooperation Regarding Regulatory Applications. In order to expedite
the receipt of Regulatory Approvals for the Licensed Products throughout the
Territory, and to ensure that all pertinent information regarding the safety and
efficacy of the Licensed Products are timely communicated between the Parties,
each Party shall, at least sixty (60) days in advance of such filings or
submissions, inform the other Parties of its intent to file Regulatory
Applications to market and sell Licensed Products. The other Parties will
cooperate with the Party that files or otherwise submits the Regulatory
Application as such Party reasonably requests in obtaining such Regulatory
Approvals. In the event that any of the consultations or disclosures required
under this Section 3.6 conflict with a Party's confidentiality or non-disclosure
obligations to a Third Party, the Party with the conflict shall use its best
efforts to make such information available to the other Parties, including
requesting the Third Party agree to enter into a confidentiality agreement with
the other Parties. Notwithstanding anything in this Agreement to the contrary,
each Party shall provide the other Parties with complete information regarding
(i) the results of any pre-clinical testing of the Licensed Products that
indicates any potential for teratogenicity, mutagenicity or toxicity in humans;
(ii) adverse events or serious adverse events associated with the administration
of the Licensed Products to patients, (iii) all protocols, summaries of all data
and the results of statistical analysis of such data with respect to the results
of any interim or final analyses of all clinical trials performed using the
Licensed Products; and (iv) any correspondence with any Government Authority,
relating to any such Regulatory Approval, to the suspension or termination of
any clinical trials regarding the Licensed Product, or the suspension or
termination of any right to market the Licensed Products, once such approvals
have been obtained.

      3.7 Maintenance of Regulatory Approvals. The Party that owns a Regulatory
Approval shall be responsible for filing all reports required to be filed under
Applicable Laws in order to maintain any Regulatory Approvals for manufacturing,
marketing, and sale of Licensed Products in the Territory, including, without
limitation, adverse drug experience reports. Each Party shall cooperate with the
other Parties in preparing and filing all such reports and, upon the filing
Party's request, provide the filing Party with any information in the non-filing
Parties' control which the filing Party deems to be relevant to any such report.
Notwithstanding the foregoing, to the extent that any Party has or receives any
information regarding any adverse drug experience which may be related to the
use of any Licensed Product, that Party shall promptly provide the other Parties
with all such information. Promptly after the Effective Date, the Parties shall,
as part of the Development Plan, determine the procedures to be followed with
respect to reporting adverse drug experiences, such procedures to be consistent
with each of the Parties' obligations under Applicable Laws.

                                       14
<PAGE>

      3.8 Improvements. In an effort to develop the most efficacious version of
the EGF Vaccine for the treatment of cancer patients in the U.S. and throughout
the Territory, each Party shall, as permitted under License number CU-73444
issued by the U.S. Department of Treasury to CancerVax Corporation, or any
subsequent modification thereof, disclose in a timely manner to Committee I and
to the other Parties all Improvements that such Party and its Affiliates or, in
the case of CIMAB, its Licensors, invents or develops, individually, or jointly,
during the term of this Agreement. Committee I shall determine whether to
incorporate an Improvement into the Development Plan. If Committee I
incorporates an Improvement into the Development Plan, Committee I shall also
recommend whether such Improvement shall occur in lieu of or in addition to the
then-current activities underway pursuant to the Development Plan.

      3.9 Maintenance of Records. Each Party shall keep and maintain, and shall
cause its Affiliates and Sublicensees, to keep and maintain, accurate and
complete records of all Development Work and all results of any trials, studies
and other investigations conducted under this Agreement by or on behalf of such
Party for the period of time retention of such records is required under all
Applicable Laws. For so long as a Party is conducting Development Work
hereunder, such Party shall prepare and, as permitted under License number
CU-73444 issued by the U.S. Department of Treasury to CancerVax Corporation, or
any subsequent modification thereof, submit to Committee I, on a semi-annual
basis, written progress reports summarizing the current status and progress of
the Development Work. Each Party shall, as permitted under License number
CU-73444 issued by the U.S. Department of Treasury to CancerVax Corporation, or
any subsequent modifications thereof, have access, on reasonable notice, to all
records required to be kept and maintained under this Section 3.9.

      3.10 Inspection. A Party, or such Party's authorized representatives, at
the Party's own expense, may visit the facilities of the other Parties or the
other Parties' Affiliates and Sublicensees where Development Work is being
performed during normal business hours upon reasonable notice without undue
interruption to normal business operations. In the event a Party's
representatives, or any of them, are not able to obtain visas, the Party may
retain and appoint other Persons reasonably acceptably to the Party being
inspected, including without limitation nationals of the country where the
facility is located, to carry out such inspections, provided, however, that all
such Persons performing such inspections shall be bound by a non-disclosure and
confidentiality agreement to the Party being inspected. A report detailing the
results of all such inspections shall be provided to the chief executive
officers of each of the Parties promptly following any such inspection.

                                   ARTICLE 4

                                    MARKETING

      4.1 Marketing. Within 180 days after the Effective Date, TARCANTA and
TARCANTA LTD., shall prepare a preliminary plan detailing TARCANTA and TARCANTA
LTD.'s plans for marketing the Licensed Products within the Territory, including
any strategy to grant sublicenses (as such plan is in effect from time to time,
the "Marketing Plan").

      4.2 Committee II. Within ninety (90) days after the Effective Date,
TARCANTA and TARCANTA LTD. shall appoint two (2) individuals and CIMAB shall
appoint two (2)

                                       15
<PAGE>

individuals to serve as its representatives on Committee II. Each Party shall
have the right to change any or all of its representatives on Committee II upon
written notice to the other Parties. Committee II may appoint individuals to
serve as representatives on subcommittees to assist Committee II with respect to
any particular area, and members of Committee I may attend all meetings of
Committee II.

            4.2.1 Committee II shall meet not less frequently than twice per
calendar year following its organization, on such dates and at such times and
locations as agreed to by the Parties. Consistent with industry practices for a
licensing agreement of this nature, Committee II shall review the Marketing Plan
for the Licensed Products. In the event any of CIMAB's representatives are not
granted visas to attend a meeting scheduled to be held in the U.S., the meeting
shall be held in a third-country or, upon mutual agreement, in Cuba. In the
event that any Party disagrees with the Marketing Plan for the Licensed
Products, the decision shall be referred to the chief executive officers of the
Parties for resolution. In the event that the chief executive officers of the
Parties are not able to reach a timely resolution of the matter in question,
TARCANTA and TARCANTA LTD. will have the right to make a final decision with
respect to all activities that impact the marketing of the Licensed Product
within the Territory, provided, however, that if the chief executive officers of
the Parties are unable to reach a timely resolution on a decision that requires
a material expenditure of funds by CIMAB, the disagreement shall be referred to
the Dispute Resolution procedure detailed in this Agreement. Members of
Committee II may attend a meeting of Committee II either in person, by
telephone, or by videoconference, but not by proxy.

                                   ARTICLE 5

                             CONSIDERATION AND COSTS

      5.1 Development Phase Payments (Access Fees, Technology Transfer Fees and
Development Phase Milestone Fees). In consideration of CIMAB's efforts in
developing the Licensed Products prior to the Effective Date, the transfer of
the Transferred Assets to be made by CIMAB to TARCANTA or TARCANTA LTD. in
accordance herewith, and in consideration of the rights granted to TARCANTA and
TARCANTA LTD. hereunder, TARCANTA and/or TARCANTA LTD. shall be responsible for
payment of the following Access Fees, Technology Transfer Fees and Development
Phase Milestone Fees in accordance with the following terms and conditions:

            5.1.1 Access Fees. TARCANTA and/or TARCANTA LTD. shall make an
Access Fee payment to CIMAB of [***] at the beginning of each calendar quarter
following the Effective Date for a period of three (3) years following the
Effective Date, which payments shall be made 100% in Barter into the Barter
Escrow Account.

            5.1.2 Technology Transfer Fees and Development Phase Milestone Fees.
TARCANTA and TARCANTA LTD. shall, upon the satisfactory completion of the
milestones listed next to each particular milestone payment, make payments in
the total amounts specified for each such milestone in this Section 5.1.2. Once
paid, said payments are non-refundable. TARCANTA and/or TARCANTA LTD. shall make
said payments 100% in Barter into the Barter Escrow Account. In addition to any
other payment obligations that may become due under

***Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                       16
<PAGE>

the Commercialization Phase of this Agreement, TARCANTA and/or TARCANTA LTD.
shall make Barter payments in the amounts specified below to CIMAB within thirty
(30) days following the successful completion of the indicated Development Phase
event triggering TARCANTA and/or TARCANTA LTD.'s obligation to make the
respective Barter payment to CIMAB:

<TABLE>
<CAPTION>
                                                                                              MILESTONE
                                     MILESTONE                                               PAYMENT (US$)
                                     ---------                                               -------------
<S>                                                                                          <C>
                             TECHNOLOGY TRANSFER FEES

Upon the execution of this Agreement by all Parties.                                              [***]

Upon the transfer by CIMAB and acceptance by TARCANTA and/or TARCANTA LTD. of all                 [***]
documentation related to the Transferred Assets, which acceptance may not be
unreasonably withheld.

Upon the transfer by CIMAB and acceptance by TARCANTA and/or TARCANTA LTD. of                     [***]
the biological materials comprising the Transferred Assets, which transfer and
acceptance will occur when requested by TARCANTA and/or TARCANTA LTD. at any
time within one (1) year following the acceptance by TARCANTA and/or TARCANTA
LTD. of all documentation related to the Transferred Assets, which acceptance
may not be unreasonably withheld.

                         DEVELOPMENT PHASE MILESTONE FEES

Upon the approval by the FDA of the first IND Submission for a Phase 2 clinical                   [***]
trial of the EGF Vaccine.

Upon the completion by TARCANTA and/or TARCANTA LTD. of the first Phase 2 clinical                [***]
trial of the EGF Vaccine, provided that such Phase 2 clinical trial evidences, to
TARCANTA and/or TARCANTA LTD.'s reasonable satisfaction, anti-tumor effects in
advanced cancer patients, as measured by: (i) objective evidence of tumor
reduction; and/or (ii) statistically significant increase in survival times
compared with historical control of patients with the same tumor localization and
clinical stage.

Upon the completion by TARCANTA and/or TARCANTA LTD. of the first Phase 3                         [***]
(pivotal) clinical trial of the EGF Vaccine, provided that such Phase 3 clinical
trial evidences, to TARCANTA and/or TARCANTA LTD.'s reasonable satisfaction,
anti-tumor effects in advanced cancer patients, as measured by: (i) objective
evidence of tumor reduction; and/or (ii) a statistically significant increase in
survival times compared with placebo or active control patients (as agreed upon
with applicable regulatory authorities) with the same tumor localization and
clinical stage.

Upon the submission to the FDA by TARCANTA and/or TARCANTA LTD. of the first BLA                  [***]
for the EGF Vaccine.
</TABLE>

***Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                       17
<PAGE>

      5.2 Commercialization Phase Payments. TARCANTA and/or TARCANTA LTD. shall,
upon the satisfactory completion of the milestones listed next to each
particular milestone, make payments to CIMAB in the total amounts specified for
each such milestone in this Section 5.2. Once paid, said payments are
non-refundable. TARCANTA and TARCANTA LTD. shall make each of these payments
100% into the Barter Escrow Account, 50% of each such payment to be made for the
purchase of Barter Goods and 50% to be made for Payment in Cash. In addition to
any other payment obligations under the Development Phase of this Agreement,
TARCANTA and/or TARCANTA LTD. shall pay to CIMAB the following amounts within
thirty (30) days following the successful completion of the indicated event
triggering TARCANTA and/or TARCANTA LTD.'s obligation to make the respective
payment to CIMAB:

<TABLE>
<CAPTION>
                                                                                                MILESTONE
                                  MILESTONE                                                   PAYMENT (US$)
                                  ---------                                                   -------------
<S>                                                                                           <C>
Upon the approval by the FDA of the first BLA submitted by TARCANTA and/or                        [***]
TARCANTA LTD. for the EGF Vaccine.

Upon the approval by FDA of any subsequent BLA submitted by TARCANTA and/or                       [***]
TARCANTA LTD. for the EGF Vaccine.

Upon the approval by the Governmental Authority of the European Union (EU) of                     [***]
the first license application to market the EGF Vaccine submitted by TARCANTA
and/or TARCANTA LTD. in the EU.

Upon the approval by the Governmental Authority of Japan of the first license                     [***]
application to market the EGF Vaccine submitted by TARCANTA and/or TARCANTA LTD.
in Japan.

At the first time as sales by TARCANTA, TARCANTA LTD. and/or their respective                     [***]
Affiliates of the EGF Vaccine in the Territory equal a total of  [***]
</TABLE>

      5.3 Royalty Payments to CIMAB. TARCANTA and/or TARCANTA LTD. shall pay
CIMAB a royalty payment of [***] of Net Sales from sales of the Licensed
Products ("Royalty(ies)"). TARCANTA and/or TARCANTA LTD. shall pay the Royalties
owed to CIMAB for sale of the Licensed Products 100% into the Barter Escrow
Account for the purchase of Barter Goods during the Development Phase, and 100%
into the Barter Escrow Account, 50% of each such payment to be made for the
purchase of Barter Goods and 50% to be made for Payment in Cash, during the
Commercialization Phase.

      5.4 Regulatory Approval Costs. TARCANTA and/or TARCANTA LTD. shall be
responsible for all costs associated with preparing and filing Regulatory
Applications, and obtaining and maintaining Regulatory Approvals for Licensed
Products in the Territory.

      5.5 Clinical Studies Costs. TARCANTA and/or TARCANTA LTD. shall be
responsible for all costs associated with the clinical studies related to
Licensed Products that are

***Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                       18
<PAGE>

undertaken by TARCANTA, TARCANTA LTD. and their respective Affiliates and
Sublicensees in accordance with this Agreement.

      5.6 Sublicensing. If TARCANTA or TARCANTA LTD. elect to grant a sublicense
to any Third Party to market or sell Licensed Products anywhere in the Territory
pursuant to Section 2.2, TARCANTA or TARCANTA LTD., depending on which had
granted the sublicense shall, in addition to all other payments provided for in
this Agreement, pay to CIMAB within thirty (30) days of receipt:

            (a) If the sublicense is executed before TARCANTA or TARCANTA LTD.
has initiated any Phase 2 Clinical Trial with a Licensed Product in the
Territory, a [***] portion of any royalty payments, license fees, milestone
payments or other monetary payments received by TARCANTA or TARCANTA LTD. as a
result of such agreement with a Third Party, but excluding any research support,
equity or other non-monetary payments or consideration received by TARCANTA or
TARCANTA LTD. TARCANTA or TARCANTA LTD. shall make each such payment by paying
100% into the Barter Escrow Account for the purchase of Barter Goods.

            (b) If the sublicense is executed after TARCANTA or TARCANTA LTD.
has initiated any Phase 2 Clinical Trial with a Licensed Product in the
Territory, a [***] portion of any royalty payments, license fees, milestone
payments or other monetary payments received by TARCANTA or TARCANTA LTD. as a
result of such agreement with a Third Party, but excluding any research support,
equity or other non-monetary payments or consideration received by TARCANTA or
TARCANTA LTD. TARCANTA or TARCANTA LTD. shall make each such payment by paying
100% of the payment into the Barter Escrow Account for the purchase of Barter
Goods during the Development Phase, and by paying 100% into the Barter Escrow
Account, 50% of each such payment to be made for the purchase of Barter Goods
and 50% to be made for Payment in Cash, during the Commercialization Phase.

      5.7 Securing Payments Under Article 5. TARCANTA and/or TARCANTA LTD. shall
periodically transfer funds in advance into an escrow account in a reputable
bank in London or Ireland (the "Holding Account"), and CIMAB shall have no
accrued interest in such funds at the time of such transfer. At such time as the
milestone is achieved, and CIMAB shall have an interest in such funds, the funds
shall be promptly transferred into the Barter Escrow Account for the making of
Barter Payments and/or Payments in Cash to CIMAB in cash, as prescribed
hereunder. Funds from the Holding Account shall be paid into the Barter Escrow
Account, to be made as payment for the purchase of Barter Goods during the
Development Phase, and to be made 50% for the purchase of Barter Goods, and 50%
for Payments in Cash, during the Commercialization Phase.

            5.7.1 TARCANTA and TARCANTA LTD. shall appoint Citibank
International plc of London, England ("Escrowee"), which is not a Cuban
national, to act as Escrowee of the Holding Account under an escrow agreement
that obligates the Escrowee to hold such funds transferred, and to be
transferred, by TARCANTA and/or TARCANTA LTD., in the Holding Account in
accordance with the terms of said escrow agreement, and to draw upon the Holding
Account to make payments into the Barter Escrow Account upon either of the
following events:

***Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                       19
<PAGE>

(i) TARCANTA or TARCANTA LTD. notifying the Escrowee of the occurrence of the
events triggering TARCANTA or TARCANTA LTD.'s obligation to make Milestone
Payments, Access Fee or Royalty payments under this Article 5 and the amounts
thereof, or (ii) in the case where the achievement of Milestones may be
unequivocably verified by a press release disclosed in a public filing by
TARCANTA or its Affiliates under the Securities Laws of the U.S., by CIMAB
providing the Escrowee with a copy of said press release, and upon Escrowee's
confirmation of the authenticity of said press release by confirming same in the
filings for TARCANTA or its Affiliates on the U.S. Securities and Exchange
Commission's internet site. TARCANTA or TARCANTA LTD. may require immediate
return of all escrowed funds to TARCANTA and/or TARCANTA LTD. in the event that
this Agreement is terminated. TARCANTA and TARCANTA LTD. further agree to
provide a true copy of said escrow agreement to CIMAB for its review and
approval prior to the execution of same, provided that such approval shall not
be unreasonably withheld.

            5.7.2 As to each payment to be made by the Escrowee, TARCANTA and/or
TARCANTA LTD. shall advise the Escrowee as to whether the payment is required to
be made under this Agreement by payment for the purchase of Barter Goods, or by
Payment in Cash to CIMAB, and the Escrowee shall act accordingly.

            5.7.3 The Escrowee and TARCANTA or TARCANTA LTD. shall each notify
CIMAB in writing of the transfer and receipt, respectively, of transfers to the
Holding Account and the amounts thereof.

            5.7.4 TARCANTA and TARCANTA LTD. shall maintain the escrow agreement
in effect during the term of this Agreement.

            5.7.5 TARCANTA and/or TARCANTA LTD. shall be entitled to receive any
interest earned on the Holding Account as it is earned.

            5.7.6 TARCANTA and/or TARCANTA LTD. shall transfer funds to the
Holding Account according to the following schedule, provided, however, that
CIMAB shall have no right or interest in these funds until the Milestone is
achieved and the funds are transferred into the Barter Escrow Account, or paid
in cash, as provided for in this Agreement:

<TABLE>
<CAPTION>
                                                        TIMING OF HOLDING ACCOUNT
           EVENT                   PAYMENT (US$)                DEPOSIT
           -----                   -------------                -------
<S>                                 <C>                 <C>
Access Fees                            [***]            [***] within 30 days after
                                    per quarter         the signing of this Agreement;[***] after 1st
                                                        anniversary of the Effective Date; [***] after 2nd
                                                        anniversary of the Effective Date.

Upon the execution of this             [***]            Not applicable.
Agreement by all Parties.
</TABLE>

***Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                       20
<PAGE>

<TABLE>
<S>                                                       <C>          <C>
Upon the transfer by CIMAB and acceptance by              [***]        Within 30 days after the
TARCANTA and/or TARCANTA LTD. of all documentation                     Effective Date
related to the Transferred Assets, which acceptance
may not be unreasonably withheld.

Upon the transfer by CIMAB and acceptance by              [***]        Within 30 days after the
TARCANTA and/or TARCANTA LTD. of the                                   Effective Date
biological materials comprising the
Transferred Assets, which acceptance may not
be unreasonably withheld.

Upon the approval by the FDA of the first IND             [***]        Upon the filing of the first IND
Submission by TARCANTA and/or TARCANTA LTD.                            for the EGF Vaccine with FDA by
for a Phase 2 clinical trial of the EGF                                TARCANTA or TARCANTA LTD..
Vaccine.

Upon the completion by TARCANTA and/or                    [***]        Upon the initiation of the first
TARCANTA LTD. of the first Phase 2 clinical                            Phase 2 clinical trial for the
trial of the EGF Vaccine, provided that such                           EGF Vaccine by TARCANTA and/or
Phase 2 clinical trial evidences, to TARCANTA                          TARCANTA LTD..
and/or TARCANTA LTD.'s reasonable
satisfaction, anti-tumor effects in advanced
cancer patients, as measured by: (i)
objective evidence of tumor reduction; and/or
(ii) a statistically significant increase in
survival times compared with historical
control of patients with the same tumor
localization and clinical stage.

Upon the completion by TARCANTA and/or                    [***]        Upon the initiation of the first
TARCANTA LTD. of the first Phase 3 (pivotal)                           Phase 3 (pivotal) clinical trial
clinical trial of the EGF Vaccine, provided                            of the EGF Vaccine by TARCANTA
that such Phase 3 clinical trial evidences,                            and/or TARCANTA LTD..
to TARCANTA and/or TARCANTA LTD.'s reasonable
satisfaction, anti-tumor effects in advanced
cancer patients, as measured by: (i)
objective evidence of tumor reduction; and/or
(ii) statistically significant increase in
survival times compared with placebo or
active control patients (as agreed upon with
applicable regulatory authorities) with the
same tumor localization and clinical stage.
</TABLE>

***Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                       21
<PAGE>

<TABLE>
<S>                                                       <C>          <C>
Upon the submission by TARCANTA and/or                    [***]        Upon the initiation by TARCANTA
TARCANTA LTD. to the FDA of the first BLA for                          and/or TARCANTA LTD. of the
the EGF Vaccine.                                                       first Phase 3 (pivotal) clinical
                                                                       trial of the EGF Vaccine.

Upon the approval by the FDA of the first BLA             [***]        Upon filing by TARCANTA and/or
submitted by TARCANTA and/or TARCANTA LTD.                             TARCANTA LTD. of the first BLA
for the EGF Vaccine.                                                   for the EGF Vaccine with FDA

Upon the approval by FDA of any subsequent                [***]        Upon filing by TARCANTA and/or
BLA submitted by TARCANTA and/or TARCANTA                              TARCANTA LTD. of each such
LTD. for the EGF Vaccine.                                              subsequent BLA for the EGF
                                                                       Vaccine with FDA (if any).

Upon the approval by the Governmental                     [***]        Upon filing by TARCANTA and/or
Authority of the European Union (EU) of the                            TARCANTA LTD. of the first
first license application submitted by                                 market application for the EGF
TARCANTA and/or TARCANTA LTD. to market the                            Vaccine in the EU
EGF Vaccine in the EU.

Upon the approval by the Governmental                     [***]        Upon filing by TARCANTA or
Authority of Japan of the first license                                TARCANTA LTD. of the first
application to market the EGF Vaccine                                  market application for the EGF
submitted by TARCANTA and/or TARCANTA LTD. in                          Vaccine in Japan
Japan.

At such time as sales by TARCANTA, TARCANTA               [***]        Not applicable.
LTD. and their Affiliates of the EGF Vaccine
in the Territory equal a total of [***].

Royalties for Other Countries.                            [***]        As marketing approval is
                                                                       received by TARCANTA and/or
                                                                       TARCANTA LTD. for each of the
                                                                       Other Countries, a balance of
                                                                       approximately 3 months estimated
                                                                       Royalties shall be maintained in
                                                                       the Escrow Account.
</TABLE>

            5.7.7 Notwithstanding any other provision of this Agreement to the
contrary, if, CIMAB does not receive timely payment of both the initial [***]
Access Fee payment for the first quarter following the Effective Date and the
initial [***] Technology Transfer Fee payable within thirty (30) days following
the execution of this Agreement by all Parties (both of which are payable 100%
for the purchase of Barter Goods), CIMAB may terminate this

***Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                       22
<PAGE>

Agreement. TARCANTA and TARCANTA LTD.'s failure to make any of the other
deposits in the amounts and at the times required by the schedule set out in
Section 5.7.5 shall be subject to CIMAB's rights and remedies as set forth in
Section 12.3.

            5.7.8 TARCANTA and TARCANTA LTD.'s transfer of funds to the Holding
Account as required by this Agreement or otherwise shall not constitute payment
to CIMAB or discharge of any of TARCANTA and/or TARCANTA LTD.'s obligations
under this Agreement to make payment to CIMAB (whether by payment for Barter
Goods or for Payment in Cash). The failure of the Escrowee to make payments for
Barter Goods or to CIMAB for Payments in Cash, shall not constitute any excuse
for TARCANTA or TARCANTA LTD.'s failure to make the payments required by this
Agreement.

      5.8 Taxes and Withholding. All payments under this Agreement will be made
without any deduction or withholding for or on account of any tax unless such
deduction or withholding is required by Applicable Laws. If the paying Party is
so required to deduct or withhold, such Party will (i) promptly notify the other
Party of such requirement, (ii) pay to the relevant authorities the full amount
required to be deducted or withheld promptly upon the earlier of determining
that such deduction or withholding is required or receiving notice that such
amount has been assessed against the other Party, (iii) promptly forward to the
other Party an official receipt (or certified copy) or other documentation
reasonably acceptable to the other Party evidencing such payment to such
authorities.

      5.9 Currency. All payments and calculations hereunder to CIMAB shall be in
Euros, in the case of Payment in Cash, in an amount equivalent to the amount due
in U.S. dollars at the exchange rate offered by the Bank of America on the date
upon which payment is due, provided, however, that in the event that CIMAB is
prevented from receiving payment in Euros by Applicable Laws, CIMAB may, during
the period when such laws are in effect, designate that all subsequent payments
shall be in another currency designated by CIMAB, provided further, however,
that such other currency shall not be any currency of Cuba. As applicable, Net
Sales and expenses incurred by either Party shall be translated into U.S.
dollars in accordance with TARCANTA's customary and usual translation
procedures, consistently applied., provided, however, that Net Sales received by
TARCANTA or TARCANTA LTD. in Euros shall not be translated into U.S. dollars,
but shall be paid as a percentage of Euros received in accordance with the terms
of this Agreement.

      5.10 Payments

            5.10.1 Payments in Cash. TARCANTA LTD. shall direct the Escrowee to
make the Payments in Cash from the Barter Escrow Account to CIMAB by wire
transfer of immediately available funds to an account at a bank in a Third
Country reasonably designated by CIMAB from time to time in writing. TARCANTA
LTD. shall so direct the Escrowee promptly upon the Barter Escrow Account
receiving funds to be used for Payments in Cash.

            5.10.2 If any sum due and payable under this Agreement shall not
have been paid or, as applicable, deposited in the Holding Account or the Barter
Escrow Account, on or before the applicable due date, compound interest shall
accrue on the unpaid amount at the rate of one percent (1%) per month or, if
less, the maximum rate permitted under applicable law from the

                                       23
<PAGE>

payment due date, until the actual date of payment without prejudice to any
other claim or remedy available to the non-paying Party.

            5.10.3 Payments into Barter Escrow Account. Where this Agreement
provides for Barter Payments, TARCANTA and/or TARCANTA LTD. shall be responsible
for all amounts due for payment into the Barter Escrow Account when due under
this Agreement, which shall be accomplished by either direct payment by TARCANTA
and/or TARCANTA LTD. into the Barter Escrow Account or by payment of the amount
due into the Barter Escrow Account by the Holding Account escrowee. The funds in
the Barter Escrow Account shall only be used to carry out CIMAB's purchase of
Barter Goods from U.S. sources or to make Payment in Cash to CIMAB, in
accordance with the terms of this Agreement. Whenever CIMAB intends to purchase
Barter Goods using the funds deposited in the Barter Escrow Account, CIMAB shall
provide the escrow agent at the bank at which the Barter Escrow Account is
maintained and TARCANTA and TARCANTA LTD. with a purchase order to a Third Party
supplier of Barter Goods that identifies the Barter Goods being purchased. Upon
confirmation by TARCANTA or TARCANTA LTD. to the bank and its escrow agent that
the goods listed on the purchase order conform to the definition of Barter
Goods, and upon further confirmation by the bank and its escrow agent that CIMAB
has declared on such purchase order that said Barter Goods are to be used for
public health purposes of the Cuban people, the bank and its escrow agent shall
pay the Third Party supplier in accordance with its invoice for the sale of the
items identified on the purchase order by transfer of funds, or honoring the
presentation of drafts, to or at the order of the Third Party supplier. Prior to
the initial payments into the Barter Account, TARCANTA or TARCANTA LTD. shall
determine that the bank at which the Barter Account is maintained has obligated
itself to act in accordance with the foregoing procedures concerning use of the
funds in the Barter Escrow Account, and shall be entitled to determine from time
to time that this obligation remains in effect. The Barter Escrow Account shall
be opened and maintained at Citibank International, plc, London, England, or
such other bank as may be mutually agreeable to the Parties, and TARCANTA and/or
TARCANTA LTD. will pay the fees required to establish and maintain the Barter
Escrow Account, including fees payable for the services of the escrow agent.
CIMAB will be entitled to all interest on the funds deposited into the Barter
Escrow Account, which interest shall also be payable in Barter Goods. CIMAB
shall be entitled to request that TARCANTA or TARCANTA LTD. transfer the Barter
Escrow Account to another first class bank that is not a Cuban national,
provided, however, that (a) such bank is a financial institution that is a U.S.
bank, a foreign subsidiary or branch of a U.S. bank, or a bank that is owned or
controlled by a U.S. bank, (b) TARCANTA or TARCANTA LTD. determines that the
successor bank has obligated itself to operate the account as set forth herein,
and (c) such transfer shall not cause TARCANTA or TARCANTA LTD. to pay
additional taxes in connection with the transfer of funds to, or the maintenance
of, such account. Use of the funds in the Barter Escrow Account for the purchase
of Barter Goods under this Section 5.10.3 shall include the purchase of Barter
Goods, as well as for shipping and insurance costs for delivery of said goods to
CIMAB in Cuba. The escrow agent of the bank shall be appointed by the bank with
the consent of CIMAB, TARCANTA and TARCANTA LTD., and shall be a national of any
country in the European Union.

            5.10.4 Immediately upon U.S. law, and/or the U.S. Treasury
Department's Office of Foreign Assets Control, permitting payments required by
this Agreement to be made into the Barter Escrow Account to be made instead in
Cash to CIMAB, all payments required by this

                                       24
<PAGE>

Agreement to be made into the Barter Escrow Account shall instead be made in
Cash directly to CIMAB. Immediately upon U.S. law, or the U.S. Treasury
Department's Office of Foreign Assets Control, removing any restrictions on
Cuban nationals engaging in the transactions that, under the express terms of
this Agreement, Cuban nationals are disqualified from undertaking, such
disqualifications shall be deemed to have been eliminated from this Agreement.

            5.10.5 In the event that U.S. law, or the decisions or orders of
U.S. government authorities, prevents CIMAB from actually receiving any of the
payments required to be paid to CIMAB under this Agreement, or prevents payment
into the Holding Account or the Barter Escrow Account, as required under this
Agreement, including without limitation payments required under this Article 5,
Article 6 and Article 7, or prevents the purchase of Bartered Goods by use of
funds in the Barter Escrow Account, or in the event of any change in United
States law or administrative practice that makes it impermissible for Cuban
nationals, or CIMAB, to purchase and import into Cuba Bartered Goods (which
circumstances hereafter in this Section 5.10.4 are described for convenience as
the "Event") CIMAB may, in its reasonable discretion, exercise the following
options:

            (a) Upon occurrence of the Event, CIMAB may immediately suspend
fulfillment of any orders for the Licensed Products under this Agreement for the
Territory until such time as it is able to receive all payments required by this
Agreement. If CIMAB exercises this option, TARCANTA and TARCANTA LTD. will have
the right to manufacture additional quantities of Licensed Product to make up
for any shortfall.

            (b) If, after six (6) months of its occurrence, the Event continues
in effect, CIMAB shall be entitled to Royalties on account of sales of the
Licensed Product in the Other Countries at the rate of [***] of Net Sales.

            (c) In addition, between six (6) months and one (1) year following
the occurrence of the Event, TARCANTA or TARCANTA LTD. may transfer its rights
and obligations under this Agreement with respect to the Other Countries and
Mexico to a Third Party to be designated by TARCANTA or TARCANTA LTD. and
approved by CIMAB, such approval will be subject to the same provisions set
forth in Section 2.2.

            (d) In addition, if, after one (1) year of the occurrence of the
Event, the Event prevents actual receipt outside the U.S. in the bank in a Third
Country designated pursuant to Section 5.10.1, or to the Barter Escrow Account,
as applicable, of the payments of Royalties for Licensed Product from the Other
Countries, or prevents the purchase of Bartered Goods by use of funds in the
Barter Escrow Account, or prevents Cuban nationals or CIMAB from purchasing and
importing into Cuba Bartered Goods, (i) TARCANTA and TARCANTA LTD. shall retain
all rights and obligations granted under this Agreement with respect to the U.S.
and Canada, and (ii) CIMAB may terminate all licenses to TARCANTA LTD. and
TARCANTA under the Licensed Patent Rights, the Licensed Know-How, and the
Improvements to make, have made, use, offer for sale, market, sell, and import
the Licensed Product in the Other Countries and Mexico, and all other rights
under this Agreement associated with the using, offering for sale, marketing,
selling and importing in the Other Countries and Mexico granted by, under or
pursuant to this Agreement. Upon such termination of rights with respect to the
Other Countries and Mexico, all Regulatory Approvals and Regulatory Applications
for the Other Countries and

***Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                       25
<PAGE>

Mexico shall be transferred, and shall be deemed transferred to, CIMAB, as well
as all data comprising preclinical and clinical studies performed by TARCANTA,
TARCANTA LTD. or their Affiliates in the Other Countries, to the extent that the
disclosure of any clinical study information is permitted under Applicable Laws
protecting the privacy of patients participating in such studies and to the
extent permitted under License number CU-73444 issued by the U.S. Department of
Treasury to CancerVax Corporation, or any subsequent modification thereof.
TARCANTA and TARCANTA LTD. shall provide all documents, and all cooperation, as
may be necessary to effectuate said transfers in a period of 3 months from the
date of receiving the Notice of Termination as prescribed below. A Notice of
Termination pursuant to this paragraph, issued by CIMAB, shall be deemed full
and sufficient proof of termination by all Third Parties, who shall be entitled
fully to rely upon same.

            (e) CIMAB's termination of the license granted to TARCANTA LTD. and
TARCANTA with respect to the Other Countries and Mexico shall constitute
termination of any sublicense granted by TARCANTA LTD. or TARCANTA with respect
to the Other Countries and Mexico pursuant to the terminating license.

            5.10.6 In the event that the Event abates, any modifications in the
Royalty rates pursuant to Section 5.10.5 and the options exercised by CIMAB in
accordance with Section 5.10.5, if any, shall remain in effect until the
following condition has been satisfied: that CIMAB has received an amount equal
to the amount it would have received had the Event not occurred, together with
(a) compound interest thereon at the rate of 1% per month, or such lesser amount
as required under Applicable Law, and upon satisfaction of the aforesaid
condition, at TARCANTA LTD. or TARCANTA's option, the status quo ante shall be
restored, and this Agreement shall continue in effect according to its terms
until expiration of its term as stated in Section 12.1.1 without any tolling of
the Term or its earlier termination with respect to the rights of TARCANTA LTD.
and TARCANTA in the Other Countries and Mexico pursuant to this Agreement.
TARCANTA LTD. and TARCANTA shall exercise their option to restore the status quo
ante within 90 days of the "condition" specified in the first sentence of this
Section 5.10.6 being satisfied. The Parties shall agree when the condition set
forth in the first sentence of this Section 5.10.6 shall have been satisfied;
pending the resolution of any dispute, pursuant to the Dispute Resolution
provisions or agreement, the condition set forth in the first sentence of this
paragraph shall be deemed not to have been satisfied.

            5.10.7 In the event that any order of any U.S. court of competent
jurisdiction (including without limitation, its federal and state courts
asserting such jurisdiction) issued on account of claims, judgments or disputes
that do not arise out of CIMAB's own activities, prevents CIMAB from receiving
Payments in Cash, or prevents payments into the Holding Account or payments into
the Barter Escrow Account under this Agreement, or prevents the purchase of
Barter Goods by use of the funds in the Barter Escrow Account, or prevents CIMAB
from purchasing and importing into Cuba Barter Goods, which circumstances
hereafter in this Section 5.10.7 are described for convenience as the "Event",
then, CIMAB may, in its reasonable discretion, exercise the following options:

            (a) Upon the occurrence of the Event, CIMAB may immediately suspend
fulfillment of any of its obligations under this Agreement to supply the
Licensed Products for the Other Countries with respect to any jurisdiction in
which the aforesaid Court order is enforceable

                                       26
<PAGE>

(hereafter, "affected jurisdiction"). If CIMAB exercises this option, TARCANTA
and TARCANTA LTD. will have the right to manufacture additional quantities of
Licensed Products to make up for any shortfalls.

            (b) During the pendency of any litigation with respect to the
aforesaid court order, CIMAB shall be entitled to a royalty of [***] of Net
Sales from sales of the Licensed Products in the Other Countries except that
this subparagraph (b) shall be inapplicable to Royalties whose payment to CIMAB
is prevented by the aforesaid Court order. In the event that the litigation
results in the withdrawal or termination of any such Court order, and any funds
that had not been paid to CIMAB as a result of said Court order or decision are
paid to CIMAB, TARCANTA and/or TARCANTA LTD. shall be entitled to recover the
additional amount paid to CIMAB under this subparagraph, which recovery shall be
taken first from any past due payments released to CIMAB upon termination of the
Court order and, if not sufficient, by reduction of the Royalties payable to
CIMAB by twenty-five percent (25%), until the amount has been recovered.

            (c) If litigation, if any, is unsuccessful in terminating the Court
order, then, upon the final decision in such litigation:

                  (i) CIMAB shall be entitled to a royalty of [***] of Net Sales
from sales of the Licensed Product in the Other Countries except that this
subparagraph (c)(i) shall be inapplicable to Royalties whose payment to CIMAB is
prevented by the aforesaid Court order;

                  (ii) TARCANTA or TARCANTA LTD. may transfer the rights and
obligations under this Agreement in the Other Countries in affected jurisdiction
to a Third Party to be designated by TARCANTA or TARCANTA LTD. and approved by
CIMAB, with such approval subject to the same provisions set forth in Section
2.2.

                  (iii) In addition, if, after 1 year of its occurrence, the
Event prevents actual receipt of Payments in Cash outside of the U.S. in the
bank in a Third Country designated pursuant to Section 5.10.1, or payment into
the Holding Account or payment into the Barter Escrow Account, of the payment of
Royalties with respect to the Other Countries due on account of sales of the
Licensed Products in any jurisdiction affected thereby, or prevents the purchase
of Barter Goods by use of the funds in the Barter Escrow Account, or prevents
CIMAB from purchasing and importing in to Cuba Bartered Goods, TARCANTA and
TARCANTA LTD. shall retain all rights and obligations granted under this
Agreement with respect to the U.S. and Canada, but CIMAB may terminate the
license under the Licensed Patent Rights, the Licensed Know-How, and the
Improvements to use, offer for sale, market, sell, and import the Licensed
Product in the Other Countries and Mexico in the affected jurisdiction, granted
by, under or pursuant to this Agreement. Upon such termination, all Regulatory
Approvals and Regulatory Applications in the Other Countries and Mexico in the
affected jurisdiction shall be transferred, and shall be deemed transferred to,
CIMAB. TARCANTA and TARCANTA LTD. shall provide all documents, and all
cooperation, as may be necessary to effectuate said transfers in a period of 3
months from the date of receiving the Notice of Termination as prescribed below.
A Notice of Termination pursuant to this paragraph, issued by CIMAB, shall be
deemed full and sufficient proof of termination by all Third Parties, who shall
be entitled fully to rely upon same.

***Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                       27
<PAGE>

                  (iv) CIMAB's termination of the license granted to TARCANTA
LTD. and TARCANTA with respect to the Other Countries and Mexico shall
constitute termination of any sublicense granted by TARCANTA and TARCANTA LTD.
with respect to the Other Countries and Mexico pursuant to the terminating
license.

            (d) In the event that, after the unsuccessful conclusion of the
aforesaid litigation, the Court order is vacated, extinguished, or expires, by
reason of satisfaction of the underlying judgment or claim or otherwise, any
modifications in Royalty rates pursuant to 5.10.6, and the options exercised by
CIMAB in accordance with 5.10.6, if any, shall remain in effect until CIMAB has
received an amount equal to the amount it would have received but for said Court
order (the "condition"). In the event the aforesaid condition is satisfied, at
TARCANTA LTD. or TARCANTA LTD.'s option, the status quo ante shall be restored,
and this Agreement shall continue in effect according to its terms until
expiration of its Term as stated in Section 12.1.1 without any tolling or its
earlier termination, pursuant to this Agreement. TARCANTA LTD. and TARCANTA
shall exercise their option to restore the status quo ante within 90 days of the
"condition" specified in the first sentence of this paragraph being satisfied.
The Parties shall agree when the condition set forth in the first sentence of
this paragraph shall have been satisfied; pending the resolution of any dispute,
pursuant to the Dispute Resolution procedures, or otherwise the condition shall
be deemed not to have been satisfied.

            5.10.8 Notwithstanding the provisions of Section 5.10.7, in the
event that any Party, in good faith, believes that the Court order referenced in
Section 5.10.7 was issued by a Court lacking competent jurisdiction, both
parties will commit to join in litigation to overturn the court order as quickly
as possible and, CIMAB shall not be entitled to implement any of its' remedies
under Section 5.10.7 (b) and 5.10.7(c) for a period of six (6) months from the
date on which the Court order was issued, and all Parties agree to join in
litigation and use their best efforts to seek a withdrawal of the Court order.

            5.10.9 In the event that any order of any court of the U.S. that
lacks competent jurisdiction, including without limitation, any U.S. federal and
state courts, issued on account of claims, judgments or disputes that do not
arise out of CIMAB's own activities, prevents actual receipt of Payments in Cash
outside of the U.S. in a bank in a Third Country designated pursuant to Section
5.10.1, or prevents payment into the Holding Account or the Barter Escrow
Account, required under this Agreement, or prevents the purchase of Barter Goods
by use of the funds in the Barter Escrow Account, or prevents CIMAB from
purchasing and importing into Cuba Barter Goods, then the Parties agree to use
Reasonable Commercial Efforts to secure the elimination of any such order as
quickly as possible.

      5.11 Books of Account. TARCANTA and TARCANTA LTD. shall keep and maintain
accurate and complete records and books of account in sufficient detail and form
so as to enable verification of the payments due to CIMAB under this Agreement.

      5.12 Audit Rights. TARCANTA and TARCANTA LTD. shall maintain records and
books of account relating to the Licensed Product for a period of not less than
seven (7) years following the year to which the records pertain. TARCANTA and
TARCANTA LTD. shall permit such records and books of account to be examined only
by independent certified public accountants selected by CIMAB who are qualified
in the application of U.S. generally accepted

                                       28
<PAGE>

accounting principles ("GAAP"), including without limitation independent
certified public accountants who are Cuban nationals. No more than one (1) such
audit may be conducted by or on behalf of CIMAB in any calendar year. All audits
shall be conducted during TARCANTA and TARCANTA LTD.'s normal business hours and
only after reasonable written prior notice. Without limitation, thirty (30) days
prior written notice shall be deemed reasonable notice. If the audit shows that
TARCANTA or TARCANTA LTD. owes a payment (including reimbursement of any
previously overpaid amount) to CIMAB under this Agreement, TARCANTA or TARCANTA
LTD., as applicable, shall promptly make such payment. The cost of such
examination shall be borne by CIMAB, unless such audit reveals that TARCANTA or
TARCANTA LTD. underpaid CIMAB by more than ten percent (10%), then TARCANTA or
TARCANTA LTD. shall bear the cost of such audit.

      5.13 Reports. Beginning after TARCANTA or TARCANTA LTD. has received a
Regulatory Approval to market the Licensed Products in the Territory, TARCANTA
and TARCANTA LTD. shall provide CIMAB with a report detailing all sales
activities for the Licensed Products in the Territory during the preceding
calendar quarter. Such reports shall be provided to CIMAB within forty-five (45)
days following the end of each calendar quarter.

                                   ARTICLE 6

                   SUPPLY COMMITMENTS AND MANUFACTURING RIGHTS

        6.1      Supply Commitment

            6.1.1 Supply Commitment. CIMAB shall, at no additional cost to
TARCANTA or TARCANTA LTD., manufacture and supply all quantities of the Licensed
Products required by TARCANTA and TARCANTA LTD. for: (a) Phase 2 clinical trials
for all countries within the Territory; and (b) Phase 3 clinical trials in the
Other Countries. In order to ensure an adequate supply of Licensed Products to
complete the necessary clinical testing and, following the receipt of Regulatory
Approvals, for the uninterrupted supply of the Licensed Products to treat
patients in the U.S. and throughout the Territory, CIMAB agrees to manufacture
and supply to TARCANTA and/or TARCANTA LTD. all quantities of the Licensed
Products required by TARCANTA LTD., TARCANTA and their Affiliates and
Sublicensees for commercial sale in the Other Countries, at a cost equal to the
Transfer Price (as such term is defined below).

            6.1.2 Transfer Price. The Transfer Price for the Licensed Products
shall be [***] of any Net Sales, without deduction of the Cost of Goods Sold,
from the sale of the Licensed Products supplied by CIMAB. Should any purchases
of Licensed Products from CIMAB occur during the Development Phase, payment will
be 100% in Barter, whereas any such purchases during the Commercialization Phase
will be 50% in Barter and 50% in Payment in Cash. Royalties owed to CIMAB for
sale by TARCANTA and/or TARCANTA LTD. of Licensed Products during the
Development Phase shall be paid 100% in Barter.

            6.1.3 Failure to Supply by CIMAB. In the event that CIMAB is unable
to support TARCANTA LTD. or TARCANTA's quantity requirements for the Licensed
Products for the Other Countries, or in the event that CIMAB fails to
manufacture the Licensed Products in compliance with the Applicable Laws,
TARCANTA and TARCANTA LTD. shall have the

***Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                       29
<PAGE>

right to manufacture the Licensed Products to meet TARCANTA and TARCANTA LTD.'s
its quantity requirements or requirements for Licensed Products in compliance
with Applicable Laws, but only to the extent that CIMAB is unable to satisfy
TARCANTA LTD. and TARCANTA's quantity requirements or Applicable Law
requirements for the Other Countries and provided that TARCANTA and TARCANTA
LTD. may only supply any Adjuvants or Carrier Proteins for use in connection
with the EGF Vaccine or other therapeutic cancer vaccines licensed from CIMAB.
Once CIMAB demonstrates to TARCANTA and TARCANTA LTD.'s reasonable satisfaction
that it is able to fully support the quantity requirements and to fully comply
with the Applicable Laws, TARCANTA LTD. and TARCANTA shall increase their
purchases of the Licensed Products for the Other Countries to the extent of
CIMAB's ability to supply the Licensed Products. To the extent that TARCANTA or
TARCANTA LTD. supplies the Licensed Products for sale in the Other Countries
because CIMAB has not been able to manufacture sufficient quantities, or because
CIMAB has not complied with the Applicable Laws, the Royalty payable to CIMAB on
such Licensed Products shall be increased from [***] to [***] of Net Sales from
the sale of such Licensed Products in the Other Countries.

            6.1.4 Failure to Supply by TARCANTA or TARCANTA LTD. In the event
that TARCANTA or TARCANTA LTD. is unable to support quantity requirements for
the Licensed Product for the U.S., Canada and Mexico, or in the event that
TARCANTA or TARCANTA LTD. fails to manufacture the Licensed Product in
compliance with the Applicable Laws, and provided that CIMAB and its Contract
Manufacturer, if any, has been approved as a supplier under any BLA or other
Regulatory Approval relevant to such countries, CIMAB or its Contract
Manufacturer shall have the right to manufacture and TARCANTA and TARCANTA LTD.
shall have the obligation to purchase from CIMAB or its Contract Manufacturer,
the Licensed Products to meet quantity requirements or Applicable Law
requirements, but only to the extent that TARCANTA or TARCANTA LTD. is unable to
satisfy quantity requirements or Applicable Law requirements. Notwithstanding
the foregoing, neither TARCANTA nor TARCANTA LTD. shall be under any obligation
to bear any costs whatsoever associated with CIMAB or its Contract Manufacturer
becoming an approved supplier under any BLA or other Regulatory Approval
relevant to the U.S., Canada or Mexico. Once TARCANTA OR TARCANTA LTD.
demonstrates that it is able to fully support the quantity requirements and to
fully comply with the Applicable Laws, TARCANTA or TARCANTA LTD. shall resume
supplying the Licensed Products to U.S., Canada and Mexico.

      6.2 Transfer of Transferred Assets and Licensed Know-How. CIMAB shall
transfer to TARCANTA or TARCANTA LTD. all rights, title and interest in and to
all of the Transferred Assets and Licensed Know-How owned or Controlled By CIMAB
that may be required by TARCANTA and TARCANTA LTD. to manufacture the Licensed
Products in accordance with the terms of this Agreement. All documentation and
information comprising the Transferred Assets and Licensed Know-How shall be
provided to TARCANTA or TARCANTA LTD. according to the technology transfer
protocol agreed upon by the Parties as part of the Development Plan. If
additional documentation related to the testing, manufacture or development of
the Licensed Products is developed by CIMAB or its Licensors during the term of
the Agreement, such additional information shall also be transferred to
TARCANTA, TARCANTA LTD. and their Affiliates in a timely manner.

***Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                       30
<PAGE>

            6.2.1 Transfer of Transferred Assets and Licensed Know-How Related
to the Adjuvants. [***]

      6.3 Engagement of Contract Manufacturers. TARCANTA and TARCANTA LTD., on
the one hand, and CIMAB, on the other hand, each for its own account, may
contract with one or more Contract Manufacturers to Finish, manufacture and
supply Licensed Products to TARCANTA and TARCANTA LTD. and their Sublicensees,
if any, in accordance with the terms of this Agreement, provided, however, that
no assignment of rights to a Contract Manufacturer hereunder shall relieve
CIMAB, TARCANTA or TARCANTA LTD. of complying fully with their obligations under
this Agreement. TARCANTA, TARCANTA LTD. and CIMAB agree that all agreements
engaging a Contract Manufacturer shall provide that the Contract Manufacturer
will comply with (i) all Applicable Laws and all specifications and
manufacturing and quality control procedures for the manufacture and quality
assurance of the Licensed Products reasonably established by TARCANTA and
TARCANTA LTD., and (ii) the Confidentiality provisions of this Agreement.
Notwithstanding the foregoing, neither TARCANTA nor TARCANTA LTD. shall be under
any obligation to bear any costs whatsoever associated with a Contract
Manufacturer contracted by CIMAB becoming an approved supplier under any BLA or
other Regulatory Approval relevant to the Territory.

***Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                       31
<PAGE>

                                   ARTICLE 7

                              PURCHASING PROCEDURES

      7.1 Purchasing Procedures

            7.1.1 In order to afford CIMAB time to produce sufficient quantities
of the Licensed Product as required to treat cancer patients in the Other
Countries, TARCANTA, TARCANTA LTD. or Sublicensee, if any, (hereafter.
"Importer" in this Article 7) shall, at least one hundred eighty (180) days
prior to the planned first commercial sale in the Other Countries, and quarterly
thereafter, provide CIMAB with a twelve (12) month rolling forecast of its
projected orders for Licensed Products in the Other Countries. The Importer will
guarantee the purchase of seventy-five percent (75%) of the quantity specified
for the first ninety (90) days of each such forecast (the "Firm Commitment
Quantities").

            7.1.2 CIMAB or its Contract Manufacturer, if any, shall notify the
Importer of its acceptance or rejection of a Purchase Order within ten (10)
business days after CIMAB's receipt of the Purchase Order. CIMAB shall promptly
notify the Importer in writing if CIMAB believes, or has reason to believe, that
CIMAB will be unable to supply the Importer with at least the Firm Commitment
Quantities of Licensed Products. CIMAB shall use Reasonable Commercial Efforts
to manufacture one hundred twenty-five percent (125%) of the Importer's rolling
six (6) month forecasted amounts.

            7.1.3 Purchase Order. The Importer shall submit to CIMAB purchase
orders for the Licensed Product ("Purchase Orders"), consistent with the
Importer's forecasts, at least forty-five (45) days before the Delivery Date set
forth in the forecast. Each Purchase Order shall specify:

                  (a) the Licensed Products to be delivered and its planned use,
i.e., whether the Importer intends to use the Licensed Products for clinical
trials or commercial sale;

                  (b) the quantity of each Licensed Product to be delivered,
whether the Licensed Products being ordered shall be provided in bulk packaging
or final, end-user packaging configuration, and the specific labeling required
to be affixed to the Licensed Product;

                  (c) the Importer's required date of delivery of such Licensed
Products (the "Delivery Date"), provided, however, that in no event shall the
Delivery Date be sooner than thirty (30) days after CIMAB receives the Purchase
Order;

                  (d) the location to which such Licensed Products are to be
delivered (the "Delivery Location(s)"); and

                  (e) the name, address and phone number of the person to
receive the notice of receipt.

      7.2 Payment, Delivery and Title. CIMAB shall deliver the Licensed Products
to the Importer at the Delivery Location in the quantities and at the Delivery
Dates set forth in any Purchase Order and the acceptance notice related thereto.
Subject to the provisions of Section

                                       32
<PAGE>

7.6, all Licensed Product delivered to the Importer shall be non-returnable.
Title and risk of loss in the Licensed Products shall transfer to the Importer
upon delivery of the Licensed Products to a carrier outside of Cuba specified by
the Importer for delivery to the Delivery Location. Payment by the Importer to
CIMAB for the Licensed Products shall be due net 30 days following delivery to
the Delivery Location, and shall be payable 100% in Barter during the
Development Phase, and 50% in Barter and 50% in Payment in Cash during the
Commercialization Phase.

      7.3 Packaging. CIMAB shall deliver the Licensed Product to the Importer in
packaging specified by the Importer.

      7.4 Shipping by CIMAB. At the instruction of the Importer as set forth in
a Purchase Order, CIMAB shall arrange, in coordination with the Importer, for
shipment to the Delivery Location, and all expenses related thereto shall be
borne by the Importer. CIMAB shall deliver monthly invoices to Importer for the
costs and fees in connection with the shipment of the Licensed Products to
Importer.

      7.5 Standard Terms. It is understood that, for convenience, use is
permitted of standard pre-printed forms of the Purchase Orders, acknowledgement
or acceptances, or invoices in the performance of obligations hereunder;
provided that any terms, conditions or provisions in such pre-printed forms
which are inconsistent with or which modify or supplement this Agreement shall
be null and void.

      7.6 Order Non-Conformance.

            7.6.1 In the event the Importer disputes the quantity of a Licensed
Product in any shipment of any Licensed Product supplied to the Importer
pursuant to this Agreement, Importer shall provide notice to CIMAB within sixty
(60) days after receipt of such shipment. In the case of any non-conformity that
results from delivery of less than the ordered quantity of Licensed Product,
CIMAB shall promptly deliver the undelivered portion of the ordered quantity of
such Licensed Product to the Importer. In such case, the Importer shall pay for
the quantity actually received. In the case of any non-conformity that results
from delivery of more than the ordered quantity of any Licensed Product, the
Importer may elect to (i) return to CIMAB any Licensed Product in excess of the
quantity of such Licensed Product ordered, or (ii) accept any Licensed Product
in excess of the quantity ordered as an offset against any future order(s) of
such Licensed Product, in which case the Importer shall pay for the quantity
actually received and accepted.

            7.6.2 In the event that the Importer disputes any invoice due to
non-conformance of any Licensed Product supplied by CIMAB with the
Specifications for such Licensed Product, such dispute shall be resolved in
accordance with the Dispute Resolution procedures. Pending resolution of such
dispute, the Importer shall pay any undisputed amount of such invoice. Upon
resolution of any such dispute in favor of CIMAB, the Importer shall pay the
unpaid disputed amount properly due within twenty (20) business days of such
resolution, together with, if applicable, interest on such amount from the date
payment would otherwise have been due at the rate of 1% per month, or such
lesser amount as required under Applicable Law. Upon resolution of any such
dispute in favor of the Importer, CIMAB shall refund any excess amounts paid by
the Importer to the Importer within thirty (30) days of such resolution.

                                       33
<PAGE>

      7.7 Records. CIMAB shall maintain, and shall cause its Affiliates and
agents to maintain, all records necessary to comply with all Applicable Laws
relating to the manufacture, filling, packaging, testing, storage and shipment
of Licensed Product. All such records shall be maintained for such period as may
be required by Applicable Laws, and shall be available for inspection upon
reasonable advance notice by TARCANTA, TARCANTA LTD., their Affiliates and
Sublicensees.

      7.8 Quality Agreement. Within ninety (90) days following the Effective
Date, the Parties agree to enter in to a Quality Agreement substantially in the
form attached hereto as Exhibit C.

                                   ARTICLE 8

                      PRODUCT WARRANTY AND NON-CONFORMANCE

      8.1 Licensed Product Warranty by CIMAB. CIMAB represents and warrants
that, upon delivery of any Licensed Product to the Delivery Location, such
Licensed Product will have been manufactured, filled, packaged, stored and
shipped materially in accordance with the Specifications for such Licensed
Product, applicable Regulatory Approvals and all Applicable Laws. CIMAB shall be
responsible for obtaining and maintaining all necessary licenses, permits or
approvals required by Applicable Laws in connection with the manufacture,
filling, package, testing, storage, and shipment of each such Licensed Product,
including, without limitation, permits related to manufacturing facilities.
TARCANTA LTD. and TARCANTA shall be responsible for obtaining all necessary
import licenses, permits or approvals required by Applicable Laws, other than
Cuban law, for the importation of each such Licensed Product into the Other
Countries as requested by TARCANTA LTD. and TARCANTA.

      8.2 Licensed Product Warranty by TARCANTA and TARCANTA LTD. TARCANTA and
TARCANTA LTD. represent and warrant that any Licensed Product manufactured, sold
or delivered by TARCANTA and TARCANTA LTD. or their Sublicensees, if any, will
have been manufactured, filled, packaged, stored and shipped materially in
accordance with the Specifications for such Licensed Product, applicable
Regulatory Approvals and all Applicable Laws.

      8.3 Licensed Product Non-Conformance

            8.3.1 TARCANTA and/or TARCANTA LTD. may elect in their discretion to
conduct laboratory testing and other chemical analyses of any shipment of
Licensed Product. If TARCANTA or TARCANTA LTD. reasonably determines that any
shipment of Licensed Product does not conform to the Specifications for such
Licensed Product, TARCANTA or TARCANTA LTD. shall give CIMAB notice thereof
(including a sample from such shipment and copies of the results of any testing
supporting TARCANTA or TARCANTA LTD.'s determination) within sixty (60) days
after receipt thereof. If CIMAB confirms such non-conformity, it shall promptly
so notify TARCANTA and TARCANTA LTD. If CIMAB does not confirm such
non-conformity, it shall promptly notify TARCANTA and TARCANTA LTD., and the
Parties shall promptly submit samples of such disputed shipment for testing to
an independent testing laboratory in the Territory or other independent Third
Party expert in the

                                       34
<PAGE>

Territory that is mutually acceptable to the Parties. The findings of the
testing laboratory or Third Party expert shall be binding on the Parties. The
expenses of such testing or other investigation shall be borne by CIMAB if the
non-conformity is confirmed, and otherwise by TARCANTA or TARCANTA LTD.

            8.3.2 If any Licensed Product upon delivery to the Delivery
Location, does not conform to the warranty provided in Section 8.1 for any
reason other than the willful or negligent acts or omissions of the Importer or
its customers or agents, CIMAB shall credit the Importer with the price for such
non-conforming Licensed Product and a credit for the Importer's actual
out-of-pocket costs for return of such Licensed Product to CIMAB. Thereafter,
CIMAB shall promptly replace the non-conforming Licensed Product with substitute
conforming Licensed Product.

      8.4 Safety Procedures. CIMAB, TARCANTA and TARCANTA LTD. shall maintain
and enforce health and safety procedures for the handling and manufacture of
Licensed Product that comply in all respects with all Applicable Laws.

      8.5 Disclaimer. EXCEPT AS EXPRESSLY SET FORTH IN THIS ARTICLE 8, NEITHER
CIMAB, TARCANTA NOR TARCANTA LTD. MAKE ANY REPRESENTATIONS OR WARRANTIES OF ANY
KIND WHATSOEVER, EITHER EXPRESS OR IMPLIED, WRITTEN OR ORAL, INCLUDING, WITHOUT
LIMITATION ANY IMPLIED WARRANTY OF MERCHANTABILITY, WARRANTY OF FITNESS FOR A
PARTICULAR PURPOSE, OR WARRANTY OF NON- INFRINGEMENT.

                                   ARTICLE 9

                    REPRESENTATIONS, WARRANTIES AND COVENANTS

      9.1 Representations and Warranties of the Parties. Each Party represents
and warrants to the other Parties that:

      (a) Such Party is duly organized and validly existing and in good standing
under the laws of the jurisdiction of its organization.

      (b) Such Party has the full corporate power and is duly authorized to
enter into, execute and deliver this Agreement, and to carry out and otherwise
perform its obligations thereunder.

      (c) This Agreement has been duly executed and delivered by, and is the
legal and valid obligations binding upon such Party and the entry into, the
execution and delivery of, and the carrying out and other performance of its
obligations under this Agreement by such Party (i) does not conflict with, or
contravene or constitute any default under, any agreement, instrument or
understanding, oral or written, to which it is a Party, including, without
limitation its certificate of incorporation or by-laws, and (ii) does not
violate Applicable Law or any judgment, injunction, order or decree of any
Government Authority having jurisdiction over it.

                                       35
<PAGE>

      (d) Such Party maintains and shall maintain throughout the term of this
Agreement a work force suitably qualified and trained, and facilities and
equipment sufficient, to enable it to perform its obligations as set forth under
this Agreement.

      9.2 Representations and Warranties of CIMAB. CIMAB represents and warrants
to TARCANTA and TARCANTA LTD. that:

      (a) As of the Effective Date, Exhibit A contains a complete and accurate
list of all intellectual property owned or Controlled By CIMAB or its Licensors
that comprises the Licensed Patent Rights, and CIMAB owns or controls all of the
Licensed Patent Rights listed therein and all of the Licensed Know-How;

      (b) The License and Supply Agreement with CIM and the License and Supply
Agreement with HEBER BIOTEC attached hereto as Exhibits D and E, respectively,
are full, true and correct English translations of said agreements; such
agreements are currently, and shall remain in full force and affect, without
amendment, throughout the Term of this Agreement, unless agreed to the contrary
in writing by the Parties; and CIMAB's execution, delivery and performance of
this Agreement and all other agreements contemplated thereby will not result in
any such violation, or be in conflict with or constitute, with or without the
passage of time and giving of notice, either a default under any such provision,
instrument, judgment, order, writ, decree or contract or an event that results
in the creation of any lien, charge or encumbrance upon any assets of CIMAB or
the suspension, revocation, impairment, forfeiture or non-renewal of any permit,
license, authorization or approval applicable to CIMAB, its business or
operations or any of its assets or properties.

      (c) As of the Effective Date, there are no pending claims, whether legal,
administrative, or regulatory, that are threatened, commenced or pending against
the Licensed Patent Rights or the Licensed Know-How; and CIMAB or the licensors
of the Licensed Patent Rights have taken all necessary and desirable actions to
maintain and protect the Licensed Patent Rights and the Licensed Patent Rights
are currently in compliance in all material respects with all applicable legal
requirements (including timely payment of filing, examination and maintenance
fees). CIMAB's Licensors have taken all necessary and desirable actions to
maintain and protect the Licensed Patent Rights that are subject to such
licenses.

      (d) Neither CIMAB nor its Licensors have received any written notice or
claim, and there have been no claims made against the Licensed Patent Rights or
the licensors of any such rights, asserting the invalidity, misuse or
unenforceability of the Licensed Patent Rights, and there are no valid grounds
for the same.

      (e) None of the Licensed Patent Rights are involved in any interference,
reissue, reexamination, opposition or cancellation proceeding or any other
material litigation or proceeding of any kind in the U.S. or in any other
jurisdiction in the Territory.

      (f) Neither CIMAB nor its Licensors are parties to any action or
proceeding that involves a claim of infringement, misappropriation or other
wrongful use or exploitation of any of the Licensed Patent Rights. Neither CIMAB
nor its Licensors have received any notices of, nor are they aware of, any facts
which indicate a likelihood of any infringement or

                                       36
<PAGE>

misappropriation by, or conflict with, any Third Party with respect to Licensed
Patent Rights (including, without limitation, any demand or request that CIMAB
or its licensors license any intellectual property rights from or to a Third
Party).

      (g) CIMAB hereby represents and warrants that this project will be carried
out without the use, lease, purchase or other involvement of any confiscated
U.S. property in Cuba.

      9.3 Representations and Warranties of TARCANTA and TARCANTA LTD. TARCANTA
and TARCANTA LTD. represent and warrant to CIMAB that the financial statements
of their Affiliate, CancerVax Corporation, filed with the U.S. Securities and
Exchange Commission by CancerVax Corporation in its Quarterly Report on Form
10-Q for the period ending March 31, 2004, were, to the best of their knowledge
as of the Effective Date, true and correct on the date of the filing of said
document with the U.S. Securities and Exchange Commission, and that there has
been no material change thereto that would materially adversely impact TARCANTA
or TARCANTA LTD.'s capacity to carry out the terms of this Agreement.

                                   ARTICLE 10

                          INTELLECTUAL PROPERTY MATTERS

      10.1 Ownership of Intellectual Property. As between the Parties, subject
only to the licenses and covenants set forth herein, CIMAB and its Licensors
shall retain all right, title and interest in and to the Licensed Patent Rights
and the Licensed Know-How, and CIMAB, TARCANTA and TARCANTA LTD. shall jointly
own all Improvements. For the purpose of clarification, except as expressly set
forth in this Agreement, no right, license or interest is granted by either
Party to the other Party, expressly or impliedly, under any of such Party's
respective intellectual property. CIMAB, TARCANTA and TARCANTA LTD., and their
Affiliates and Sublicensees, may use any of the Improvements, during and after
the Term of this Agreement, without payment of any royalty, fee or consideration
to the other Parties.

      10.2 Ownership of Regulatory Applications and Regulatory Approvals:

            10.2.1 In the Territory, TARCANTA and TARCANTA LTD. shall own all
right, title and interest in all Regulatory Applications necessary to obtain
Regulatory Approvals required to conduct clinical trials for Licensed Products
or for marketing and sale of Licensed Products, together with any Regulatory
Approval obtained in connection therewith. All Regulatory Applications in the
Territory, together with any Regulatory Approvals obtained in connection
therewith, shall be filed in the name of TARCANTA or TARCANTA LTD.

            10.2.2 Each Party shall retain ownership and control of any of its
Confidential Information included in any Regulatory Application. Notwithstanding
the previous sentence, each Party agrees that, except as restricted under
License number CU-73444 issued by the U.S. Department of Treasury to CancerVax
Corporation, or any subsequent modification thereof, it shall not withhold from
the other Party any Confidential Information necessary for the filing,
maintenance, modification or protection of any Regulatory Application by such
other Party, or as required under any reporting obligation under the Applicable
Laws.

                                       37
<PAGE>

      10.3 Prosecution and Maintenance of Licensed Patent Rights. Except as
otherwise agreed by the Parties, beginning on the Effective Date, TARCANTA and
TARCANTA LTD. shall be responsible for the preparation, filing, prosecution and
maintenance of any and all patent applications and patents in the Territory that
are included in the Licensed Patent Rights, including all payment obligations,
with the exception of (a) those patents and patent applications designated in
Exhibit A as related to the "Neisseria P64K Protein" technology, which shall be
prepared, filed, prosecuted and maintained by HEBER or its Licensor, consistent
with its obligations to CIMAB, and (b) the patents and patent applications
designated in Exhibit A as "HER-1" technology, which shall be prepared, filed,
prosecuted and maintained by CIM, in consultation with TARCANTA and TARCANTA
LTD., consistent with its obligations to CIMAB and CIMAB's obligations to
TARCANTA and TARCANTA LTD.; provided, however, that if the Parties agree in the
future to separate the claims thereof into applications which solely cover the
HER-1 technology, then TARCANTA and TARCANTA LTD. shall from such point forward,
bear the responsibility for the preparation, filing, prosecution and maintenance
of patents and patent applications which relate solely to the HER-1 technology.

            10.3.1 CIMAB shall execute all necessary documents and otherwise
provide reasonable assistance, free of charge to TARCANTA and TARCANTA LTD., for
all actions TARCANTA and TARCANTA LTD. reasonably deem necessary to undertake
relating to the preparation, filing, prosecution, and maintenance of any and all
patent applications and patents in the Territory that are included in the
Licensed Patent Rights.

            10.3.2 CIMAB shall promptly inform TARCANTA and TARCANTA LTD. as to
all matters that come to its attention or to the attention of its Licensors that
may affect the preparation, filing, prosecution or maintenance of the Licensed
Patent Rights in the Territory or elsewhere, including, without limitation, all
information with respect to the preparation, filing, prosecution and maintenance
of those patent applications designated in Exhibit A as related to the
"Neisseria P64K Protein" technology and to the "HER-1" technology.

            10.3.3 Upon thirty (30) days written notice to CIMAB, TARCANTA
and/or TARCANTA LTD. may abandon their rights under this Agreement in any
country(ies) in the Territory and thereafter owe no payment under Section 10.3
or any other obligation of this Agreement in those country(ies) as of the
effective date of such written notice. CIMAB shall thereafter have a right, but
not an obligation, to assume the responsibility for the preparation, filing,
presentation and maintenance of any and all patent applications and patents that
are included in the Licensed Patent Rights in such country(ies) in the Territory
where TARCANTA or TARCANTA LTD. has elected to abandon its rights. In the event
that CIMAB has assumed the responsibility for the preparation, filing,
presentation and maintenance of any and all patent applications and patents that
are included in the Licensed Patent Rights in such country(ies) in the Territory
where TARCANTA and/or TARCANTA LTD. have elected to abandon such rights,
TARCANTA and TARCANTA LTD.'s rights, as the case may be, with respect to the
Licensed Product in such country(ies) under this Agreement shall no longer be of
any effect.

      10.4 Enforcement of Licensed Patent Rights

            10.4.1 If any patent within the Licensed Patent Rights is or might
reasonably be infringed by a Third Party in the Territory (an "Infringement"),
the Party first having knowledge

                                       38
<PAGE>

of such Infringement shall promptly notify the other Parties in writing. Such
notice shall set forth the facts of such Infringement in reasonable detail.

            10.4.2 TARCANTA and TARCANTA LTD. shall have the right, but not the
obligation, to take action in their own names and at their sole expense to
secure the cessation of any Infringement or to institute, prosecute and control
legal proceedings to prevent or restrain such Infringement. CIMAB agrees to
timely assist TARCANTA and TARCANTA LTD. in the prosecution of any action or
legal proceedings related to such Infringement, and agrees to be joined, and to
cause its Licensors to be joined, as party plaintiffs and to give the TARCANTA
and TARCANTA LTD. reasonable assistance and authority to control, file,
prosecute and settle the suit. Subject to the foregoing, CIMAB shall have the
right, but not the obligation, to participate at its own cost and expense in any
suit or other proceeding wherein the validity or enforceability of any Licensed
Patent Right is at issue in the context of a claim or defense. All of TARCANTA
and TARCANTA LTD.'s costs and expenses in bringing such suits (including
TARCANTA and TARCANTA LTD.'s internal costs and expenses that are specifically
attributable thereto) shall be reimbursed first out of any damages or other
monetary awards recovered in favor of the Parties. Any remaining damages or
other monetary awards shall be allocated [***] to CIMAB and [***] to TARCANTA
and TARCANTA LTD.

            10.4.3 If TARCANTA and TARCANTA LTD. elect not to exercise their
right to prosecute or take other appropriate action in connection with an
Infringement or fail to take any such action within ninety (90) days of first
receiving notice of such Infringement, CIMAB may do so at its own expense. If
such case, TARCANTA and TARCANTA LTD. agree to assist CIMAB in the prosecution
of any action or legal proceedings related to such Infringement. Notwithstanding
anything in this Agreement to the contrary, TARCANTA and TARCANTA LTD. shall
have the right, but not an obligation, to participate at their own cost and
expense in any suit or other proceeding wherein the validly or enforceability of
any Licensed Patent Right is being invoked in the context of a claim or defense.
All of CIMAB's costs and expenses in bringing such suits (including CIMAB's
internal costs and expenses that are specifically attributable thereto) shall be
reimbursed first out of any damages or other monetary awards recovered in favor
of the Parties. Any remaining damages or other monetary awards shall be
allocated [***] to TARCANTA and TARCANTA LTD. and [***] to CIMAB.

            10.4.4 The Party that takes action or prosecutes legal proceedings
relating to the Infringement in accordance with this Agreement shall be
responsible for the selection of counsel to prosecute legal proceedings.

            10.4.5 In no event shall either Party settle an action or proceeding
against an infringer with respect to an Infringement in the Territory without
the prior written consent of the other Parties. Such consent shall not be
unreasonably withheld or delayed, and may be withheld only if such settlement
would materially and adversely affect the interest of such other Parties.

            10.4.6 Infringement of Third Party(ies) Rights. If any activities by
TARCANTA or TARCANTA LTD. under this Agreement, including the practice of the
Licensed Patent Rights, the Licensed Know-How, or the manufacture, use or sale
of the Licensed Products by TARCANTA or TARCANTA LTD., their Affiliates or
Sublicensees consistent with the rights granted under this Agreement within the
Territory results in a claim of infringement of the

***Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                       39
<PAGE>

intellectual property rights of a Third Party against TARCANTA or TARCANTA LTD.,
their Affiliates or Sublicensees, TARCANTA and TARCANTA LTD. shall have the
right, using counsel of their own choice, to defend such claim. CIMAB agrees to
cooperate fully with TARCANTA and TARCANTA LTD. in their defense of the claim.
Notwithstanding anything in this Agreement to the contrary, CIMAB shall have the
right, but not the obligation, to participate at its own cost in the defense of
such claim. All of TARCANTA and TARCANTA LTD.'s costs and expenses in defending
such claims (including TARCANTA and TARCANTA LTD.'s internal costs and expenses
which are specifically attributable thereto) shall be offset by TARCANTA and
TARCANTA LTD. exclusively against [***] of any Royalties and any other amounts
due to CIMAB under this Agreement. Such offset rights shall be made only where
the claim of infringement arises from the sale, use, manufacture or importation
of the Licensed Products, provided that such claim of infringement does not
arise due to any invention or improvement incorporated into the Licensed
Products by TARCANTA or TARCANTA LTD. without the knowledge of CIMAB.

      10.5 Trademarks and Identification.

            10.5.1 TARCANTA and TARCANTA LTD. shall, at their own expense,
select, register and maintain the trademarks used by each such entity with
respect to the Licensed Products. Neither CIMAB nor any of its Affiliates,
Licensors or sublicensees, other than TARCANTA and TARCANTA LTD., shall have any
rights in respect of such trademarks, and CIMAB agrees to use its best efforts
to prevent any of its Affiliates, Licensors and sublicensees other than TARCANTA
and TARCANTA LTD., from using such trademarks in any way.

            10.5.2 CIMAB agrees to give TARCANTA and TARCANTA LTD. prompt
written notice of any unlicensed use by Third Parties of any trademark used by
TARCANTA or TARCANTA LTD. with respect to the Licensed Products of which CIMAB
has knowledge.

            10.5.3 TARCANTA and TARCANTA LTD. shall have the exclusive right,
but not the obligation, to take action in their own names and at their sole
expense to secure the cessation of any infringement or misappropriation of its
trademarks or to institute, prosecute and control legal proceedings to prevent
or restrain such infringement or misappropriation of its trademarks. CIMAB
agrees to use its best efforts to assist TARCANTA and TARCANTA LTD., at TARCANTA
or TARCANTA LTD.'s expense, in the prosecution of any action or legal
proceedings related to the infringement or misappropriation of such trademarks.

            10.5.4 If permitted by Applicable Laws, all Licensed Products shall
bear labeling that states that such products are either manufactured under
license from CIMAB, in the case of Licensed Products manufactured by TARCANTA or
TARCANTA LTD., their Sublicensees and Contract Manufacturers, or, in the case of
Licensed Products purchased from CIMAB, that identifies CIMAB, with its address,
as the manufacturer of the Licensed Products. TARCANTA and TARCANTA LTD. shall
mark all Licensed Products that they manufacture for commercial sale with a
legend identifying the issued patents that pertain thereto.

***Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                       40
<PAGE>

                                   ARTICLE 11

                                 CONFIDENTIALITY

      11.1 Confidentiality; Exceptions. Except as otherwise provided in this
Agreement, the Parties agree that, during the term of this Agreement and for
five (5) years thereafter, all non-public, proprietary or "confidential" marked
invention disclosures, know-how, data, and technical, financial and other
information of any nature whatsoever (collectively, "Confidential Information"),
disclosed or submitted, either orally or in writing (including, without
limitation by electronic means) or through observation, by one Party (the
"Disclosing Party") to the other Party (the "Receiving Party") hereunder shall
be received and maintained by the Receiving Party in strict confidence, shall
not be used for any purpose other than the purposes expressly permitted by this
Agreement, and shall not be disclosed to any Third Party (including, without
limitation in connection with any publications, presentations or other
disclosures). Notwithstanding the foregoing, the Receiving Party may, subject to
the provisions of this Agreement, disclose the Disclosing Party's Confidential
Information to those of its and its Affiliates' and its Sublicensees' directors,
officers, employees, agents, consultants, clinical investigators and Contract
Manufacturers that have a need to know such Confidential Information to achieve
the purposes of this Agreement; provided, however, that such Party shall ensure
that it and its Affiliates' and Sublicensees' directors, officers, employees,
agents, consultants, clinical investigators or Contract Manufacturers to whom
disclosure is to be made are bound by, and take reasonable efforts to ensure
compliance with, the confidentiality terms hereof. Each Party will promptly
notify the other upon discovery of any unauthorized use or disclosure of the
Confidential Information. Confidential Information belongs to and shall remain
the property of the Disclosing Party. The provisions of this Article 11 shall
not apply to any information that can be shown by the Receiving Party:

      (a) To have been known to or in the possession of the Receiving Party
prior to the date of its actual receipt from the Disclosing Party;

      (b) To be or to have become readily available to the public other than
through any act or omission of the Receiving Party in breach of this Agreement
or any other agreement between the Parties;

      (c) To have been disclosed to the Receiving Party, other than under an
obligation of confidentiality, by a Third Party which had no obligation to the
Disclosing Party not to disclose such information to others; or

      (d) To have been subsequently independently developed by the Receiving
Party without use of the Confidential Information as demonstrated by competent
written records.

      11.2 Authorized Disclosures. Notwithstanding anything in Section 11.1 to
the contrary, each Party may disclose Confidential Information hereunder solely
to the extent such disclosure is reasonably necessary in connection with
submissions to any Government Authority or in filing or prosecuting patent
applications contemplated or prosecuting or defending litigation or complying
with Applicable Laws or conducting Development Work for the purposes expressly
permitted by this Agreement; provided that in the event of any such disclosure
of the

                                       41
<PAGE>

Disclosing Party's Confidential Information by the Receiving Party, the
Receiving Party will, except where impracticable, give reasonable advance notice
to the Disclosing Party of such disclosure requirement (so that the Disclosing
Party may seek a protective order and or other appropriate remedy or waive
compliance with the confidentiality provisions of this Article 11) and will use
its reasonable efforts to secure confidential treatment of such Confidential
Information required to be disclosed. Notwithstanding the above, each Party may
disclose pre-clinical and clinical data and results relating to Licensed Product
to qualified medical professionals for the limited purposes of marketing
Licensed Product and conducting medical education initiatives reasonably
designed to increase sales of Licensed Product.

      11.3 Return of Confidential Information. The Receiving Party shall keep
Confidential Information belonging to the Disclosing Party in appropriately
secure locations. Upon the expiration or termination of this Agreement, any and
all Confidential Information possessed in tangible form by a Receiving Party,
its Affiliates or Sublicensees, or its or any of their officers, directors,
employees, agents, consultants or clinical investigators and belonging to the
Disclosing Party, shall, upon written request, be immediately returned to the
Disclosing Party (or destroyed if so requested) and not retained by the
Receiving Party, its Affiliates or Sublicensees, or any of their officers,
directors, employees, agents, consultants or clinical investigators; provided
however that a Party may retain one (1) copy of any Confidential Information in
an appropriately secure location, which by Applicable Laws it must retain, for
so long as such Applicable Laws require such retention but thereafter shall
dispose of such retained Confidential Information in accordance with Applicable
Laws or this Section 11.3.

      11.4 Publications and Announcements. Except as otherwise permitted under
this Agreement or as required by law, regulation, or court order, each Party
agrees not to publish any Confidential Information received from the other
Party. Except as required by law, regulation or court order, each Party agrees
that, without obtaining the other Party's prior written approval for any
publication or any presentation, which shall not be unreasonably withheld, such
Party shall not publish or present (i) any Confidential Information generated by
either Party related to the development or commercialization of Licensed
Product, or (ii) the results of any clinical trial studies or non-clinical
studies or investigations carried out by either Party related to the development
of Licensed Product. At least sixty (60) days prior to any such publication or
presentation, the Party seeking to publish such information (the "Publishing
Party") shall provide the other Party with a copy of the proposed abstract,
manuscript or presentation (including, without limitation information to be
presented verbally) for review. The other Party shall respond in writing to the
Publishing Party within such time period with either approval of the proposed
material or a specific statement of (a) concern based upon the need to seek
patent protection, (b) concern regarding competitive disadvantage arising from
the proposal, or (c) concern regarding the timing and circumstances of such
disclosure in light of the other Party's business. In the event that the other
Party has concerns about disclosure of Confidential Information, the Publishing
Party agrees to provide the other Party with any additional information relating
to the proposed disclosure, as reasonably requested. In the event of concern
relating to patent protection, the Publishing Party agrees not to submit such
abstract or manuscript for publication or to make such presentation until the
other Party has had a reasonable period of time to seek patent protection for
any material in such publication or presentation which it believes is patentable
or to resolve any other issues, such period not to exceed sixty (60) additional
days. In the event of concern regarding competitive disadvantage or

                                       42
<PAGE>

the timing and other circumstances relevant to the disclosure, the Parties will
negotiate in good faith to attempt to arrive at a compromise to permit the
Publishing Party an opportunity to publish or present the disclosure within a
reasonable period of time. The Publishing Party also agrees to delete from any
such abstract or manuscript or presentation any Confidential Information that
the other Party reasonably believes has commercial value based upon the secrecy
of such information. Once approval for a publication or presentation has been
granted, the Publishing Party shall be entitled to use information contained in
such publication or presentation after the date of its publication or
presentation without seeking further approval. It is understood that general
comments made by either Party relating to the relationship between the Parties
established by this Agreement, including, for example, general comments made in
response to inquiries at professional meetings and other similar circumstances,
are not intended to be restricted by the provisions of this Article 11 provided
that such information has been disclosed to the public previously or cleared for
such disclosure by the non-disclosing Party. It is understood further that
Confidential Information may be disclosed by either Party to Third Parties bound
by non-disclosure agreements to the extent such Confidential Information (1) is
not specific to the Licensed Product and (2) is disclosed in relation to matters
outside the Parties' collaboration efforts with respect to Licensed Product.
Prior to any such disclosure, the disclosing Party will provide such disclosures
to the other Party for such Party's approval, which shall not be unreasonably
withheld.

                                   ARTICLE 12

                              TERM AND TERMINATION

      12.1 Term

            12.1.1 This Agreement shall commence as of the Effective Date and
shall expire by its own terms on the later of (i) the earlier of, on a
country-by-country basis (a) the expiration of the term of the last patent
within the Licensed Patent Rights or (b) a determination by a court or
administrative agency of competent jurisdiction that the last claim in the last
patent within the Licensed Patent Rights is invalid or unenforceable, or (ii) on
a country by country basis, fifteen (15) years after the First Commercial Sale
of a Licensed Product developed under this Agreement, unless the term of such
right and license is earlier terminated pursuant to the provisions of this
Article 12 (the "Term").

            12.1.2 Notwithstanding the provisions of Section 12.1 above, this
Agreement may be terminated prior to expiration in accordance with the terms and
conditions of this Article 12.

      12.2 Termination at Will. TARCANTA and TARCANTA LTD. may terminate this
Agreement at any time in TARCANTA and TARCANTA LTD.'s sole discretion, upon not
less than one hundred eighty (180) days' prior written notice to CIMAB.

      12.3 Termination for Cause. Any Party may terminate this Agreement for
cause if any other Party commits a material breach of a material term of this
Agreement, which material breach is not materially cured within sixty (60) days
after written notice from a non-breaching Party specifying the material breach,
or, if such material breach is not susceptible of material

                                       43
<PAGE>

cure within such period, the breaching Party is not making diligent, good faith,
best efforts to materially cure such material breach. The Parties acknowledge
and agree that failure to exercise any right or option, or to take any action
expressly within the discretion of a Party shall not be deemed to be a material
breach hereunder.

      12.4 Other Terminations. Notwithstanding anything in this Article 12 or
any other provision of this Agreement to the contrary, CIMAB shall have the
right to terminate this Agreement pursuant to Sections 5.7.7, 5.10.5 and 5.10.7
according to the terms of such sections or in case of the occurrence of one of
the following events:

      (i) If TARCANTA and/or TARCANTA LTD. have not used Reasonable Commercial
Efforts to file an IND Submission for a Phase 2 clinical trial of the EGF
Vaccine, or any other therapeutic cancer vaccine of which the EGF Vaccine
comprises a portion thereof, within two (2) years after the Effective Date,
provided, however, that CIMAB has timely complied with all of its obligations
under this Agreement.

      (ii) If the first Regulatory Approval for marketing the EGF Vaccine in the
Territory is not obtained within twelve (12) years after the Effective Date,
provided, however, that CIMAB has timely complied with all of its obligations
under this Agreement.

      12.5 Termination for Insolvency. To the extent permitted by Applicable
Laws, any Party may terminate this Agreement upon written notice to the other
Parties on or after the occurrence of any of the following events: (i) the
appointment of a trustee, receiver or custodian for all or substantially all of
the property of the other Party, or for any lesser portion of such property, if
the result materially and adversely affects the ability of the other Party to
fulfill its obligations hereunder or thereunder, which appointment is not
dismissed within sixty (60) days, (ii) the determination by a court or tribunal
of competent jurisdiction that the other Party is insolvent such that a Party's
liabilities exceed the fair market value of its assets, (iii) the filing of a
petition for relief in bankruptcy by the other Party on its own behalf, or the
filing of any such petition against the other Party if the proceeding is not
dismissed or withdrawn within sixty (60) days thereafter, (iv) an assignment by
the other Party for the benefit of creditors, or (v) the dissolution or
liquidation of the other Party. All rights and licenses granted under or
pursuant to this Agreement by one Party to the other Party are, and shall
otherwise be deemed to be, for the purposes of Section 365(n) of the Bankruptcy
Code of the U.S., licenses of rights to "intellectual property." The Parties
agree that both Parties, as licensees of such rights and licenses, shall retain
and may fully exercise all of their rights and elections under such Bankruptcy
Code.

      12.6 Rights on Termination.

            12.6.1 In the event that CIMAB terminates this Agreement pursuant to
Sections 12.2 (Termination at Will), 12.3 (Termination for Cause), Section 12.4
(Other Terminations) or pursuant to Section 12.5 (Termination for Insolvency),
or Sections 5.7.7, 5.10.5 or 5.10.7, CIMAB shall not have any obligation to
complete any clinical or other study in progress or any project underway
pursuant to the Development Plan, as of the effective date of such termination,
CIMAB shall have no obligation to refund any monies previously paid to CIMAB,
and TARCANTA, TARCANTA LTD. and their Sublicensees shall pay to CIMAB all
monetary

                                       44
<PAGE>

obligations to CIMAB that were due and owing to CIMAB under the terms of this
Agreement prior the effective date of such termination.

            12.6.2 Except as otherwise required to effect the other provisions
of this Article 12, in the event this Agreement is terminated prior to its
expiration for any reason, (i) all rights and obligations of the Parties and
sublicenses under this Agreement shall terminate; (ii) TARCANTA, TARCANTA LTD.
and their Sublicensees shall surrender to CIMAB, or, at CIMAB's sole option,
TARCANTA, TARCANTA LTD. and their Sublicensees shall destroy and provide CIMAB
with a certificate signed by a Vice-President or higher ranking executive of
TARCANTA, TARCANTA LTD. and their Sublicensees attesting to the destruction of,
copies of any Licensed Know-How or other Confidential Information provided by
CIMAB hereunder, except as noted to the contrary below in this Section 12.6.2,
and the Transferred Assets; (iii) CIMAB shall surrender to TARCANTA, TARCANTA
LTD. and their Sublicensees, or, at TARCANTA, TARCANTA LTD.'s and their
Sublicensees sole option, CIMAB shall destroy and provide TARCANTA, TARCANTA
LTD. and their Sublicensees with a certificate signed by a Vice-President or
higher ranking executive of CIMAB attesting to the destruction of, all copies of
any Confidential Information provided by TARCANTA, TARCANTA LTD. and their
Sublicensees hereunder, except as noted to the contrary in this Section 12.6.2;
(iv) TARCANTA, TARCANTA LTD. or their Sublicensees will immediately upon
termination, take all steps necessary for the issuance (or re-issuance, if
appropriate) in the name of CIMAB or its designee of all Regulatory Approvals
theretofore obtained or held by TARCANTA, TARCANTA LTD. and their Sublicensees
with respect to Licensed Products; and (v) neither TARCANTA, TARCANTA LTD. nor
their Sublicensees will have the right to use the Licensed Products, Licensed
Know How, Licensed Patent Rights, Confidential Information, Transferred Assets
and/or any other right granted to TARCANTA, TARCANTA LTD. or their Sublicensees
under this Agreement, except as noted to the contrary in this Section 12.6.2.
Notwithstanding anything in this Section or elsewhere in this Agreement to the
contrary, in the event of any termination of this Agreement prior to its
expiration, TARCANTA, TARCANTA LTD. and their Sublicensees may retain a copy of
all Licensed Know-How or other Confidential Information solely for purposes
related to any litigation arising out of this Agreement, including without
limitation, the sale of any of the Licensed Products by TARCANTA, TARCANTA LTD.
and their respective Affiliates, subsidiaries and Sublicensees.

      12.7 Accrued Rights . Termination, relinquishment or expiration of this
Agreement for any reason shall be without prejudice to any right that shall have
accrued to the benefit of either Party prior to such termination, relinquishment
or expiration, including damages arising from any breach under this Agreement.
Such termination, relinquishment or expiration shall not relieve either Party
from obligations that are expressly indicated to survive termination or
expiration of this Agreement.

      12.8 Survival The following articles and sections of this Agreement shall
survive the expiration or termination of this Agreement for any reason: Section
3.9, 5.11, 8.1, 8.2, 8.4, 10.1, 10.2, 10.3, 10.5.1, 12.6, 12.7, 12.8, and
Articles 11, 13, 14 and 15

      12.9 One hundred and eighty days (180 days) before expiration of this
Agreement in accordance with Section 12.1.1 of this Agreement, CIMAB shall have
the option to initiate negotiations for CIMAB to supply the Licensed Products to
TARCANTA and TARCANTA

                                       45
`
<PAGE>

LTD. and their Affiliates and Sublicensees for sale in those portions of the
Territory where CIMAB had supplied same under this Agreement. If CIMAB exercises
this option, the Parties agree to negotiate in good faith and shall enter into
such a supply agreement, provided that (i) the terms offered by CIMAB for the
supply agreement are commercially reasonable and are at least as favorable to
TARCANTA and TARCANTA LTD., in the aggregate, as terms offered by any other
party, (ii) TARCANTA or TARCANTA LTD. are not able to supply the Licensed
Products more economically than CIMAB, (iii) CIMAB has consistently complied
with its obligations to comply with all Applicable Laws during the Term of this
Agreement, and (iv) the quality of the Licensed Products supplied by CIMAB has
been consistently acceptable to TARCANTA and TARCANTA LTD. throughout the Term
of this Agreement.

                                   ARTICLE 13

               INDEMNIFICATION; INSURANCE; LIMITATION OF LIABILITY

      13.1 Indemnification by CIMAB. CIMAB shall, at its sole cost and expense,
indemnify, defend and hold harmless TARCANTA, TARCANTA LTD., their Affiliates,
Sublicensees, officers, directors, employees and agents from and against any and
all losses, liabilities, claims, obligations, damages, costs, expenses
(including, without limitation, reasonable attorneys' fees) which result from,
arise in connection with or are related in any way to claims by a Third Party
arising out of or in connection with (a) CIMAB's breach of the representations
and warranties made by CIMAB in this Agreement; (b) CIMAB's willful misconduct
or gross negligence; (c) any violations of Applicable Laws or regulations by
CIMAB; or (d) CIMAB's material breach of the provisions of this Agreement;
provided that: (i) TARCANTA or TARCANTA LTD. promptly notifies CIMAB in writing
of the claim; and (ii) TARCANTA and TARCANTA LTD. provide CIMAB with all
reasonable assistance, information and authority to perform the foregoing.

      13.2 Indemnification by TARCANTA and TARCANTA LTD. TARCANTA and TARCANTA
LTD. shall, at their sole cost and expense, indemnify, defend and hold harmless
CIMAB and its officers, directors, employees and agents from and against any and
all losses, liabilities, claims, obligations, damages, costs, expenses
(including, without limitation, reasonable attorneys' fees) which result from,
arise in connection with or are related in any way to claims by a Third Party
arising out of or in connection with (a) TARCANTA or TARCANTA LTD.'s breach of
the representations and warranties made by TARCANTA or TARCANTA LTD. in this
Agreement; (b) TARCANTA or TARCANTA LTD.'s willful misconduct or gross
negligence; (c) any violations of Applicable Laws or regulations by TARCANTA or
TARCANTA LTD.; or (d) TARCANTA or TARCANTA LTD.'s material breach of the
provisions of this Agreement; provided that: (i) CIMAB promptly notifies
TARCANTA and TARCANTA LTD. in writing of the claim; and (ii) CIMAB provides
TARCANTA and TARCANTA LTD. with all reasonable assistance, information and
authority to perform the foregoing.

      13.3 Insurance. TARCANTA and TARCANTA LTD. shall, during the Term and at
their sole cost and expense, be insured under a comprehensive, commercial
general liability insurance policy against claims for damage (including, without
limitation, claims for bodily and personal injury, death and property damage)
caused by or occurring in connection with the

                                       46
<PAGE>

performance or breach of this Agreement. At TARCANTA and TARCANTA LTD.'s cost,
and if permitted under Applicable Laws, TARCANTA and TARCANTA LTD. shall use
Reasonable Commercial Efforts to name CIMAB as an additional insured Party on
each insurance policy. The coverage shall be maintained under one or more
policies of insurance from a financially sound and reputable insurance company
reasonably acceptable to CIMAB, providing a minimum liability protection in the
amount of [***] per occurrence. Such insurance shall be primary for all
purposes, and contain standard cross-liability or severability provisions. All
of the policies of insurance shall contain a provision or endorsement that the
coverage afforded will not be canceled, materially changed, or have renewal
refused unless at least thirty (30) days' prior written notice has been given to
TARCANTA, TARCANTA LTD. and CIMAB. If requested, TARCANTA and/or TARCANTA LTD.
shall deliver to CIMAB insurance certificates in form and substance reasonably
acceptable to CIMAB.

      13.4 Limitation of Liability; Remedies Cumulative

            13.4.1 IN NO EVENT SHALL ANY PARTY BE LIABLE UNDER THIS AGREEMENT
FOR ANY CONSEQUENTIAL, INCIDENTAL, PUNITIVE OR SPECIAL DAMAGES OF ANY KIND,
INCLUDING, WITHOUT LIMITATION, LOSS OF PROFITS, WHETHER SUCH DAMAGES ARE ALLEGED
AS A RESULT OF TORTIOUS CONDUCT OR BREACH OF CONTRACT OR OTHERWISE EVEN IF THE
OTHER PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES. THESE
LIMITATIONS SHALL APPLY NOTWITHSTANDING ANY FAILURE OF ESSENTIAL PURPOSE OF ANY
LIMITED REMEDY.

            13.4.2 THE REMEDIES PROVIDED IN THIS AGREEMENT ARE CUMULATIVE AND
NOT EXCLUSIVE OR IN LIMITATION OF ANY OTHER REMEDY AVAILABLE UNDER THIS
AGREEMENT OR AT LAW OR IN EQUITY.

                                   ARTICLE 14

                   GOVERNING LAW AND FORUM; DISPUTE RESOLUTION

      14.1 Governing Law. This Agreement shall be governed by the laws of
England and Wales, excluding that body of law known as the conflicts of law.

      14.2 Dispute Resolution.

            14.2.1 In the event of any dispute, controversy or claim arising out
of or in connection with or related to this Agreement (a "Dispute"), the Parties
shall first seek to settle the Dispute in good faith by negotiation and
consultation between themselves, including referral of the Dispute to the chief
executive officers of each Party. When a Party believes that a Dispute has
arisen, that Party will give the other Parties prompt written notice of the
Dispute (a "Dispute Notice"). All negotiations pursuant to this Section 14.2,1
shall be on a without prejudice basis, and nothing said or disclosed, nor any
document produced, in the course of such negotiations which is not otherwise
independently discloseable shall be offered or received as evidence or for any
other purpose in any current or future arbitration or litigation. In the event
the Parties do not

***Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                       47
<PAGE>

resolve the Dispute (or agree upon a mechanism to resolve the Dispute) within
thirty (30) days of the date of the Dispute Notice, such Dispute shall be
referred by any Party to arbitration proceedings pursuant to Section 14.2.2.

      14.2.2 Subject to Section 14.2.1, the Parties agree that any Dispute shall
be finally settled under the Rules of Arbitration of the International Chamber
of Commerce (the "Rules"), to the extent that the Rules are not varied by the
terms of this Section 14.2.2. The seat of the arbitration shall be London,
England, unless another location is mutually agreed by the Parties, provided
always that the seat of the arbitration is in a state which has ratified the New
York Convention on the Recognition and Enforcement of Foreign Arbitral Awards
(the "New York Convention"). The arbitral tribunal shall be composed of three
(3) independent arbitrators, two (2) of whom shall be nominated by the Parties
to the Dispute and the third, who shall act as Chairman, who shall be jointly
nominated by the party-nominated arbitrators. In the event that there are three
Parties to the Dispute, the Claimant party(ies) shall (together) nominate one
arbitrator and the Respondent Party(ies) shall (together) nominate one
arbitrator. None of the arbitrators shall be nationals of the U.S. or Cuba. The
joint languages of the arbitration shall be Spanish and English, unless the
Parties agree otherwise. The arbitral tribunal may award interim or ancillary
relief. Judgment on the award, and on any interim or ancillary relief, may be
entered in any court having jurisdiction thereof or having jurisdiction over the
Parties or their assets, or over the subject matter at issue. The arbitral
tribunal shall have the power to rule on its own jurisdiction, including any
objections with respect to the existence or validity of this arbitration
agreement. The arbitral award shall be final and binding on the Parties, who
hereby waive any right of appeal. Such award shall be enforceable pursuant to
the New York Convention. The Parties agree that this Agreement and any Dispute
are commercial in nature under the laws of the Republic of Cuba, the U.S. and
England and Wales, including the laws relating to arbitration. This paragraph
shall be treated as an agreement independent of the other terms of this
Agreement. A decision by the arbitral tribunal that this Agreement is null and
void shall not entail ipso jure the invalidity of this arbitration clause.

                                   ARTICLE 15

                                  MISCELLANEOUS

      15.1 Assignment

            15.1.1 None of the Parties may assign or otherwise transfer their
rights or obligations under this Agreement without the prior written consent of
the other Parties, such consent not to be unreasonably withheld, except that a
Party may assign or otherwise transfer its rights or obligations in whole or in
part without such consent (i) to an Affiliate of such Party, provided that no
such assignment shall relieve any Party as the primary obligor hereunder, or
(ii) to a Third Party in connection with the merger, consolidation, or sale of
substantially all of the assets of the assigning Party, or reorganization
affecting substantially all of the assets or voting control of the assigning
Party, provided that no such assignment shall relieve any Party as the primary
obligor hereunder.

                                       48
<PAGE>

            15.1.2 This Agreement shall be binding upon and inure to the benefit
of the successors and permitted assigns of the Parties. Any assignment not in
accordance with this Agreement shall be void.

      15.2 Force Majeure Except as provided for in Sections 5.7.6, 5.10.5 and
5.10.7, no Party shall lose any rights hereunder or be liable to the other
Parties for damages or losses on account of failure of performance by the
defaulting Party if the failure is occasioned by government action, war, fire,
explosion, flood, strike, lockout, embargo, act of God, or any other similar
cause beyond the control of the defaulting Party, provided that the Party
claiming force majeure shall promptly notify the other Parties in writing
setting forth the nature of such force majeure, shall use its best efforts to
eliminate, remedy or overcome such force majeure and shall resume performance of
its obligations hereunder as soon as reasonably practicable after such force
majeure ceases.

      15.3 Separate Entities. Without limitations, CIMAB and its property are
not and shall not be responsible for the acts, omissions, obligations or debts
of the Republic of Cuba or any of its agencies or instrumentalities. Neither the
Republic of Cuba nor any of its agencies or instrumentalities, nor any of their
property, are responsible, or shall be responsible, for the acts, omissions,
obligations or debts of CIMAB.

      15.4 Further Actions. Each Party agrees to execute, acknowledge and
deliver such further instruments, and to do all such other acts, as may be
necessary or appropriate in order to carry out the purposes and intent of this
Agreement.

      15.5 Governmental Approvals; Compliance with Law. The Parties shall make
all filings with Government Authorities as shall be required by Applicable Laws
in connection with this Agreement and the activities contemplated hereunder or
thereunder. It is understood and agreed that neither TARCANTA nor TARCANTA LTD.
shall be required to undertake, and TARCANTA and TARCANTA LTD. shall not
undertake, to sell any CIMAB product unrelated to the Licensed Products. It is
understood and agreed that neither TARCANTA nor TARCANTA LTD. shall be required
to transfer, and neither TARCANTA nor TARCANTA LTD. (including their officers,
directors, employees and agents) will transfer to CIMAB, any technology or
know-how unrelated to the Licensed Products.

      15.6 Public Announcement. No announcement, news release, public statement,
publication or presentation relating to the existence of this Agreement, or the
terms hereof or thereof, will be made without the other Parties' prior written
approval, which approval shall not be unreasonably withheld. Notwithstanding the
foregoing, each Party consents to references to this Agreement in reports or
documents or other disclosures sent to stockholders or filed with or submitted
to any Government Authority or stock exchange or as may be required by law to be
made. The Parties each agree that once approval for disclosure of information
subject to this Section 15.6 has been obtained, the Party that requested such
approval shall be entitled to use such information substantially in the form
initially presented without an obligation to seek further approval.

      15.7 Notices. All notices required or permitted to be given under this
Agreement shall be deemed given if delivered personally, on the date of
delivery, or sent by express courier

                                       49
<PAGE>

service, on the date of receipt, or by email or facsimile if receipt is
acknowledged by email or by fax by the other Parties, on the date of receipt
acknowledged, to the Parties at the following addresses, or at such other
address for a Party as shall be specified by like notice:

      If to CIMAB, addressed to:
      CIMAB, S.A.
      Address: Calle 206, No. 1926, e/ 19 y 21
      Atabey, Playa
                Ciudad de La Habana Cuba
                Attention: Norkis Arteaga Morales
                Title: Vice President
                Facsimile:  53 (7) 273 3509

      If to TARCANTA addressed to:
      TARCANTA Inc.
      Address: 2110 Rutherford Road
      Carlsbad, CA 92008
      U.S.A.
      Attention: General Counsel
      Facsimile:  (760) 494-4282

      If to TARCANTA LTD. addressed to:
      TARCANTA LTD. Ltd.
      Address: 2110 Rutherford Road
      Carlsbad, CA 92008
      U.S.A.
      Attention: General Counsel
      Facsimile: (760) 944-4282

      15.8 Waiver. No failure of any Party to exercise and no delay in
exercising any right or remedy in connection with this Agreement will operate as
a waiver thereof, nor will any single or partial exercise of any right or remedy
preclude any other or further exercise of such right or remedy or the exercise
of any other right or remedy.

      15.9 Disclaimer of Agency. The relationship between CIMAB, on the one
hand, and TARCANTA and TARCANTA LTD., on the other hand, established by this
Agreement is that of independent contractors, and nothing contained herein shall
be construed to (i) give any Party the power to direct or control the day-to-day
activities of the other, (ii) constitute the Parties as the legal representative
or agent of the other Parties or as partners, joint venturers, co-owners or
otherwise as participants in a joint or common undertaking, or (iii) allow any
Party to create or assume any liability or obligation of any kind, express or
implied, against or in the name of or on behalf of the other Parties for any
purpose whatsoever, except as expressly set forth in this Agreement.

      15.10 Severability. If any term, covenant or condition of this Agreement
or the application thereof to any Party or circumstance shall, to any extent, be
held to be invalid or unenforceable by a court or administrative agency of
competent jurisdiction, then (i) the

                                       50
<PAGE>

remainder of such documents, or the application of such term, covenant or
condition to Parties or circumstances other than those as to which it is held
invalid or unenforceable, shall not be affected thereby and each term, covenant
or condition of such documents shall be valid and be enforced to the fullest
extent permitted by law; and (ii) the Parties hereto covenant and agree to
renegotiate any such term, covenant or application thereof in good faith in
order to provide a reasonably acceptable alternative to the term, covenant or
condition of such documents or the application thereof that is invalid or
unenforceable, it being the intent of the Parties that the basic purposes of
this Agreement are to be effectuated.

      15.11 Third Party Beneficiaries. This Agreement and each and every
provision thereof is for the exclusive benefit of the Parties hereto and not for
the benefit of any third party other than as expressly stated herein.

      15.12 Entire Agreement. This Agreement, including all schedules and
exhibits attached thereto, which are hereby incorporated herein by reference,
set forth all covenants, promises, agreements, warranties, representations,
conditions and understandings between the Parties hereto and supersedes and
terminates all prior and contemporaneous agreements and understandings between
the Parties. There are no covenants, promises, agreements, warranties,
representations, conditions or understandings, either oral or written, between
the Parties other than as set forth in this Agreement. No subsequent alteration,
amendment, change or addition to this Agreement shall be binding upon the
Parties hereto unless reduced to writing and signed by the respective authorized
officers of the Parties.

      15.13 Compliance with U.S. Law and Court Orders. Notwithstanding anything
in this agreement to the contrary, the Parties understand and agree that any and
all actions that can or must be taken by TARCANTA, TARCANTA LTD., and/or their
Affiliates or Sublicensees, or from which any such persons can or must refrain
hereunder from performing, including, without limitation, the obligations for
each such entity set forth under Sections 5.10.5, 5.10.7, 12.6.2 and 15.1.1, are
and shall continue to be limited to the extent that the performance or
non-performance of such obligations is permitted by U.S. law and/or any
applicable Court order, but that non-performance or other failure to fully
perform by TARCANTA, TARCANTA LTD. and/or their Affiliates and Sublicensees on
account of U.S. law and/or any applicable Court order in no way limits CIMAB'S
rights and remedies as delineated in Sections 5.10, 12.6.2 and 15.1.1.

                (Remainder of this page intentionally left blank)

                                       51
<PAGE>

      15.14 Counterparts. This Agreement may be executed in counterparts, each
of which shall be deemed an original, but all of which together shall constitute
one and the same instrument.

      IN WITNESS WHEREOF, the Parties have executed this Agreement by their
proper officers as of the date and year first above written.

         TARCANTA                             CIMAB, S.A.
         INC.

                                                By:   /s/ Norkis Arteaga Morales
                                                      --------------------------
By:  /s/ Hazel M. Aker                          Name: Norkis Arteaga Morales
     -----------------------                    Title: Vice President
Name:  Hazel M. Aker
Title: SVP, General Counsel

         TARCANTA LTD., LTD.

By:  /s/ Hazel M. Aker
     -----------------------
Name:  Hazel M. Aker
Title: SVP, General Counsel

         WITNESSED BY:                        WITNESSED BY:

         /s/ David F. Hale                   /s/ Agustin Bienvenido Lage Davila
         --------------------------          -----------------------------------
         David F. Hale,                      Agustin Bienvenido Lage Davila
         President and CEO,                  Director General,
         CancerVax Corporation               Centro de Inmunologia Molecular

                                       52
<PAGE>

                                    EXHIBIT A
                 EGF AGREEMENT: PATENTS AND PATENT APPLICATIONS
                                      [***]

***Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

<PAGE>

                                      [***]

***Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                       2
<PAGE>

                                      [***]

***Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                       3
<PAGE>

                                      [***]

***Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                       4
<PAGE>

                                      [***]

***Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                       5
<PAGE>

                                      [***]

***Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                       6
<PAGE>

                                      [***]

***Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                       7
<PAGE>

                                      [***]

***Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                       8
<PAGE>

                                      [***]

***Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                       9
<PAGE>

                                      [***]

***Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                       10
<PAGE>

                                      [***]

***Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                       11
<PAGE>

                                      [***]

***Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                       12
<PAGE>

                                      [***]

***Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                       13
<PAGE>

                                    EXHIBIT B
                          FOR THE EGF VACCINE AGREEMENT
                                      [***]

CONFIDENTIAL

***Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                  page 1 of 4

<PAGE>

                                      [***]

CONFIDENTIAL

***Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                  page 2 of 4

<PAGE>

                                      [***]

CONFIDENTIAL

***Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                  page 3 of 4
<PAGE>

                                      [***]

CONFIDENTIAL

***Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                   page 4 of 4

<PAGE>

                                                                    CONFIDENTIAL

                                    EXHIBIT C

                                     FORM OF
                                QUALITY AGREEMENT
                                     BETWEEN
                          TARCANTA INC. / TARCANTA LTD.
                                       AND
                                   CIMAB, S.A.

      THIS QUALITY AGREEMENT (the "Quality Agreement") is made effective as of
the ___ day of ___________, 2004 (the "Effective Date") by and between CIMAB,
S.A., a corporation organized under the laws of Cuba, having offices at Calle
206, No. 1926, e/ 19 y 21, Atabey, Playa, Ciudad de La Habana, Cuba ("CIMAB"),
on the one hand, and TARCANTA Inc., a corporation organized under the laws of
the State of Delaware, United States of America, having offices at 2110
Rutherford Road, Carlsbad, California 92008 ("TARCANTA") and TARCANTA, Ltd., a
corporation organized under the laws of the Republic of Ireland, having offices
at 30 Herbert Street, Dublin 2, Ireland ("TARCANTA LTD."), on the other hand.
TARCANTA, TARCANTA LTD. and CIMAB are sometimes referred to herein individually
as a "Party" and collectively as the "Parties."

                                    RECITALS

      1.    CIMAB, TARCANTA and TARCANTA LTD. have entered into a License,
Development, Manufacturing and Supply Agreement (the "Agreement"), which governs
the supply by CIMAB of certain Licensed Products (as defined in the Agreement;
collectively, the "Products") to TARCANTA and TARCANTA LTD.; and

2.    CIM has assigned the right to enter into this Agreement to CIMAB.

      3.    CIMAB, TARCANTA and TARCANTA LTD. intend that this Agreement shall
provide certain quality assurance requirements appertaining to the supply of the
Products.

In consideration of the premises and of the mutual covenants and obligations set
forth herein, the Parties hereby agree as set forth below.

1.0   DEFINITIONS

      1.1   All initially capitalized terms not defined in this Quality
Agreement shall have the meaning ascribed to such terms in the Agreement.

      1.2   "Vendor" means any supplier of goods or services used by CIMAB in
the manufacture, testing, quality control, quality assurance, shipping,
distribution or storage of the Products or the facilities where CIMAB
manufactures the Products.

2.0   SUPPLY OF PRODUCTS

                                       1
<PAGE>

                                                                    CONFIDENTIAL

      2.1   Adherence to Specifications.

            2.1.1 CIMAB shall manufacture the Products in accordance with the
Specifications applicable thereto in effect at the time of the manufacture of
the Products.

            2.1.2 CIMAB may change the Specifications to ensure the safety and
efficacy of, or to comply with Applicable Laws related to, the Products;
however, before making any such change, CIMAB shall give TARCANTA and TARCANTA
LTD. one hundred and eighty (180) days advance written notification of such
proposed change and the date the change will be made. The Parties shall
cooperate in good faith to attempt to resolve any objections or concerns
TARCANTA and TARCANTA LTD. may have with all such proposed changes.

            2.1.3 TARCANTA and TARCANTA LTD. may request a change to the
Specification to ensure the safety and efficacy of, or to comply with Applicable
Laws related to, the Products. TARCANTA and TARCANTA LTD. shall give CIMAB one
hundred and eighty (180) days advance written notification of such proposed
change and the date the change is requested to be made. Such changes shall be
made unless CIMAB raises objections or concerns with the proposed change, in
which event the Parties shall cooperate in good faith to attempt to resolve
those objections or concerns.

            2.1.4 Except to the extent Sections 2.1.2 or 2.1.3 apply, either
Party may suggest or request a change to the Specifications (including but not
limited to new, changed or unforeseen clinical patterns or usage, circumstances
or developments). Such suggestions and requests shall be made in writing. The
Parties agree to confer in good faith to consider adoption of, and either
Party's objections to or concerns with, any such changes or related or
comparable changes. The Parties agree to establish jointly reasonable schedules
for implementing any such agreed upon changes.

            2.1.5 No other change shall be made to the Specifications except
pursuant to this Section 2.1. Any change made to the Specifications pursuant to
Section 2.1 shall be effective on the date specified or as otherwise mutually
agreed. Products provided thereafter shall conform to the Specifications as
amended, unless otherwise mutually agreed.

      2.2   Change of Vendors.

            2.2.1 CIMAB may change Vendors, to ensure the safety and efficacy
of, or to comply with regulatory requirements related to, the Products; however,
before making any such change, CIMAB shall, as far as practically possible, give
TARCANTA and TARCANTA LTD. one hundred and eighty (180) days advance written
notification of such proposed change and the date the change will be made. The
Parties shall cooperate in good faith to attempt to resolve any objections or
concerns TARCANTA and TARCANTA LTD. may have with the proposed change.

            2.2.2 TARCANTA and TARCANTA LTD. may request a change of Vendors to
ensure the safety and efficacy of, or to comply with regulatory requirements
related to, the Products. TARCANTA and TARCANTA LTD. shall, as far as
practically possible, give

                                       2
<PAGE>

                                                                    CONFIDENTIAL

CIMAB one hundred and eighty (180) days advance written notification of such
proposed change and the date the change is requested to be made. Such changes
shall be made unless CIMAB raises objections or concerns with the proposed
change, in which event the Parties shall cooperate in good faith to attempt to
resolve those objections or concerns.

            2.2.3 Except to the extent Sections 2.2.1 or 2.2.2 apply, either
Party may suggest or request a change of Vendors, for any other reason
(including but not limited to new, changed or unforeseen clinical patterns or
usage, circumstances or developments). Such suggestion or request shall be made
in writing. The Parties agree to confer in good faith to consider adoption of,
and either Party's objections to or concerns with, such change or a related or
comparable change. The Parties agree to establish jointly a reasonable schedule
for implementing any such agreed upon change.

            2.2.4 No other change of Vendors shall be made except pursuant to
this Section 2.2. Any change made pursuant to Section 2.2 shall be effective on
the date specified or as otherwise mutually agreed.

      2.3   Quality System Regulations. CIMAB shall manufacture all Products,
and shall operate and manage its facilities, in compliance with all Applicable
Laws. It shall be the sole responsibility of CIMAB to maintain regulatory
compliance at its facilities.

      2.4   Vendors. CIMAB shall have in place appropriate Standard Operating
Procedures (SOPs) and other written procedures governing the review and audit of
its Vendors. CIMAB shall ensure that its Vendors have in place and follow
appropriate written procedures and SOPs for the provision of products and
services as necessary for CIMAB to remain in compliance with all Applicable
Laws.

      2.5   Inspections. CIMAB shall permit TARCANTA and TARCANTA LTD. to (a)
periodically review and take copies of CIMAB's production and quality control
procedures, manufacturing, quality control and regulatory documents and records
related to the Products at CIMAB's facilities, and (b) visit CIMAB's facilities
in order to assure satisfaction of the requirements of this Agreement and the
Applicable Laws by CIMAB. Any such review or visit shall be at TARCANTA and
TARCANTA LTD.'s expense, upon reasonable advance written request to CIMAB, to
which CIMAB shall promptly respond and cooperate, and, if at a CIMAB facility,
shall be during CIMAB's normal business hours for that facility and with a
representative of CIMAB present. CIMAB shall permit TARCANTA and TARCANTA LTD.
to conduct Audits no less frequently than semi-annually.

3.0   CORRECTIVE ACTION

      3.1   Corrective Action. In the event that CIMAB or TARCANTA and TARCANTA
LTD. believes it necessary to take any corrective action with respect to any of
the Products provided to TARCANTA and TARCANTA LTD., regardless of whether such
action is initiated to comply with Applicable Laws or for other reasons, the
Parties hereto agree that, after discussion between the Parties hereto, TARCANTA
and TARCANTA LTD. and CIMAB will jointly "define the action to be taken" and
CIMAB agrees to implement such action. As used

                                       3
<PAGE>

                                                                    CONFIDENTIAL

herein, "define the action to be taken" means: (a) defining the corrective
action strategy and (b) defining the effectiveness check procedure (to establish
that the corrective action has been completed).

      3.2   Complaints.

            3.2.1 TARCANTA and TARCANTA LTD. shall be responsible for filing all
reports required to be filed under Applicable Laws in order to maintain any
Regulatory Approvals for manufacturing, marketing, and sale of Licensed Products
in the Territory, including, without limitation, adverse drug experience
reports. Each Party shall cooperate with the other Party in preparing and filing
all such reports and, upon the filing Party's request, provide the filing Party
with any information in the non-filing Party's control which the filing Party
deems to be relevant to any such report. Notwithstanding the foregoing, to the
extent that either Party has or receives any information regarding any adverse
drug experience which may be related to the use of any Licensed Product, CIMAB
shall promptly provide TARCANTA and TARCANTA LTD. with all such information.
Promptly after the Effective Date, the Parties shall, as part of the Development
Agreement, determine the procedures to be followed with respect to reporting
adverse drug experiences, such procedures to be consistent with each of the
Parties' obligations under Applicable Laws.

            3.2.2 Within ten (10) working days after receiving notification
about any Licensed Product that has been the subject of a complaint or adverse
event, CIMAB shall, to the extent possible based upon the information available
to CIMAB, provide TARCANTA and TARCANTA LTD. with: (a) the results of CIMAB's
failure investigation on the complaint; (b) a corrective and, where applicable,
preventative action plan; and (c) documentation of the completion of the
corrective action and/or preventative action plan, in accordance with applicable
provisions of the United States Code of Federal Regulations ("CFR") and other
Applicable Laws. The Parties shall cooperate with each other concerning the
investigation of such complaints and adverse events, including information about
specific complaints, on request.

            3.2.3 CIMAB shall maintain a complaint management process compliant
with Applicable Laws for reporting of adverse events outside the Territory,
including, but not be limited to, government product approvals, post-market
surveillance, product complaint management and reporting, corrective actions,
and all activities related to safety alerts and recalls.

      3.3   Warning Letters and Regulatory Actions

      CIMAB agrees to give prompt written notice to TARCANTA and TARCANTA LTD.
of any reports of observations on form 483, warning letters, "untitled" letters
or other similar notices of non-compliance with Applicable Laws with respect to
its facilities or operations used in the provision of Products that it receives
from any Government Authority. CIMAB shall cooperate with TARCANTA and TARCANTA
LTD. and make available to TARCANTA and TARCANTA LTD. such information as
TARCANTA and TARCANTA LTD. reasonably requests from CIMAB as necessary to
respond to any Government Authority in the Territory.

                                       4
<PAGE>

                                                                    CONFIDENTIAL

CIMAB agrees to keep TARCANTA and TARCANTA LTD. apprised as to the status of
such regulatory actions and shall promptly notify TARCANTA and TARCANTA LTD.
when such matters have been resolved.

      IN WITNESS WHEREOF, the Parties have executed this Agreement by their
proper officers as of the date and year first written above.

TARCANTA, INC.                                     CIMAB, S.A.

By:                                                By:
   --------------------------                         --------------------------
  Name:                                             Name:
  Title:                                            Title:

TARCANTA, LTD.

By: --------------------------
    Name:
    Title:

                      [SIGNATURE PAGE TO QUALITY AGREEMENT]

                                       5
<PAGE>

                                    EXHIBIT D
                      PATENT AND KNOW HOW LICENSE AGREEMENT
                                      [***]

***Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                                                               1

<PAGE>

                                      [***]

***Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                                                               2
<PAGE>

                                      [***]

***Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                                                               3
<PAGE>

                                  [CIMAB LOGO]

                                    EXHIBIT E
                            PATENT LICENSE AGREEMENT
                                      [***]

***Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.
<PAGE>

                                  [CIMAB LOGO]

                                      [***]

***Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

<PAGE>

                                  [CIMAB LOGO]

                                      [***]

***Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.<PAGE>

                                                                    EXHIBIT 10.1

                          AGREEMENT AND PLAN OF MERGER

<PAGE>

                          AGREEMENT AND PLAN OF MERGER

                              DATED AUGUST 9, 2004

                                  BY AND AMONG

                          CAPITAL GROWTH SYSTEMS, INC.

                          FRONTRUNNER ACQUISITION, INC.

                                       AND

                       FRONTRUNNER NETWORK SYSTEMS, CORP.

<PAGE>

                          AGREEMENT AND PLAN OF MERGER

         This Agreement and Plan of Merger ("Agreement") is entered into this
9th day of August, 2004, by and among Capital Growth Systems, Inc., a Florida
corporation ("Parent"); Frontrunner Acquisition, Inc., a Delaware corporation,
and a wholly owned subsidiary of Parent ("Mergeco"), and Frontrunner Network
Systems, Corp., a Delaware corporation ("Target" or "Company"). Certain other
capitalized terms used herein are defined in Article XI or elsewhere throughout
this Agreement.

                                    RECITALS

         A. Upon the terms and subject to the conditions set forth herein,
Parent desires to acquire all of the shares of capital stock of the Company (the
"Target Shares"), consisting of Target Preferred Shares and Target Common Shares
(each as defined in Article XI), in exchange for shares of common stock, $0.0001
par value per share, of Parent (the "Parent Common Stock");

         B. Parent and the Company have agreed to accomplish this transaction
through a reverse triangular merger whereby Mergeco will merge with and into
Target, and Target will be the surviving corporation (the "Merger");

         C. The parties hereto intend that the merger qualify as a
"reorganization" within the meaning of Section 368(a)(1) of the Code; and

         D. Each of the Boards of Directors of Target, Parent and Mergeco has
approved this Agreement, and prior to the Closing Date, the Stockholders of the
Company will have approved this Agreement.

         NOW, THEREFORE, in consideration of the mutual representations,
warranties, covenants and agreements contained herein, the parties hereto agree
as follows:

                                    ARTICLE I
                                   THE MERGER

         1.1 Merger. Upon and subject to the terms and conditions set forth in
this Agreement and in accordance with Delaware General Corporation Law, as
amended ("DGCL"), Mergeco shall be merged with and into Target. Following the
Merger, Target shall continue to exist as the surviving corporation (sometimes
referred to as the "Surviving Corporation") and the separate corporate existence
of Mergeco shall cease.

         1.2 Filing and Effective Time. At the Closing, Mergeco and Target shall
file with the Secretary of State of the State of Delaware, a Certificate of
Merger, appropriately completed and executed in accordance with the relevant
provisions of the DGCL. The Merger shall become effective upon filing of the
Certificate of Merger, in accordance with the relevant provisions of the DGCL
(the "Effective Time," and the date thereof hereinafter referred to as the
"Effective Date").

                                       2
<PAGE>

         1.3 Effects of the Merger. The Merger shall have the effects set forth
in the DGCL. Without limiting the generality of the foregoing, and subject
thereto, at the Effective Time, all the rights and property of the Target and
Mergeco shall vest in the Surviving Corporation, and all debts and liabilities
of the Target and Mergeco shall become the debts, liabilities and duties of the
Surviving Corporation. In addition:

                  (a) The Certificate of Incorporation of Target as in effect at
the Effective Time shall be amended and restated in the form of Exhibit A
attached hereto, and shall thereafter remain in effect until duly amended as
provided therein or by applicable law;

                  (b) The By-Laws of Target as in effect at the Effective Time
shall be amended and restated in the form of Exhibit B attached hereto, and
shall thereafter remain in effect until duly amended as provided therein or by
applicable law;

                  (c) The officers of Target immediately prior to the Merger
shall continue to serve as the officers of the Surviving Corporation until the
earlier of their resignation or removal or until their respective successors are
duly elected and qualified, as the case may be; and

                  (d) The directors of Mergeco shall become the directors of the
Surviving Corporation until the earlier of their resignation or removal or until
their respective successors are duly elected and qualified, as the case may be.

         1.4 Merger Consideration.

             (a) In consideration for the Target Shares, the Parent shall (i)
pay in the aggregate $222.18 in exchange for all of shares of 8% Preferred Stock
of the Company ("Senior Preferred") and (ii) all of the shares of (A) Series A
Junior Convertible Preferred Stock of the Company ("Series A Preferred"), (B)
Preferred Stock of the Company (the "Junior Preferred"), (C) the Target Common
Shares and (D) all outstanding unexpired and unexercised options and warrants to
acquire Target Common Shares shall be cancelled and extinguished without
consideration therefore. Subject to the terms and conditions of this Agreement,
as of the Effective Time, by virtue of the Merger and without any action on the
part of Mergeco, the Company or the holder of the Target Shares, the holder of
any options, warrants or other rights to acquire or receive Target Shares, the
following shall occur:

                  (i) Conversion of 8% Senior Preferred Stock. Each share of
Senior Preferred issued and outstanding immediately prior to the Effective Time
will be canceled and extinguished and be converted automatically into the right
to receive $1.00 per share.

                  (ii) Series A Junior Convertible Preferred Stock and Preferred
Stock. Each share of Series A Preferred and Junior Preferred issued and
outstanding immediately prior to the Effective Time will be canceled and
extinguished and be entitled to no payment of any kind.

                  (iii) Cancellation of Company Common Stock. Each Target Common
Share issued and outstanding immediately prior to the Effective Time (other than
any Target Common Shares to be canceled pursuant to Section 1.4(a)(v) and any
Dissenting Target Shares

                                       3
<PAGE>

(to the extent provided in Section 1.9 of this Agreement)) will be canceled and
entitled to no payment of any kind.

                  (iv) Cancellation of Options and Warrants. Any outstanding
options, warrants, convertible notes or other convertible securities, or other
right to acquire shares of capital stock of the Company shall be extinguished
and cancelled without conversion or exercise, and shall thereafter be void and
of no further force and effect and shall not represent any right to acquire
shares in the Surviving Corporation or Parent.

                  (v) Cancellation of Company-Owned Stock. Each share of Target
Shares owned by the Company or any direct or indirect wholly-owned subsidiary of
the Company immediately prior to the Effective Time shall be canceled and
extinguished without any conversion thereof.

             (b) The parties hereto further acknowledge that as additional
consideration for the benefit of Target prior to the Effective Time, Parent is
obligated to issue up to 1,000,000 of its shares of Parent Common Stock to
certain creditors of Company to be exchanged for cancellation of indebtedness of
Company to such creditors in an amount in excess of $1,000,000.

         1.5 Mergeco Shares. Each share of $0.00001 par value common stock of
Mergeco issued and outstanding to Parent immediately prior to the Effective Time
shall by virtue of the Merger be converted into one share of common stock of the
Surviving Corporation.

         1.6 Payment of Merger Consideration.

             (a) At the Closing, the Stockholders who own shares of Senior
         Preferred shall surrender to Parent their stock certificate(s)
         representing their shares of Senior Preferred, accompanied by the
         properly completed and duly executed transmittal materials delivered by
         Parent. Upon receipt of the stock certificates and transmittal
         materials, Parent shall cancel such stock certificates and Parent shall
         thereupon issue to the holders of the shares Senior Preferred the sum
         of $1.00 per share.

             (b) From and after the Effective Time, until so surrendered, the
stock certificates representing shares of Senior Preferred shall be deemed for
all purposes to represent and evidence only the right to receive the per share
consideration set forth in Section 1.4, for each share represented by such
certificates, and no interest shall be paid or accrued on such amount and the
holders of such stock certificates shall cease to have any rights as
stockholders of the Target.

             (c) From and after the Effective Time, the stock certificates
representing the Target Shares other than the Senior Preferred shall be deemed
cancelled and retired, and of no further force and effect, and there shall be no
obligation or requirement for the holders of such Target Shares to surrender
such certificates.

         1.7 No Liability. Neither the Parent, nor the Surviving Corporation
shall be liable to any holder of Target Shares who fails to duly tender his, her
or its certificate and transmittal materials for shares or cash delivered to a
public official pursuant to any applicable abandoned property, escheat or
similar law.

                                       4
<PAGE>

         1.8 Lost, Stolen or Destroyed Certificates. In the event any
certificates for Target Shares shall have been lost, stolen or destroyed, Parent
shall issue in exchange for such lost, stolen or destroyed certificates, upon
the making of an affidavit of that fact by the holder thereof, such cash as may
be required pursuant to this Agreement; provided, however, that Parent may, in
its discretion and as a condition precedent to the issuance thereof, require the
owner of such lost, stolen or destroyed certificates to deliver a bond in such
sum as it may reasonably direct as indemnity against any claim that may be made
against Parent, the Company, the Surviving Corporation or the transfer agent
with respect to the certificates alleged to have been lost, stolen or destroyed.

         1.9 Appraisal Rights.

             (a) Notwithstanding anything herein to the contrary, any Target
Common Shares, Target Junior Preferred Shares and Target Series A Junior Shares
owned by a Dissenting Stockholder ("Dissenting Target Shares") shall not be
converted into the right to receive the consideration hereunder, but such
Dissenting Stockholder shall be entitled to only such payments as are provided
for by the DGCL, which shall be paid by the Surviving Corporation.

             (b) Notwithstanding the provisions of this Section 1.9, if any
Dissenting Stockholder shall effectively withdraw or lose (through failure to
perfect or otherwise) his appraisal rights provided for by the DGCL for his
Target Shares, then, as of the Effective Time, such Dissenting Stockholder's
Target Shares shall automatically be converted into the right to receive only
the merger consideration as provided herein, without interest thereon.

             (c) Prior to the Closing Date, the Company shall give Parent (i)
prompt notice of any written demands by Dissenting Stockholders, withdrawals of
such demands and any other similar instruments served pursuant to the DGCL and
received by the Company and (ii) the opportunity to discuss with the Company any
negotiations and proceedings with respect to such demands and to participate
with the Company in such negotiations and proceedings. Prior to the Closing
Date, the Company shall not, except with the prior written consent of Parent,
voluntarily make any payment with respect to any demands by Dissenting
Stockholders or settle or offer to settle any such demands.

         1.10 The Closing. The Closing of the Merger (the "Closing") shall take
place as soon as the conditions set forth in Articles VII and VIII are satisfied
or at such later date as the parties may agree (the "Closing Date"), at such
place as the parties may agree.

                                   ARTICLE II
                    REPRESENTATIONS AND WARRANTIES OF PARENT

         As a material inducement to the Company to enter into this Agreement
and to consummate the transactions contemplated hereby, Parent makes the
following representations and warranties to the Company, the Stockholders and
Principals:

         2.1 Corporate Status. Parent is a corporation duly organized, validly
existing and in good standing under the laws of the State of Florida and has
full corporate power and authority to own or lease and to operate and use its
properties and assets and to carry on its business as now conducted.

                                       5

<PAGE>

         2.2 Corporate Power and Authority. Parent has the corporate power and
authority to execute and deliver this Agreement and the Parent Ancillary
Documents, to perform its obligations hereunder and thereunder and to consummate
the transactions contemplated hereby and thereby. Parent has taken all corporate
action necessary to authorize its execution and delivery of this Agreement and
the Parent Ancillary Documents, the performance of its obligations hereunder and
thereunder and the consummation of the transactions contemplated hereby and
thereby. No approval of the stockholders of Parent is required to authorize the
transactions contemplated hereby.

         2.3 Enforceability. This Agreement has been duly executed and delivered
by Parent and constitutes a legal, valid and binding obligation of Parent,
enforceable against Parent in accordance with its terms and each of the Parent
Ancillary Documents, upon execution and delivery by Parent, will be a legal,
valid and binding obligation of Parent enforceable in accordance with its terms.

         2.4 No Violation. The execution and delivery of this Agreement and the
Parent Ancillary Documents by Parent, the performance by it of its obligations
hereunder and thereunder and the consummation by it of the transactions
contemplated by this Agreement and the Parent Ancillary Documents will not (i)
contravene any provision of its Certificate of Incorporation or By-Laws, (ii)
violate or conflict with any law, statute, ordinance, rule, regulation, decree,
writ, injunction, judgment or order of any Governmental Authority or of any
arbitration award which is either applicable to, binding upon or enforceable
against Parent, (iii) conflict with, result in any breach of, or constitute a
default (or an event which would, with the passage of time or the giving of
notice or both, constitute a default) under, or give rise to a right to
terminate, amend, modify, abandon or accelerate, any Contract which is
applicable to, binding upon or enforceable against Parent, (iv) result in or
require the creation or imposition of any Lien upon or with respect to any of
the property or assets of Parent, or (v) require the consent, approval,
authorization or permit of, or filing with or notification to, any Governmental
Authority, any court or tribunal or any other Person, except the Secretary of
State of the State of Illinois, or the SEC or other filings required to be made
by Parent.

         2.5 No Commissions. Parent has incurred no obligation for any finder's
or broker's or agent's fees or commissions or similar compensation in connection
with the transactions contemplated hereby.

         2.6 Capitalization. Schedule 2.6 sets forth, with respect to the
Parent, as of the date hereof and as of the Closing Date: (i) the number of
authorized shares of each class and series of its capital stock; (ii) the number
of issued and outstanding shares of each class and series of its capital stock;
and (iii) the number of shares of each class of its capital stock which are held
in treasury. All of the issued and outstanding shares of capital stock of the
Parent (i) have been and will be duly authorized and validly issued and are
fully paid and non assessable, (ii) were and will be issued in compliance with
all applicable state and federal securities laws, and (iii) were not, and will
not be, issued in violation of any preemptive rights or rights of first refusal.
No preemptive rights or rights of first refusal exist or will exist with respect
to the outstanding shares of capital stock of the Parent and no such rights
arise by virtue of or in connection with the transactions contemplated hereby.
Except as set forth on Schedule 2.6, there are no outstanding or authorized
rights, options, warrants, convertible securities, subscription rights,
conversion

                                       6

<PAGE>

rights, exchange rights or other agreements or commitments of any kind that
could require the Parent to issue or sell any shares of its capital stock (or
securities convertible into or exchangeable for shares of its capital stock).
Except as disclosed or specifically referred to on Schedule 2.6, there are no
outstanding stock appreciation, phantom stock, profit participation or other
similar rights with respect to the Parent.

                                   ARTICLE III
                    REPRESENTATIONS AND WARRANTIES OF MERGECO

         As a material inducement to the Company to enter into this Agreement
and to consummate the transactions contemplated hereby, Parent and Mergeco
jointly and severally make the following representations and warranties to the
Company:

         3.1 Corporate Status. Mergeco is a corporation duly organized, validly
existing and in good standing under the laws of the State of Delaware and has
full corporate power and authority to own or lease and to operate and use its
properties and assets and to carry on its business as now conducted.

         3.2 Corporate Power and Authority. Mergeco has the corporate power and
authority to execute and deliver this Agreement and the Mergeco Ancillary
Agreements, to perform its obligations hereunder and thereunder and to
consummate the transactions contemplated hereby and thereby. Mergeco has taken
all action necessary to authorize its execution and delivery of this Agreement,
the performance of its obligations hereunder and thereunder and the consummation
of the transactions contemplated hereby and thereby.

         3.3 Enforceability. This Agreement has been duly executed and delivered
by Mergeco and constitutes a legal, valid and binding obligation of Mergeco,
enforceable against Mergeco in accordance with its terms and each of the Mergeco
Ancillary Agreements, upon execution and delivery by Mergeco, will be a legal,
valid and binding obligation of Mergeco enforceable in accordance with its
terms.

         3.4 No Violation. The execution and delivery of this Agreement and the
Mergeco Ancillary Agreements by Mergeco, the performance by it of its
obligations hereunder and thereunder and the consummation by it of the
transactions contemplated by this Agreement and the Mergeco Ancillary Agreements
will not (i) contravene any provision of the Articles of Incorporation or
By-Laws of Mergeco, (ii) violate or conflict with any law, statute, ordinance,
rule, regulation, decree, writ, injunction, judgment or order of any
Governmental Authority or of any arbitration award which is either applicable
to, binding upon or enforceable against Mergeco, (iii) conflict with, result in
any breach of, or constitute a default (or an event which would, with the
passage of time or the giving of notice or both, constitute a default) under, or
give rise to a right to terminate, amend, modify, abandon or accelerate, any
Contract which is applicable to, binding upon or enforceable against Mergeco,
(iv) result in or require the creation or imposition of any Lien upon or with
respect to any of the property or assets of Mergeco, or (v) require the consent,
approval, authorization or permit of, or filing with or notification to, any
Governmental Authority, any court or tribunal or any other Person, except the
Secretary of State of the State of Illinois, the SEC or other filings required
to be made by Parent.

                                       7

<PAGE>

         3.5 No Commissions. Mergeco has incurred no obligation for any finder's
or broker's or agent's fees or commissions or similar compensation in connection
with the transactions contemplated hereby.

         3.6 Mergeco Capitalization. Mergeco's authorized capital stock consists
of one million (1,000,000) shares of common stock, $0.00001 par value, of which
one thousand (1000) shares are issued and outstanding all of which are validly
issued, fully paid and non assessable, and 1,000,000 shares of blank check
preferred stock, $0.00001 par value per share, none of which is authorized or
outstanding. There are no options, warrants, preemptive rights, conversion
privileges or other contracts which give any Person the right to acquire any
capital stock of Mergeco or any interest therein. Parent is the beneficial and
record owner of all of the outstanding shares of common stock of Mergeco, free
and clear of all Liens.

         3.7 Business Activity. Mergeco has not engaged in any business activity
of any nature prior to the date of this Agreement.

                                   ARTICLE IV
                        REPRESENTATIONS AND WARRANTIES OF
                                   THE COMPANY

         As a material inducement to Parent and Mergeco to enter into this
Agreement and to consummate the transactions contemplated hereby, the Company
makes the following representations and warranties to Parent and Mergeco:

         4.1 Corporate Status. The Company is a corporation duly organized,
validly existing and in good standing under the laws of the State of Delaware.
The Company has the corporate power and authority to own or lease its property
and to carry on its business as now being conducted. The Company is legally
qualified to transact business and is in good standing as a foreign corporation
in each foreign jurisdiction where the nature of its property and the conduct of
its business requires such qualification, except for such jurisdictions where
the failure to so qualify would not have a material adverse effect on the
financial condition or results of operation of the Company (a "Material Adverse
Effect"). There is no pending or threatened proceeding for the dissolution,
liquidation, insolvency or rehabilitation of the Company.

         4.2 Corporate Power and Authority. The Company has full corporate power
and authority to execute and deliver this Agreement and the Company Ancillary
Documents, to perform its obligations hereunder and thereunder and to consummate
the transactions contemplated hereby and thereby. The Company has taken all
corporate action necessary to authorize its execution and delivery of this
Agreement and the Company Ancillary Documents, the performance of its
obligations hereunder and thereunder and the consummation of the transactions
contemplated hereby and thereby.

         4.3 Enforceability. This Agreement has been duly executed and delivered
by the Company and constitutes the legal, valid and binding obligation of the
Company, enforceable against it in accordance with its terms and each of the
Company Ancillary Documents, upon execution and delivery by the Company, will be
a legal, valid and binding obligation of the Company enforceable in accordance
with its terms.

                                       8

<PAGE>

         4.4 No Violation. Except as set forth on Schedule 4.4, the execution
and delivery of this Agreement and the Company Ancillary Documents by the
Company, the performance by it of its obligations hereunder and thereunder and
the consummation by it of the transactions contemplated by this Agreement and
the Company Ancillary Documents will not (i) contravene any provision of the
Articles of Incorporation or By-Laws of the Company, (ii) violate or conflict
with any law, statute, ordinance, rule, regulation, decree, writ, injunction,
judgment or order of any Governmental Authority or of any arbitration award
which is either applicable to, binding upon or enforceable against the Company;
(iii) conflict with, result in any breach of, or constitute a default (or an
event which would, with the passage of time or the giving of notice or both,
constitute a default) under, or give rise to a right to terminate, amend,
modify, abandon or accelerate, any Contract which is applicable to, binding upon
or enforceable against the Company, (iv) result in or require the creation or
imposition of any Lien upon or with respect to any of the property or assets of
the Company, or (v) require the consent, approval, authorization or permit of,
or filing with or notification to, any Governmental Authority, any court or
tribunal or any other Person, except the Secretary of State of the State of
Delaware.

         4.5 Capitalization. Schedule 4.5 sets forth, with respect to the
Company, (i) the number of authorized shares of each class of its capital stock,
(ii) the number of issued and outstanding shares of each class of its capital
stock, and (iii) the number of shares of each class of its capital stock which
are held in treasury. All of the issued and outstanding shares of capital stock
of the Company (i) are legally and beneficially owned by the Person in such
amounts as set forth each Person's name on Schedule 4.5, (ii) have been duly
authorized and validly issued and are fully paid and non assessable, (iii) were
issued in compliance with all applicable state and federal securities laws, and
(iv) were not issued in violation of any preemptive rights or rights of first
refusal. No preemptive rights or rights of first refusal exist with respect to
the outstanding shares of capital stock of the Company, and no such rights arise
by virtue of or in connection with the transactions contemplated hereby. Except
as disclosed or specifically referred to on Schedule 4.5 there are no
outstanding or authorized rights, options, warrants, convertible securities,
subscription rights, conversion rights, exchange rights or other agreements or
commitments of any kind that could require the Company to issue or sell any
shares of its capital stock (or securities convertible into or exchangeable for
shares of its capital stock). There are no outstanding stock appreciation,
phantom stock, profit participation or other similar rights with respect to the
Company. There are no proxies, voting rights or other agreements or
understandings with respect to the voting or transfer of the outstanding capital
stock of the Company. The Company is not obligated to redeem or otherwise
acquire any of its outstanding shares of capital stock.

         4.6 Subsidiaries. The Company does not own, directly or indirectly, any
outstanding voting securities of or other interests in, or control, any other
corporation, partnership, joint venture or other business entity.

         4.7 Financial Statements. The Company has delivered to Parent (i) the
unaudited financial statements of the Company for the fiscal year ended March
31, 2004 and (ii) the unaudited financial statements of the Company as of June
30, 2004 for the three months then ended (collectively, the "Financial
Statements"), copies of which are attached as Schedule 4.7 hereto. The balance
sheet dated as of March 31, 2004 included in the Financial Statements is
referred to herein as the "Current Balance Sheet." The Financial Statements have
been prepared

                                       9

<PAGE>

from the books and records of the Company in accordance with GAAP, except as set
forth on Schedule 4.7. The Financial Statements, fairly present the financial
position of the Company as of the dates of the balance sheets included in the
Financial Statements and the results of the Company's operations for the periods
covered by the statements of operations included in the Financial Statements.

         4.8 Changes Since January 1, 2004. Except as disclosed in Schedule 4.8
or as contemplated herein, since March 31, 2004, the Company has not:

                        (i) issued any capital stock or other securities;

                        (ii) made any dividends or distribution of or with
respect to its capital stock or other securities or purchased or redeemed any of
its securities;

                        (iii) paid any bonus to or increased the rate of
compensation of any of its officers or salaried employees or amended any other
terms of employment of such persons;

                        (iv) sold, leased or transferred any of its properties
or assets other than in the ordinary course of business consistent with past
practice;

                        (v) made or obligated itself to make capital
expenditures in excess of $5,000 in any one case or $20,000 in the aggregate;

                        (vi) made any payment in respect of its liabilities
other than in the ordinary course of business consistent with past practice;

                        (vii) incurred any obligations or liabilities (including
any indebtedness) or entered into any transaction or series of transactions
involving in excess of $50,000 in the aggregate out of the ordinary course of
business, except for this Agreement and the transactions contemplated hereby;

                        (viii) suffered any theft, damage, destruction or
casualty loss;

                        (ix) made or adopted any change in its accounting
practice or policies;

                        (x) waived, canceled, compromised or released any rights
having a value in excess of $10,000 in the aggregate

                        (xi) terminated, amended or modified any contract,
except in the ordinary course of business or in connection with adoption of
payment programs to Creditors for past due accounts payable;

                        (xii) made any adjustment to its books and records other
than in respect of the conduct of its business activities in the ordinary course
consistent with past practice;

                        (xiii) entered into any transaction with any Affiliate
other than intercompany transactions in the ordinary course of business
consistent with past practice;

                                       10

<PAGE>

                        (xiv) entered into any employment agreement;

                        (xv) imposed any security interest or other Lien on any
of its assets;

                        (xvi) delayed paying any accounts payable, not being
contested in good faith, otherwise than in the ordinary course of business
consistent with past practice; or

                        (xvii) agreed to do or authorized any of the foregoing.

         4.9 Liabilities. Except as set forth on Schedule 4.9, the Company does
not have any liabilities or obligations, whether accrued, absolute, contingent
or otherwise, except (i) to the extent reflected or taken into account in the
Current Balance Sheet and heretofore not paid or discharged, (ii) to the extent
specifically set forth in or incorporated by express reference in any of the
Schedules attached hereto, and (iii) liabilities incurred in the ordinary course
of business consistent with past practice since the date of the Current Balance
Sheet, none of which are past due or arose from a breach of a contract, a
lawsuit, claim or violation of law.

         4.10 Litigation. Except for potential creditor claims for past due
accounts payable, there is no action, suit, or other legal or administrative
proceeding or governmental investigation, pending or, to the Company's
Knowledge, threatened, anticipated or contemplated against, by or affecting the
Company or any of its properties or assets, or which question the validity or
enforceability of this Agreement or the transactions contemplated hereby, and to
the Company's knowledge, there is no basis for any of the foregoing. There are
no outstanding orders, decrees or stipulations issued by any Governmental
Authority in any proceeding to which the Company is or was a party which have
not been complied with in full or which continue to impose any material
obligations on the Company.

         4.11 Real Estate.

              (a) There is no real property legally or beneficially owned by the
Company (the "Owned Real Properties").

              (b) Schedule 4.11(b) sets forth a list of all leases, licenses or
similar agreements (the "Leases") relating to the real property (the "Leased
Real Properties") to which the Company is a party (copies of which have
previously been furnished to Parent). The Leases are in full force and effect
and have not been amended. The Company is not in default or breach of any Lease,
and to the Company's Knowledge, no other party is in default or breach of any
Lease. No event has occurred which, with the passage of time or the giving of
notice or both, would cause a material breach of or default by the Company under
any of such Leases.

              (c) With respect to each parcel constituting the Owned Real
Properties and the Leased Real Properties (collectively, the "Real Properties"):

                        (i) The Company has not received written notice of any
pending or threatened condemnation, eminent domain or similar proceedings with
respect to the Real Properties and have no knowledge that any such proceedings
are threatened or contemplated.

                                       11

<PAGE>

                        (ii) Except for Permitted Liens, there are no Contracts
granting to any party or parties (other than the Company) the right of use or
occupancy of any portion of the Real Properties. There are no outstanding
options or rights of first refusal to purchase any parcel of the Real
Properties.

                        (iii) All improvements and buildings on the Owned Real
Properties are in good repair, ordinary wear and tear excepted; and the
structural components and systems (including plumbing, electrical, air
conditioning/heating and sprinklers) are in good working order in all material
respects, ordinary wear and tear and ordinary course maintenance and replacement
excepted.

                        (iv) The Company has title to the Owned Real Properties,
free and clear of all Liens, and adverse claims of any kind or character, other
than the Permitted Liens.

                        (v) The Company has not requested, and, to the knowledge
of the Company, there is no pending request for, rezoning of the Owned Real
Properties or any other zoning variance for the Owned Real Properties.

                        (vi) There are no material pending tax certiorari
proceedings with respect to the Real Properties, or any tax abatements or
exemptions affecting the Real Properties. The Company has received in the twelve
months prior to the Closing Date any notice of, or has any knowledge of, any
proposed increase in the assessed valuation of the Real Properties or of any
proposed public improvement assessment.

                        (vii) Within the past two years, no casualty has
occurred at the Real Properties.

         4.12 Good Title to and Condition of Personal Property Assets. The
Company has good and valid title to all of its Assets, free and clear of any
Liens or restrictions on use. The tangible personal property owned by the
Company and currently in use by the business and operations of the Company is in
good operating condition, normal wear and tear excepted, and has been maintained
in accordance with sound industry practices.

         4.13 Personal Property Leases. Schedule 4.13 contains a brief
description of each lease or other Contract with an annual rent exceeding
$20,000 under which the Company is lessee of, or holds or operates, any
machinery, equipment, vehicle or other tangible personal property owned by a
third Person and used in or relating to the Company's business (an "Equipment
Lease"). The assets being leased pursuant to Equipment Leases are is in good
operating condition, normal wear and tear excepted, and has been maintained in
accordance with sound industry practices. The Company has complied in all
material respects with the terms and conditions of each Equipment Lease and, to
the Company's knowledge, all of the covenants to be performed by any other party
thereto have been fully performed and there are no claims for breach or
indemnification or notice of default or termination under any Equipment Lease.
The Company is not, nor will it be, as a result of the execution and delivery of
this Agreement or the performance of its obligations under this Agreement, in
breach of any Equipment Lease.

                                       12

<PAGE>

         4.14 Intellectual Property.

              (a) The Company owns all right, title, and interest in (free and
clear of all Liens) all of the Intellectual Property described on Schedule 4.14
("Owned Intellectual Property").

              (b) Schedule 4.14 lists (i) all patents and patent applications
and all registered and unregistered trademarks, trade names and service marks,
registered and material unregistered copyrights, and mask works included in the
Owned Intellectual Property, including the jurisdictions in which each such
Owned Intellectual Property right has been issued or registered or in which any
application for such issuance and registration has been filed; (ii) all
licenses, sublicenses and other agreements to which the Company is a party
pursuant to which any Person is authorized to use any Owned Intellectual
Property; and (iii) all licenses, sublicenses and other agreements to which the
Company is a party pursuant to which the Company is authorized to use any
third-party (including without limitation for the purposes of this Section 4.14
any employees of the Company) Intellectual Property which is not Owned
Intellectual Property, or which is incorporated in, is, or forms a part of, any
Owned Intellectual Property (the "Third Party Intellectual Property"). Except as
set forth in Schedule 4.14, no royalties or other continuing payment obligations
are due in respect of the Owned Intellectual Property. Except as set forth in
Schedule 4.14, all patents and registrations or applications therefore included
in Owned Intellectual Property are valid and subsisting and in full force and
effect and are applied for and owned in the name of the Company.

              (c) The Company is not, nor will it be, as a result of the
execution and delivery of this Agreement or the performance of its obligations
under this Agreement, in breach of any license, sublicense or other agreement
relating to Owned Intellectual Property.

              (d) The Owned Intellectual Property does not dilute, misuse,
infringe, misappropriate or otherwise come into conflict with any Intellectual
Property of any other Person (including without limitation any Employee). No
charge, complaint, demand, notice or claim is pending or has been made to such
effect and the Company has not received written notice so alleging (including
any claim that the Company must license or refrain from using any Intellectual
Property of any other such Person). No action, suit, proceeding, hearing,
investigation, charge, complaint, claim or demand is pending or, to the
Company's Knowledge, threatened, that challenges the legality, validity,
enforceability, use or ownership of any item of Owned Intellectual Property, nor
is any Owned Intellectual Property subject to any outstanding injunction,
judgment, order, decree, ruling or charge.

              (e) Except for the Third Party Intellectual Property, all
Intellectual Property used in or necessary to the conduct of the Company's
business as presently conducted or currently contemplated to be conducted by the
Company is Owned Intellectual Property and was written and created solely by
either (i) employees of the Company acting within the scope of their employment
or (ii) by third parties who have validly and irrevocably assigned all of their
rights therein to the Company, and no third party owns or has any right to any
of the Owned Intellectual Property. Except as described in Schedule 4.14, no
person who has licensed Intellectual Property to the Company has ownership
rights or license rights to improvements made by the Company in such
Intellectual Property.

                                       13

<PAGE>

              (f) To the Company's knowledge, no third party has interfered
with, infringed upon, misappropriated, misused, diluted or otherwise come into
conflict with any Owned Intellectual Property.

         4.15 Adequacy of the Assets. The Assets, the Leased Assets, and any
Third Party Intellectual Property licensed by the Company, constitutes, in the
aggregate, all of the assets, rights and properties necessary for the conduct by
the Company of its business in the manner in which and to the extent to which
such business is currently being conducted.

         4.16 Licenses and Permits. The Company possesses all licenses and
required governmental or official approvals, permits or authorizations
(collectively, the "Permits") necessary to lawfully conduct its business and
operations which Permits are listed on Schedule 4.16. All such Permits are valid
and in full force and effect, the Company is in material compliance with the
requirements thereof, and no proceeding is pending or threatened to revoke or
amend any of them.

         4.17 Compliance with Laws.

              (a) The Company has complied in all material respects with all
laws, regulations and orders applicable to it, its business, operations, Assets
and Leased Assets. The Company has not been cited, fined or otherwise notified
of any asserted past or present failure to comply with any laws, regulations or
orders and no proceeding with respect to any such violation is pending or
threatened.

              (b) The Company has not made any payment of funds in connection
with its business which is prohibited by law, and no funds have been set aside
to be used in connection with its business for any payment prohibited by law.

         4.18 Environmental Matters.

              (a) The operations of the Company are and have at all times been
in compliance in all material respects with all applicable Environmental Laws.
The Company has not received written notice of any violation of any
Environmental Laws applicable to the Real Properties, Assets, Leased Assets or
the Company's operations;

              (b) The Company has in all material respects obtained, maintained
and complied with all Permits required by Environmental Laws and necessary for
the operation of its business;

              (c) No Hazardous Substances have been generated, transported,
stored, treated, recycled or otherwise handled in any way in the operation of
the Company's business, except for inventories of raw materials and supplies
used or to be used in the ordinary and normal course of operating the business
(all of which were or are stored in all material respects in accordance with
applicable Environmental Laws);

              (d) There are no locations not owned or operated by the Company
where Hazardous Substances generated by the Company have been stored, treated,
recycled or disposed of;

                                       14

<PAGE>

              (e) No Hazardous Substances generated by the Company are located
on, contained in or otherwise form a part of the Property of the Company, except
for inventories of raw materials and supplies used or to be used in the ordinary
and normal course of operating the Company's business (all of which were or are
stored in all material respects in accordance with applicable Environmental
Laws);

              (f) To the Company's Knowledge, there is no past or ongoing
Release from Properties associated with the operation of the Company's business
or from other locations where Hazardous Substances associated with the operation
of the Company's business have been or are located, except for federally
permitted Releases;

              (g) The Company has not received any written notice indicating
that any Person may have impaired health as a result of the operation of the
Company's business or the ownership or use of any Property associated with the
operation of the Company's business or as the result of the Release from such
Properties;

              (h) The Company has not treated, stored for more than ninety (90)
days, or disposed of any hazardous waste (as such term is used within the
meaning of the RCRA or similar applicable state or municipal law) associated
with the operation of the Company's business, except in compliance in all
material respects with applicable Environmental Laws;

              (i) The Company has not received any written notice from any
Governmental Authority or other Person advising that any of them is potentially
responsible for Remedial Action with respect to a Release or threatened Release;

              (j) No underground storage tanks are or, to the Company's
Knowledge, ever were located on any properties owned or leased by the Company;

              (k) No court order, litigation, settlement or citation in an
action to which the Company is a party with respect to Hazardous Substances
exists with respect to or in connection with the operation of the Company's
business;

              (l) To the Company's Knowledge, there has been no environmental
investigation conducted by any Governmental Authority with respect to the
operation of the Company's business; and

              (m) To the Company's Knowledge, there are no PCBs which are
located on, contained in or otherwise form a part of any of the Property.

         4.19 Tax Matters. Except as set forth in Schedule 4.19 hereto, all Tax
Returns required to be filed prior to the date hereof with respect to the
Company, or any of its income, properties, franchises or operations have been
filed, each such Tax Return has been prepared in compliance with the Internal
Revenue Code of 1986, as amended (the "Code") or other foreign, federal, state
or local applicable laws and regulations, and all such Tax Returns are true,
complete and accurate in all respects. All Taxes due and payable by or with
respect to the Company have been paid or accrued on the Current Balance Sheet or
will be accrued on its books and records as of the Closing. Except as set forth
in Schedule 4.19 hereto: (i) with respect to each taxable period of the Company,
no taxable period has been audited by the relevant taxing authority; (ii) no

                                       15
<PAGE>

deficiency or proposed adjustment which has not been settled or otherwise
resolved for any amount of Taxes has been asserted or assessed by any taxing
authority; (iii) the Company has not consented to extend the time in which any
Taxes may be assessed or collected by any taxing authority; (iv) the Company has
not requested or been granted an extension of the time for filing any Tax Return
to a date later than the Closing Date; (v) there is no action, suit, taxing
authority proceeding, or audit or claim for refund now in progress, pending or
threatened against or with respect to the Company regarding Taxes; (vi) the
Company has not made an election or filed a consent under Section 341(f) of the
Code (or any corresponding provision of state, local or foreign law) on or prior
to the Closing Date; (vii) there are no Liens for Taxes (other than for current
Taxes not yet due and payable) upon the assets of the Company; (viii) the
Company will not be required (A) as a result of a change in method of accounting
for a taxable period ending on or prior to the Closing Date, to include any
adjustment under Section 481(c) of the Code (or any corresponding provision of
state, local or foreign law) in taxable income for any taxable period (or
portion thereof) beginning after the Closing Date or (B) as a result of any
"closing agreement," as described in Section 7121 of the Code (or any
corresponding provision of state, local or foreign law), to include any item of
income or exclude any item of deduction from any taxable period (or portion
thereof) beginning after the Closing Date; (ix) the Company is not a party to or
bound by any tax allocation or tax sharing agreement or has any current or
potential contractual obligation to indemnify any other Person with respect to
Taxes; (x) there is no basis for any assessment, deficiency notice, 30-day
letter or similar notice with respect to any Tax to be issued to the Company
with respect to any period on or before the Closing Date; (xi) the Company has
not made any payments, and is or will not become obligated (under any contract
entered into on or before the Closing Date) to make any payments, that will be
non deductible under Section 280G of the Code (or any corresponding provision of
state, local or foreign law); (xii) the Company has not been a United States
real property holding corporation within the meaning of Section 897(c)(2) of the
Code (or any corresponding provision of state, local or foreign law) during the
applicable period specified in Section 897(c)(1)(a)(ii) of the Code (or any
corresponding provision of state, local or foreign law); (xiii) no claim has
ever been made by a taxing authority in a jurisdiction where the Company does
not file Tax Returns that is or may be subject to Taxes assessed by such
jurisdiction; (xiv) the Company does not have any permanent establishment in any
foreign country, as defined in the relevant tax treaty between the United States
of America and such foreign country; (xv) true, correct and complete copies of
all income and sales Tax Returns filed by or with respect to the Company for the
past two years has been furnished or made available to Parent; (xvi) the Company
will not be subject to any Taxes for the period ending at or before the Closing
Date for which period a Tax Return has not then or theretofore been filed
imposed pursuant to Section 1374 or Section 1375 of the Code (or any
corresponding provision of state, local or foreign law); and (xvii) no sales or
use tax or property transfer tax (other than sales tax on aircraft, boats,
mobile homes and motor vehicles), non recurring intangibles tax, documentary
stamp tax or other excise tax (or comparable tax imposed by any Governmental
Authority) will be payable by the Company or Parent by virtue of the
transactions completed in this Agreement.

         4.20 Labor and Employment Matters. The Company is not a party to or
bound by any collective bargaining agreement or any other agreement with a labor
union, and there have been no efforts by any labor union during the 24 months
prior to the date hereof to organize any employees of the Company into one or
more collective bargaining units. There is no pending or threatened labor
dispute, strike or work stoppage which affects or which may affect the business

                                       16

<PAGE>

of the Company which may interfere with its continued operations. The Company is
not aware that any executive or key employee or group of employees has any plans
to terminate his, her or their employment with the Company as a result of this
Agreement or otherwise. To the Company's Knowledge, the Company has complied
with applicable laws, rules and regulations relating to employment, civil
rights, immigration and equal employment opportunities, including but not
limited to, the Civil Rights Act of 1964, the Fair Labor Standards Act, the
Worker Adjustment and Retraining Notification Act of 1988 and the Immigration
Reform and Control Act of 1986, as amended..

         4.21     Employee Benefit Plans.

                  (a) Employee Benefit Plans. Schedule 4.21 contains a list
setting forth each employee benefit plan or arrangement of the Company,
including but not limited to employee pension benefit plans, as defined in
Section 3(2) of the Employee Retirement Income Security Act of 1974, as amended
("ERISA"), multiemployer plans, as defined in Section 3(37) of ERISA, employee
welfare benefit plans, as defined in Section 3(1) of ERISA, deferred
compensation plans, stock option plans, bonus plans, stock purchase plans,
hospitalization, disability and other insurance plans, severance or termination
pay plans and policies, whether or not described in Section 3(3) of ERISA, in
which employees, their spouses or dependents, of the Company participate
("Employee Benefit Plans").

                  (b) Compliance with Law. With respect to each Employee Benefit
Plan (i) each has been administered in all material respects in compliance with
its terms and with all applicable laws, including, but not limited to, ERISA and
the Code; (ii) no actions, suits, claims or disputes are pending, or threatened;
(iii) no audits, inquiries, reviews, proceedings, claims, or demands are pending
with any governmental or regulatory agency; (iv) there are no facts which could
give rise to any material liability in the event of any such investigation,
claim, action, suit, audit, review, or other proceeding; (v) all material
reports, returns, and similar documents required to be filed with any
governmental agency or distributed to any plan participant have been duly or
timely filed or distributed; and (vi) no "prohibited transaction" has occurred
within the meaning of the applicable provisions of ERISA or the Code.

                  (c) Qualified Plans. With respect to each Employee Benefit
Plan intended to qualify under Code Section 401(a) or 403(a): (i) the Internal
Revenue Service has issued a favorable determination letter that such plans are
qualified and exempt from federal income taxes; (ii) no such determination
letter has been revoked nor has revocation been threatened, nor has any
amendment or other action or omission occurred with respect to any such plan
since the date of its most recent determination letter or application therefore
in any respect which would adversely affect its qualification or materially
increase its costs; (iii) no such plan has been amended in a manner that would
require security to be provided in accordance with Section 401(a)(29) of the
Code; (iv) no reportable event (within the meaning of Section 4043 of ERISA) has
occurred, other than one for which the 30 day notice requirement has been
waived; (v) as of the Effective Date, the present value of all liabilities that
would be "benefit liabilities" under Section 4001(a)(16) of ERISA if benefits
described in Code Section 411(d)(6)(B) were included will not exceed the then
current fair market value of the assets of such plan (determined using the
actuarial assumptions used for the most recent actuarial valuation for such
plan); (vi) except as

                                       17

<PAGE>

disclosed on Schedule 4.21, all contributions to, and payments from and with
respect to such plans, which may have been required to be made in accordance
with such plans and, when applicable, Section 302 of ERISA or Section 412 of
the Code, have been timely made; and (vii) all such contributions to the
plans, and all payments under the plans (except those to be made from a trust
qualified under Section 401(a) of the Code) and all payments with respect
to the plans (including, without limitation, PBGC and insurance premiums) for
any period ending before the Closing Date that are not yet, but will be,
required to be made are properly accrued and reflected on the Current Balance
Sheet or are disclosed on Schedule 4.21.

                  (d) Multiemployer Plans.  The Company is not subject to any
multiemployer plan, as described in Section 4001(a)(3) of ERISA ("MPPA Plan").

                  (e) Welfare Plans. The Company represents that: (i) the
Company is not obligated under any employee welfare benefit plan as described in
Section 3(1) of ERISA ("Welfare Plan"), whether or not disclosed in Schedule
4.21, to provide medical or death benefits with respect to any employee or
former employee of the Company, or its predecessors after termination of
employment; (ii) the Company has complied with the notice and continuation
coverage requirements of Section 4980B of the Code and the regulations
thereunder with respect to each Welfare Plan that is, or was during any taxable
year for which the statute of limitations on the assessment of federal income
taxes remains, open, by consent or otherwise, a group health plan within the
meaning of Section 5000(b)(1) of the Code, and (iii) there are no reserves,
assets, surplus or prepaid premiums under any Welfare Plan which is an Employee
Benefit Plan. The consummation of the transactions contemplated by this
Agreement will not entitle any individual to severance pay, and, will not
accelerate the time of payment or vesting, or increase the amount of
compensation, due to any individual.

                  (f) Controlled Group Liability. Neither the Company nor any
entity that would be aggregated with them under Code Section 414(b), (c), (m) or
(o): (i) has ever terminated or withdrawn from an employee benefit plan under
circumstances resulting (or expected to result) in liability to the Pension
Benefit Guaranty Corporation ("PBGC"), the fund by which the employee benefit
plan is funded, or any employee or beneficiary for whose benefit the plan is or
was maintained (other than routine claims for benefits); (ii) has any assets
subject to (or expected to be subject to) a lien for unpaid contributions to any
employee benefit plan; (iii) has failed to pay premiums to the PBGC when due;
(iv) is subject to (or expected to be subject to) an excise tax under Code
Section 4971; (v) has engaged in any transaction which would give rise to
liability under Section 4069 or Section 4212(c) of ERISA; or (vi) has violated
Code Section 4980B or Section 601 through 608 of ERISA.

                  (g) Other Liabilities. Except as set forth on Schedule 4.21,
(i) none of the Employee Benefit Plans obligates the Company to pay separation,
severance, termination or similar benefits solely as a result of any transaction
contemplated by this Agreement or solely as a result of a "change of control"
(as such term is defined in Section 280G of the Code), (ii) all required or
discretionary (in accordance with historical practices) payments, premiums,
contributions, reimbursements, or accruals for all periods ending prior to or as
of the Effective Date shall have been made or properly accrued on the Current
Balance Sheet or will be properly accrued on the books and records of the
Company as of the Effective Date, and (iii) none of the

                                       18

<PAGE>

Employee Benefit Plans has any unfunded liabilities which are not reflected on
the Current Balance Sheet or the books and records of the Company

         4.22 Contracts. Schedule 4.22 sets forth a list of each Designated
Contract to which the Company is a party or by which its properties and assets
are bound, true and correct copies of which have been provided to Parent. Except
as noted in Schedule 4.22, the Company has not violated any of the terms or
conditions of any Designated Contract or any term or condition which would
permit termination or material modification of any Designated Contract, and the
Company has not received any claim for breach or indemnification or notice of
default or termination under any Designated Contract. No event has occurred
which constitutes, or after notice or the passage of time, or both, would
constitute, a default by the Company under any Designated Contract, and to the
Company's Knowledge, no such event has occurred which constitutes or would
constitute a material default by any other party. As used in this Section,
"Designated Contracts" shall include, without limitation, (a) loan agreements,
indentures, mortgages, pledges, hypothecations, deeds of trust, conditional sale
or title retention agreements, security agreements, equipment financing
obligations or guaranties, or other sources of contingent liability in respect
of any indebtedness or obligations to any other Person, or letters of intent or
commitment letters with respect to same; (b) contracts obligating the Company to
purchase or sell products or services; (c) leases of real property, and leases
of personal property not cancelable without penalty on notice of 30 days or less
or calling for payment of an annual gross rental exceeding $10,000.00 in any one
case; (d) distribution, sales agency or franchise or similar agreements, or
agreements providing for an independent contractor's services, or letters of
intent with respect to same; (e) employment agreements, management service
agreements, consulting agreements, confidentiality agreements, noncompetition
agreements and any other agreements relating to any employee, officer or
director of the Company; (f) licenses, assignments or transfers of Intellectual
Property, or other agreements regarding proprietary rights or intellectual
property; (g) any Contract relating to pending capital expenditures by the
Company; and (h) other material Contracts or understandings, irrespective of
subject matter and whether or not in writing, not entered into in the ordinary
course of business by the Company and not otherwise disclosed on the Schedules
attached hereto.

         4.23 Restrictions. Schedule 4.23 sets forth a list of all
non-competition, non-solicitation, confidentiality and other restrictive
covenants to which the Company, its officers, directors, employees or managers
is a party or otherwise bound. Except as set forth on Schedule 4.23, neither the
Company nor any of its officers, directors, managers is a party to any Contract
which would in any way limit or restrict the rights of Parent, Parent's
Affiliates or the Surviving Corporation from engaging in any business anywhere
in the world.

         4.24 Accuracy of Information Furnished by the Company. No
representation contained in this Article IV contains, and the certificate
referred to in Section 7.1 when delivered will not contain, any untrue statement
of a material fact or omits (or in the case of such certificate, will omit) to
state a material fact necessary to make the statements contained therein not
misleading.

         4.25 No Commissions.  None of the Company or its Affiliates has
incurred any obligation for any finder's or broker's or agent's fees or
commissions or similar compensation in connection with the transactions
contemplated hereby.

                                       19

<PAGE>

                                    ARTICLE V
                     CONDUCT OF BUSINESS PENDING THE CLOSING

         5.1 Conduct of Business Pending the Closing. Except pursuant to
commitments disclosed in, or permitted or contemplated by this Agreement, the
Company covenants and agrees that, between the date of this Agreement and the
Closing Date, the business of the Company shall be conducted only in, and the
Company shall not take any action except in, the ordinary course of business,
consistent with past practice and in compliance with all Laws. By way of
amplification and not limitation, except pursuant to commitments disclosed in,
or permitted or contemplated by this Agreement, the Company shall not, between
the date of this Agreement and the Closing Date, directly or indirectly, do or
propose or agree to do any of the following without the prior written consent of
Parent:

                  (a) amend or otherwise change its Certificate of
Incorporation or By-Laws;

                  (b) issue, sell, pledge, dispose of, encumber, or, authorize
the issuance, sale, pledge, disposition, grant or encumbrance of (i) any shares
of its capital stock of any class, or any options, warrants, convertible
securities or other rights of any kind to acquire any shares of such capital
stock, or any other ownership interest, thereof, or (ii) any of its assets,
tangible or intangible, except in the ordinary course of business consistent
with past practice;

                  (c) declare, set aside, make or pay any dividend or
other distribution, payable in cash, stock, property or otherwise, with respect
to any of its capital stock;

                  (d) reclassify, combine, split, subdivide or redeem,
purchase or otherwise acquire, directly or indirectly, any of its capital stock;

                  (e) (i) acquire (including, without limitation, for cash or
shares of stock, by merger, consolidation, or acquisition of stock or assets)
any interest in any corporation, partnership or other business organization or
division thereof or any assets, or make any investment either by purchase of
stock or securities, contributions of capital or property transfer, or, except
in the ordinary course of business, consistent with past practice, purchase any
property or assets of any other Person, (ii) incur any indebtedness for borrowed
money or issue any debt securities or assume, guarantee or endorse or otherwise
as an accommodation become responsible for, the obligations of any Person, or
make any loans or advances, or (iii) enter into any Contract other than in the
ordinary course of business, consistent with past practice;

                  (f) make any capital expenditure in excess of $10,000 or
 enter into any contract or commitment therefore;

                  (g) amend, terminate or extend any Contract;

                  (h) sell, lease (as lessor), transfer or otherwise dispose of,
or mortgage or pledge, or impose or suffer to be imposed any Lien on, any of the
Company's Assets, other than inventory and minor amounts of personal property
sold or otherwise disposed of for fair value in the ordinary course of business
consistent with past practice;

                                       20

<PAGE>

                  (i) delay or accelerate payment of any account payable or
other liability of the Company beyond or in advance of its due date or the date
when such liability would have been paid in the ordinary course of business
consistent with past practice;

                  (j) increase the compensation payable or to become payable to
its respective officers or directors, or, except as presently bound to do, grant
any severance or termination pay to, or enter into any employment or severance
agreement with, any of its respective directors or officers, or establish,
adopt, enter into or amend or take any action to accelerate any rights or
benefits under any collective bargaining, bonus, profit sharing, trust,
compensation, stock option, restricted stock, pension, retirement, deferred
compensation, employment, termination, severance or other plan, agreement,
trust, fund, policy or arrangement for the benefit of any directors, officers or
employees;

                  (k) sell, lease (as lessor), transfer or otherwise dispose of,
or mortgage or pledge, or impose or suffer to be imposed any Lien on any of the
Company's Assets, other than inventory and minor amounts of personal property
sold or otherwise disposed of for fair value in the ordinary course of business
consistent with past practice;

                  (l) increase or decrease prices charged to its
respective customers, except for previously announced price changes or except in
the ordinary course of business; or

                  (m) agree, in writing or otherwise, to take or authorize any
of the foregoing actions or any action which would make any representation or
warranty contained in Article IV untrue or incorrect.

         5.2 Investigation of the Company by Parent. The Company shall afford to
the officers, employees and authorized representatives of Parent (including,
without limitation, independent public accountants and attorneys) complete
access during normal business hours to the offices, properties, employees and
business and financial records (including computer files, retrieval programs and
similar documentation) of the Company prior to the Closing Date to the extent
Parent shall deem necessary or desirable and shall furnish to Parent or its
authorized representatives such additional information concerning the Company as
shall be reasonably requested. Parent agrees that such investigation shall be
conducted in such a manner as not to interfere unreasonably with the operations
of the Company. No investigation made by Parent or its representatives hereunder
shall affect the representations and warranties of the Company hereunder.

         5.3      Cancellation and Termination of Obligations.  Prior to the
 Closing Date, the Company shall take the following actions:

                  (a) Stockholder Obligations.  The Company shall cause
each of the entities listed in Schedule 5.3 to enter into a form of Creditor
Waiver and Consent Agreement in form and substance satisfactory to Parent.

                  (b) Employment Agreements.  James Cuppini shall enter
into an employment agreement with Company in form and substance satisfactory to
Parent.

                                       21

<PAGE>

                  (c) Creditor Agreements. Entry by the Company into payment
agreements calling for amortization of outstanding past due obligations to the
Company, plus a market rate of interest (without equity participation) on the
following period (or longer) for each of the following creditors:

                           (i)      Nortel Networks - 5 years; and

                           (ii)     Video At Home - 3 years.

                  (d) Harris Bank Loan. The Company shall have obtained from
Harris Trust and Savings Bank at its office at 111 West Monroe, Chicago,
Illinois 60603, a consent to the Merger and a commitment that it will extend and
maintain a loan to the Company with a principal amount of not less than the
principal balance outstanding as of the date of this Agreement (subject to
Company's maintaining on a current basis all interest obligations from time to
time) for an additional twelve months following the Closing Date.

         5.4 Pre-Clear Merger. Parent, Mergeco and the Company shall take all
necessary steps to pre clear the Merger with the Secretary of State of the State
of Delaware, in order that on the Closing Date, the Certificate of Merger may be
filed with the Secretary of State of the State of Delaware and become effective
upon filing.

         5.5 Notification of Certain Matters. The Company, on the one hand, and
Parent, on the other, shall give prompt notice to the other of the occurrence or
non occurrence of any event which would likely cause any representation or
warranty contained herein to be untrue or inaccurate, or any covenant,
condition, or agreement contained herein not to be complied with or satisfied.

         5.6 Approval of Merger. The Company shall take all actions necessary,
in accordance with the DGCL and its Certificate of Incorporation and By-Laws, to
duly call, give notice of, convene, and hold a meeting of its Stockholders as
promptly as practicable, or obtain the necessary written shareholder consent (to
be followed by the necessary form of information statement) to consider and vote
upon the adoption and approval of the Merger and this Agreement, to the extent
approval is required by the Stockholders. The Company shall recommend to the
Stockholders that they vote their Target Shares in favor of the Merger and
approval of the Agreement. The Company shall obtain the prior approval of Parent
as to the form and content of the notice and any additional material to be
provided to the holders of the Target Shares in connection with such meeting or
solicitations of written consents.

                                   ARTICLE VI
                              ADDITIONAL AGREEMENTS

         6.1 Further Assurances. Each party shall execute and deliver such
additional instruments and other documents and shall take such further actions
as may be necessary or appropriate to effectuate, carry out and comply with all
of the terms of this Agreement and the transactions contemplated hereby.

         6.2 Confidentiality; Publicity.  Except as may be required by law
or as otherwise permitted or expressly contemplated herein, prior to the
Closing, no party hereto or their

                                       22

<PAGE>

respective Affiliates, employees, agents and representatives shall disclose to
any third party this Agreement or the subject matter or terms hereof without the
prior consent of the other parties hereto. No press release or other public
announcement related to this Agreement or the transactions contemplated hereby
shall be issued by any party hereto without the prior approval of the other
parties, except that Parent may make such public disclosure which Parent
believes in good faith is required by law or by the terms of any listing
agreement with or requirements of a securities exchange.

         6.3 No Other Discussions. None of the Company, its directors, officers,
principal stockholders, and their respective Affiliates, employees, agents or
representatives shall (i) initiate or encourage the initiation by others of
discussions or negotiations with third parties or respond to solicitations by
third persons relating to any merger, sale or other disposition of any
substantial part of the assets, business or properties of the Company (whether
by merger, consolidation, sale of stock or otherwise) or (ii) enter into any
agreement or commitment (whether or not binding) with respect to any of the
foregoing transactions. The Company will immediately notify Parent if any third
party attempts to initiate any solicitation, discussion or negotiation with
respect to any of the foregoing transactions.

         6.4 Transfer Taxes. Any Taxes solely relating to the transfer and
conveyance of the Target Shares from the Stockholders to Parent pursuant to the
Merger (including documentary stamps or transfer taxes) shall be paid by the
Stockholders.

         6.5 Tax-Free Reorganization. The parties to this Agreement intend the
Merger to qualify as a tax-free organization pursuant to Section 368(a) of the
Code and shall not take any positions inconsistent therewith unless required to
do so by law.

                                   ARTICLE VII
               CONDITIONS TO THE OBLIGATIONS OF PARENT AND MERGECO

         The obligations of Parent and Mergeco to effect the Merger and the
other transaction contemplated hereby shall be subject to the fulfillment at or
prior to the Closing Date of the following conditions, any or all of which may
be waived in whole or in part by Parent:

         7.1 Accuracy of Representations and Warranties and Compliance with
Obligations. The representations and warranties of the Company contained in
Article IV of this Agreement shall be true and correct at and as of the Closing
Date with the same force and effect as though made at and as of that time except
(i) for changes specifically permitted by or disclosed in this Agreement, and
(ii) that those representations and warranties which address matters only as of
a particular date shall remain true and correct as of such date. The Company
shall have performed and complied with all of its obligations required by this
Agreement to be performed or complied with at or prior to the Closing Date. The
Company shall have delivered to Parent a certificate, dated as of the Closing
Date, duly signed (in the case of the Company by its chief executive officer),
stating that such representations and warranties are true and correct and that
all such obligations have been performed and complied with.

                                       23

<PAGE>

         7.2 Consents. The Company shall have received the consents and
approvals, in form and substance reasonably satisfactory to Parent, to the
transactions contemplated hereby from the Persons specified in Schedule 4.4.

         7.3 Secretary's Certificate. The Company shall have delivered to Parent
(i) copies of the Certificate of Incorporation and By-Laws of the Company since
a specified date; (ii) copies of resolutions adopted by the Board of Directors
of the Company and the Stockholders authorizing the transactions contemplated by
this Agreement, and (iii) certificates of good standing of the Company issued by
the State of Delaware, certified in each case as of the Closing Date by the
Secretary as being true, correct and complete.

         7.4 No Adverse Litigation. There shall not be pending or threatened any
action or proceeding by or before any court or other Governmental Authority
which shall seek to restrain, prohibit, invalidate or collect damages arising
out of the Agreement or any other transaction contemplated hereby, and which, in
the judgment of Parent, makes it inadvisable to proceed with the Agreement and
other transactions contemplated hereby, including any action pending or
threatened by any Stockholder or creditor of the Company seeking to block the
Merger.

         7.5 No Material Adverse Change. At any time after the date of this
Agreement, there must not have occurred any Material Adverse Change (as
hereafter defined) relating to the Company. "Material Adverse Change" shall mean
any change, effect, event, occurrence or state of facts that is, or would
reasonably be expected to be, materially adverse to the business, financial
condition or results of operations of the Company other than any change, effect,
event or occurrence relating to the economy or securities markets of the United
States.

         7.6 Other Closing Deliveries.  At Closing, Parent shall have
received:

             (a) Each of the Persons listed on Schedule 7.6 shall have
executed and delivered an Employment Agreement and/or non-compete and
confidentiality agreement in form and substance reasonably satisfactory to the
Company;

             (b) resignations effective as of the Closing Date from
such officers and directors of the Company as Parent shall have requested in
writing; and

             (c) the stock books, stock ledgers, minute books,
corporate seal and other books and records of the Company.

         7.7 Appraisal Rights. There shall not be any existing Stockholder or
holder of any option, warrant or other security of the Company exercising
appraisal rights or claiming entitlement to equity in the Surviving Corporation
or Parent greater than that contemplated by this Agreement.

         7.8 Due Diligence.  Parent shall have completed its due diligence
investigation and the results of such investigation shall be satisfactory to
Parent, in its sole discretion.

                                       24

<PAGE>

                                  ARTICLE VIII
                        CONDITIONS TO THE OBLIGATIONS OF
                                   THE COMPANY

         The obligations of the Company to effect the Merger and the other
transaction contemplated hereby shall be subject to the fulfillment at or prior
to the Closing Date of the following conditions, any or all of which may be
waived in whole or in part by the Company:

         8.1 Accuracy of Representations and Warranties and Compliance with
Obligations. The representations and warranties of Parent and Mergeco contained
in this Agreement shall be true and correct at and as of the Closing Date with
the same force and effect as though made at and as of that time except (i) for
changes specifically permitted by or disclosed pursuant to this Agreement, and
(ii) that those representations and warranties which address matters only as of
a particular date shall remain true and correct as of such date. Parent and
Mergeco shall have performed and complied with all of their respective
obligations required by this Agreement to be performed or complied with at or
prior to the Closing Date. Parent and Mergeco shall have delivered to the
Stockholder a certificate, dated as of the Closing Date, and signed by an
executive officer, certifying that such representations and warranties are true
and correct and that all such obligations have been performed and complied with.

         8.2 No Adverse Litigation. There shall not be pending or threatened any
action or proceeding by or before any court or other Governmental Authority
which shall seek to restrain, prohibit, invalidate or collect damages arising
out of the Agreement or any of the transactions contemplated hereby, and which
in the judgment of the Stockholder makes it inadvisable to proceed with the
Agreement or any other transaction contemplated hereby.

         8.3 Secretary's Certificate. The Parent shall have delivered to the
Stockholders (i) copies of the Articles of Incorporation and By-Laws of Parent
and Mergeco since a specified date, (ii) copies of resolutions adopted by the
Board of Directors of the Parent and Mergeco authorizing the transactions
contemplated by this Agreement, and (iii) certificate of good standing of the
Parent and Mergeco issued by the States of Florida and Delaware, respectively,
certified in each case as of the Closing Date by the Secretary as being true,
correct and complete.

         8.4 Other Closing Deliveries.  At Closing, the Company shall have
received each Parent Ancillary Document and Mergeco Ancillary Agreement, duly
executed by Parent, Mergeco and/or its Affiliates, as the case may be.

                                   ARTICLE IX
                                   DEFINITIONS

         9.1 Defined Terms.  As used herein, the following terms shall
have the following meanings:

         "Affiliate" means, with respect to any Person, any other Person which
directly or indirectly controls, is controlled by or is under control with such
Person.

                                       25

<PAGE>

         "Assets" means all of machinery, equipment, inventory, supplies,
property and other assets of the Company, except the Leased Assets, whether
real, personal or mixed, tangible or intangible, and wherever located, including
the Owned Real Property.

         "Closing" shall have the meaning as set forth in Section 1.10.

         "Closing Date" shall have the meaning as set forth in Section 1.10.

         "Code" shall have the meaning as set forth in Section 4.19.

         "Company Ancillary Documents" all agreements, instruments and
documents, being or to be executed and delivered by the Company under this
Agreement or in connection herewith.

         "Company's Knowledge," or words to that effect as used herein refer to
the personal actual knowledge of the Stockholders and Principals, and to the
knowledge which they should have had after a reasonable investigation.

         "Contract" means any indenture, lease, sublease, license, loan
agreement, mortgage, note, indenture, restriction, will, trust, commitment,
obligation or other contract, agreement or instrument, whether written or oral.

         "Current Balance Sheet" shall have the meaning as set forth in Section
4.7.

         "Designated Contracts" shall have the meaning as set forth in Section
4.22.

         "DGCL" shall have the meaning as set forth in Section 1.1.

         "Dissenting Stockholder" means any holder of capital stock of the
Company who, as a result of the transaction contemplated hereby, perfects his,
her or its demand for appraisal rights in accordance with Section 262(a) and (d)
of the DGCL.

         "Dissenting Target Shares" shall have the meaning as set forth in
Section 1.9(a).

         "Effective Date" shall have the meaning as set forth in Section 1.2.

         "Effective Time" shall have the meaning as set forth in Section 1.2.

         "Employee Benefit Plans" shall have the meaning as set forth in Section
4.21(a).

         "Environmental Law" means all laws, statutes, regulations, rules, codes
or ordinances derived from or relating to all federal, state and local laws or
regulations relating to or addressing the environmental, health or safety,
including, but not limited to, the Comprehensive Environmental Response,
Compensation and Liability Act of 1980, as amended by the Superfund Amendment
and Reauthorization Act of 1986, 42 U.S.C. Section 9601, et seq. (hereinafter
collectively "CERCLA"); the Solid Waste Disposal Act, as amended by the Resource
Conservation and Recovery Act of 1976 and subsequent Hazardous and Solid Waste
Amendments of 1984, 42 U.S.C. Section 6901 et seq. ("SARA") (hereinafter,
collectively "RCRA"), the Hazardous Materials Transportation Act, as amended, 49
U.S.C. Section 1801, et seq.; the Clean

                                       26
<PAGE>

Water Act, as amended, 33 U.S.C. Section 1311, et seq.; the Clean Air Act, as
amended (42 U.S.C. Section 7401-7642); Toxic Substances Control Act, as amended,
15 U.S. C. Section 2601 et seq.; the Federal Insecticide, Fungicide, and
Rodenticide Act, as amended, 7 U.S.C. Section 136-136y ("FIFRA"); the Emergency
Planning and Community Right-to-Know Act of 1986, as amended, 42 U.S.C. Section
11001, et seq. (Title III of SARA) ("EPCRA"); the Occupational Safety and Health
Act of 1970, as amended, 29 U.S.C. Section 651, et seq. ("OSHA").

         "Environmental Lien" means a Lien in favor of any Governmental
Authority for (i) any liability under any Environmental Law, or (ii) damages
arising from, or costs incurred by such Governmental Authority in response to, a
Release or threatened Release of a Hazardous Substance into the environment.

         "Equipment Lease" shall have the meaning as set forth in Section 4.13.

         "ERISA" means the Employee Retirement Income Security Act of 1974, as
amended.

         "Exchange Act" means the Securities Exchange Act of 1934, as amended.

         "Expenses" means any and all expenses incurred in connection with
investigating, defending or asserting any claim, action, suit or proceeding
incident to any matter indemnified against hereunder (including, without
limitation, court filing fees, court costs, arbitration fees or costs, witness
fees, and reasonable fees and disbursements of legal counsel, investigators,
expert witnesses, consultants, accountants and other professionals).

         "Financial Statements" shall have the meaning as set forth in Section
4.7.

         "GAAP" means generally accepted accounting principles in effect in the
United States of America from time to time.

         "Governmental Authority" means any nation or government, any state,
regional, local or other political subdivision thereof, and any entity or
official exercising executive, legislative, judicial, regulatory or
administrative functions of or pertaining to government.

         "Hazardous Substances" means any substance, chemical or waste that is
listed, or contains material amounts of one or more components that are defined,
designated, classified, considered or listed, as hazardous, toxic or radioactive
under any Environmental Law; as well as any asbestos or asbestos-containing
material, petroleum, petroleum product or by-product, crude oil or any fraction
thereof, natural gas, natural gas liquids, liquefied natural gas, synthetic gas
usable as fuel, or polychlorinated biphenyls ("PCBs").

         "Intellectual Property" means (i) all names, brands, logos and slogans
embodying business or product goodwill or indications of origin, and all
trademarks, corporate names, trade names, service marks, trade dress, domain
names and universal resource locators, together with all translations,
adaptations, derivations and combinations thereof and all applications,
registrations and renewals in connection therewith, and all of the goodwill
associated therewith; (ii) all patents, patent applications, patent disclosures,
inventions (whether patentable or unpatentable and whether or not reduced to
practice) and all improvements thereof, including, but not limited to, any
provisional, utility, continuation, continuation-in-part or divisional

                                       27
<PAGE>

applications filed in the U.S. or other jurisdictions and all reissues,
revisions and extensions thereof and all reexamination certificates issuing
therefrom; (iii) all websites, copyrights, and copyrightable works both
published and unpublished, including all registrations, applications and
renewals in connection therewith; (iv) all computer and electronic data
processing programs and software programs (in both source code and object code
form), data, databases and related documentation; (v) all inventions,
improvements, developments, modifications, derivative works, know-how, trade
secrets, and confidential information (including research and development,
know-how formulas, compositions, manufacturing and production processes and
techniques, methods, schematics, technology, technical data, designs, drawings,
flowcharts, block diagrams, specifications, customer and supplier lists, pricing
and cost information and business and marketing plans and proposals); (vi) all
licenses, sublicenses, permissions and other agreements relating to any of the
foregoing; and (vii) all other intellectual property rights (in whatever form or
medium) relating to any of the foregoing (including remedies and recoveries
against infringement hereof and rights of protection of interest therein under
the laws of all jurisdictions).

         "Junior Preferred" shall have the meaning as set forth in Section 1.4.

         "Leased Assets" collectively refers to the machinery, equipment and
other personal property the Company leases to carry on its operations as set
forth on Schedule 4.13, and the Leased Real Properties.

         "Leased Real Properties" shall have the meaning as set forth in Section
4.11(b).

         "Leases" shall have the meaning as set forth in Section 4.11(b).

         "Lien" means any mortgage, pledge, security interest, encumbrance, lien
or charge of any kind (including, but not limited to, any conditional sale or
other title retention agreement, any lease in the nature thereof, and the filing
of or agreement to give any financing statement under the Uniform Commercial
Code or comparable law or any jurisdiction in connection with such mortgage,
pledge, security interest, encumbrance, lien or charge).

         "Losses" means any loss, cost, obligation, liability, settlement
payment, award, judgment, fine, penalty, damage, expense, deficiency or other
charge, but not including Expenses.

         "Material Adverse Effect" shall have the meaning as set forth in
Section 4.1.

         "Mergeco Ancillary Agreements" means all agreements, instruments and
documents being or to be executed and delivered by Mergeco under this Agreement
or in connection herewith.

         "Merger" shall have the meaning as set forth in the Recitals.

         "MPPA Plan" shall have the meaning as set forth in Section 4.21(d).

         "Owned Intellectual Property" shall have the meaning as set forth in
Section 4.14(a).

         "Owned Real Properties" shall have the meaning as set forth in Section
4.11(a).

                                       28
<PAGE>

         "Parent Ancillary Documents" means all agreements, instruments and
documents being or to be executed and delivered by Parent under this Agreement
or in connection herewith.

         "Parent Common Stock" shall have the meaning as set forth in Paragraph
A of the Recitals.

         "PBGC" shall have the meaning as set forth in Section 4.21(f).

         "Permitted Lien" means (i) liens for taxes and other governmental
charges and assessments which are not yet due and payable, (ii) liens of
landlords and liens of carriers, warehousemen, mechanics and materialmen and
other like liens arising in the ordinary course of business for sums not yet due
and payable and (iii) other liens or imperfections on property which are not
material in amount and do not materially detract from the value of or materially
impair the existing use of the property affected by such lien or imperfection.

         "Person" means an individual, partnership, corporation, business trust,
joint stock company, estate, trust, unincorporated association, joint venture,
Governmental Authority or other entity, of whatever nature.

         "Property" means any real or personal property, plant, building,
facility, structure, underground storage tank, equipment or unit, or other asset
owned, leased or operated by the Company prior to the Closing Date (including
any surface water thereon or adjacent thereto, and soil or groundwater
thereunder).

         "Real Properties" shall have the meaning as set forth in Section
4.11(c).

         "Release" means release, spill, emission, leaking, pumping, injection,
deposit, disposal, discharge, dispersal, leaching or migration of a Hazardous
Substance into the indoor or outdoor environment or into or out of any Property,
including the movement of Hazardous Substances through or in the air, soil,
surface water, groundwater or Property.

         "Remedial Action" means actions required to (i) clean up, remove, treat
or in any other way address Hazardous Substances in the indoor or outdoor
environment; (ii) prevent the Release or threatened Release or minimize the
further Release of Hazardous Substances; or (iii) investigate and determine if a
remedial response is needed and to design such a response and post-remedial
investigation, monitoring, operation and maintenance and care.

         "SEC" means the Securities and Exchange Commission.

         "Securities Act" means the Securities Act of 1933, as amended.

         "Senior Preferred" shall have the meaning as set forth in Section 1.4.

         "Series A Preferred" shall have the meaning as set forth in Section
1.4.

         "Stockholders" collectively refers to all of the holders of the Target
Shares.

         "Surviving Corporation" shall have the meaning as set forth in Section
1.1.

                                       29
<PAGE>

         "Target Common Shares" means the issued and outstanding shares of the
Company's common stock, par value $.001 per share.

         "Target Preferred Shares" collectively refers to the issued and
outstanding shares of Senior Preferred, Junior Preferred, and Series A
Preferred.

         "Target Shares" shall have the meaning as set forth in Paragraph A of
the Recitals.

         "Tax Return" means any tax return, filing or information statement
required to be filed in connection with or with respect to any Taxes.

         "Taxes" means all taxes, fees or other assessments, including, but not
limited to, income, excise, property, sales, franchise, intangible, withholding,
social security and unemployment taxes imposed by any federal, state, local or
foreign governmental agency, and any interest or penalties related thereto.

         "Third Party Intellectual Property" shall have the meaning as set forth
in Section 4.14(b).

         "Welfare Plan" shall have the meaning as set forth in Section 4.21(e).

         9.2 Other Definitional Provisions.

                  (a) All terms defined in this Agreement shall have the defined
meanings when used in any certificates, reports or other documents made or
delivered pursuant hereto or thereto, unless the context otherwise requires.

                  (b) Terms defined in the singular shall have a comparable
meaning when used in the plural, and vice versa.

                  (c) All matters of an accounting nature in connection with
this Agreement and the transactions contemplated hereby shall be determined in
accordance with GAAP applied on a basis consistent with prior periods, where
applicable.

                  (d) As used herein, the neuter gender shall also denote the
masculine and feminine, and the masculine gender shall also denote the neuter
and feminine, where the context so permits.

                                    ARTICLE X
                        TERMINATION, AMENDMENT AND WAIVER

         10.1 Termination. Notwithstanding any approval of the Merger or this
Agreement by the Stockholders and/or directors of the Company or Parent, this
Agreement may be terminated as follows:

                  (a) at any time prior to the Closing Date, by mutual written
consent of Parent and the Company at any time prior to the Closing;

                                       30
<PAGE>

                  (b) at any time prior to the Closing Date, by Parent in the
event of a material breach by the Company of any provision of this Agreement, by
giving notice thereof to the Company specifying in reasonable detail the
material breach;

                  (c) at any time prior to the Closing Date, by the Company in
the event of a material breach by Parent or Mergeco of any provision of this
Agreement, by giving notice thereof to Parent specifying in reasonable detail
the material breach; or

                  (d) at any time prior to the Closing Date, by any of Parent or
the Company if the Closing shall not have occurred by November 30, 2004;
provided, however, that neither Parent, nor the Company shall be entitled to
terminate this Agreement pursuant to this Section 12.1(d), if such party's
knowing or willful breach of this Agreement has prevented the consummation of
the transactions contemplated hereby.

         10.2 Effect of Termination. Except as a party may otherwise agree in
writing, the termination of this Agreement by a party pursuant to this Section
will not be deemed to be a waiver of any rights of such party or its Affiliates
who are parties to this Agreement arising from any default thereunder by another
party.

                                   ARTICLE XI
                               GENERAL PROVISIONS

         11.1 Notices. All notices, requests, demands, claims, and other
communications hereunder shall be in writing and shall be delivered (which
delivery may be by contract carrier, receipt acknowledged, or by telecopy or
other electronic transmission) to a party at the following address or telecopy
number for such party (or to such other address or telecopy number which such
party shall designate in writing to the other party):

                  (a)      if to Parent to:

                           Rory Herriman
                           100 East Woodfield Road
                           Suite 100
                           Schaumburg, Illinois 60611
                           Phone:  (630) 872-5800
                           Fax:  (630) 872-5801

                           with a copy to:

                           Shefsky & Froelich Ltd.
                           444 North Michigan Avenue
                           Suite 2500
                           Chicago, Illinois 60611
                           Attn:  Mitchell D. Goldsmith
                           Phone:  (312) 836-4006
                           Fax:  (312) 527-5921

                  (b)      if to the Company prior to the Effective Date:

                                       31
<PAGE>

                           James Cuppini
                           50 East Commerce Drive-Suite A
                           Schaumburg, Illinois 60173
                           Phone:  (847) 252-1400
                           Fax:  (847) 252-1416

                           with a copy to:

                           Gerald L. Fishman
                           Law Offices Gerald L. Fishman
                           216 West Jackson Boulevard-Fourth Floor
                           Chicago, Illinois 60606
                           Phone:  (312) 795-7636
                           Fax:  (312) 795-7630

                  (c)      if to the Company after the Effective Date:

                           James Cuppini
                           100 East Woodfield Road -- Suite 100
                           Schaumburg, Illinois 60173
                           Phone:  (630) 872-5800
                           Fax:  (630) 872-5801

                           with a copy to:

                           Gerald L. Fishman
                           Law Offices Gerald L. Fishman
                           216 West Jackson Boulevard-Fourth Floor
                           Chicago, Illinois 60606
                           Phone:  (312) 795-7636
                           Fax:  (312) 795-7630

         11.2 Counsel. No inference shall be drawn in favor or against any party
by virtue of who has served as principal draftsman of this document. The parties
acknowledge and agree that Shefsky & Froelich Ltd. ("S&F") has served as counsel
for Parent and Mergeco in connection with matters related to the drafting of
this Agreement, including the formation of Mergeco. The parties further
acknowledge that S&F has not provided legal advice to or acted as counsel for
the Company, which has relied upon the advice of independent counsel. All
parties consent to S&F's further representation of Parent following the Closing
of the Merger.

         11.3 Entire Agreement. This Agreement (including the Exhibits and
Schedules attached hereto) contains the entire understanding of the parties in
respect of its subject matter and supersedes all prior agreements and
understandings (oral or written) between or among the parties with respect to
such subject matter. The Exhibits and Schedules constitute a part hereof as
though set forth in full above.

                                       32
<PAGE>

         11.4 Expenses. Except as otherwise provided herein, the parties shall
pay their own fees and expenses, including their own counsel fees, incurred in
connection with this Agreement or any transaction contemplated hereby.

         11.5 Amendment; Waiver. This Agreement may not be modified, amended,
supplemented, canceled or discharged, except by written instrument executed by
all parties. No failure to exercise, and no delay in exercising, any right,
power or privilege under this Agreement shall operate as a waiver, nor shall any
single or partial exercise of any right, power or privilege hereunder preclude
the exercise of any other right, power or privilege. No waiver of any breach of
any provision shall be deemed to be a waiver of any preceding or succeeding
breach of the same or any other provision, nor shall any waiver be implied from
any course of dealing between the parties. No extension of time for performance
of any obligations or other acts hereunder or under any other agreement shall be
deemed to be an extension of the time for performance of any other obligations
or any other acts.

         11.6 Binding Effect; Assignment. The rights and obligations of this
Agreement shall bind and inure to the benefit of the parties and their
respective successors, heirs and assigns. Nothing expressed or implied herein
shall be construed to give any other person any legal or equitable rights
hereunder.

         11.7 Counterparts. This Agreement may be executed in any number of
counterparts, each of which shall be an original but all of which together shall
constitute one and the same instrument.

         11.8 Interpretation. When a reference is made in this Agreement to an
article, section, paragraph, clause, schedule or exhibit, such reference shall
be deemed to be to this Agreement unless otherwise indicated. The headings
contained in this Agreement are for reference purposes only and shall not affect
in any way the meaning or interpretation of this Agreement. Whenever the words
"include," "includes" or "including" are used in this Agreement, they shall be
deemed to be followed by the words "without limitation." Time shall be of the
essence in this Agreement.

         11.9 Governing Law; Interpretation. This Agreement shall be construed
in accordance with and governed for all purposes by the laws of the State of
Illinois applicable to contracts executed and to be wholly performed within such
State, except that with respect to the effects of the Merger, the applicable
provisions of the DGCL shall also apply.

         11.10 Arm's Length Negotiations. Each party herein expressly represents
and warrants to all other parties hereto that (a) before executing this
Agreement, said party has fully informed itself of the terms, contents,
conditions and effects of this Agreement; (b) said party has relied solely and
completely upon its own judgment in executing this Agreement; (c) said party has
had the opportunity to seek and has obtained the advice of counsel before
executing this Agreement; (d) said party has acted voluntarily and of its own
free will in executing this Agreement; (e) said party is not acting under
duress, whether economic or physical, in executing this Agreement; and (f) this
Agreement is the result of arm's length negotiations conducted by and among the
parties and their respective counsel.

                                       33
<PAGE>

         11.11 Survival of Obligations; No Stockholder Liability. All
representations and warranties contained in this Agreement shall terminate as of
the Closing Date and not survive the Closing. All covenants and obligations
contained in this Agreement to be fully performed or complied with at or prior
to Closing shall not survive Closing. All covenants and obligations contained in
this Agreement to be performed or complied with after shall survive for the
periods specified therein, or if no such period is specified, indefinitely. The
Stockholders shall not have any liability for any breach or inaccuracy of any
representations or warranties set forth herein or the breach by the Company of
any of its covenants and obligations contained in this Agreement.

                                       34
<PAGE>

         IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be
duly executed and delivered as of the day and year first above written.

                              CAPITAL GROWTH SYSTEMS, INC.

                              By:      /s/ Rory Herriman
                                 -----------------------------------------------
                              Name:    Rory Herriman
                                   ---------------------------------------------
                              Title:   Secretary, Treasurer and Chief Technology
                                    --------------------------------------------
                                       Officer
                                    --------------------------------------------

                              FRONTRUNNER ACQUISITION, INC.

                              By:      /s/ D. Skip Behm
                                 -----------------------------------------------
                              Name:    D. Skip Behm
                                   ---------------------------------------------
                              Title:   Secretary and Treasurer
                                    --------------------------------------------

                              FRONTRUNNER NETWORK SYSTEMS, CORP.

                              By:      /s/ James Cuppini
                                 -----------------------------------------------
                              Name:    James Cuppini
                                   ---------------------------------------------
                              Title:   President
                                    --------------------------------------------

                                       35

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00070-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00070-of-00352.parquet"}]]